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CHAPTER 1 — INTRODUCTION
1.1 Overviews and Objectives
Cancer is one of the most deadly disease in both men and women throughout the US.[1, 2]
An estimated 1.7 million new cases will be diagnosed in 2014, and 600 thousand patients are
expected to die of cancer.[1, 2] Among many malignant tumors, lung cancer is of great relevance
as it is the leading cause of cancer death. Lung cancers cause more death cases than three most
common cancers combined (prostate, breast and colon) (cases of death: 160,340 in 2012, 159,480
in 2013).[1, 2] Lung cancer is mainly divided into two groups: non-small cell lung cancer
(NSCLC, 85-90%) and small cell lung cancer (SCLC, 10-15%) [3]. The largest type in NSCLC
is adenocarcinoma (50-60%) which is pulmonary neoplasia of epithelial tissues that contains
glandular origin and glandular characteristics.[4] Common treatments of lung cancer include
surgery, chemotherapy, radiotherapy and all combined. Because of the challenges in early
detection of lung cancer, it is usually diagnosed at later stages of the disease, and thus only a small
number of patients are eligible for surgery. Even in those cases where surgery is possible, the rate
of recurrence is high. Due to most of lung cancers are metastatic, surgical treatment in patients
with metastatic lung cancer is also not usually recommended due to the generally poor respiratory
and overall clinical profile of the patients. Therefore, chemotherapy is widely used against primary
and secondary lung cancers. However, chemotherapeutic strategies have done limited roles to
improve therapeutic outcomes for patients with lung cancer, who have a 5 year survival rate after
initial prognosis of only 16.6%.[5] One major challenge is the low concentration (2-4% of initial
dose) of chemotherapeutics found in the lung cancer spots upon i.v. administration.[6-8] Dose
limiting toxicity for chemotherapeutics also limits lung cancer treatment.[9] This problem is
complicated as high i.v. dosages are usually required due the poor distribution profile of anti-
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cancer therapeutics to the lung tumor.[8] Drug delivery systems of combined chemotherapeutics
are promising means to overcome most of issues above such as targeted delivery of chemotherapy
agents, dose level increase in neoplastic lesion, sustained drug release and protection of attached
cargo from metabolism.[10-18]
Chemotherapy agent, such as doxorubicin (DOX), plays a vital role in cancer treatment. It
is also used in conjunction with other treatments such as surgery, radiation therapy and
hyperthermia therapy.[19] However, hydrophobic nature of most of chemotherapy agents result
in limited aqueous solubility and rapid elimination from blood circulation.

Common

administration route of chemotherapeutics is intravenous injection which non-specificially
distributes DOX to whole body. Systemic distribution, however, does not just significantly reduce
local concentration level at lesion, but damage healthy tissues.[20, 21] The accumulation of DOX
in the heart results in increased oxidative stress, down-regulated protein function, decreased
cardiac gene expression, and up-regulated apoptosis of cardiomyocytes, which eventually leads to
lethal cardiomyopathy.[22] Synthetic polymeric nanocarriers (PNCs) have been widely used and
validated in anticancer therapeutics delivery, since PNCs are able to protect its cargos from
enzymatic degradation, improve pharmacokinetics/pharmacodynamics of therapeutics, promote
sustainable drug release and reduce cytotoxicity to healthy tissues.[23-26] Among these PNCs,
dendrimer nanocarriers (DNCs) as drug vehicles or scaffolds is one of the most promising frontiers
in designing anticancer therapeutics delivery system.[27] In addition to those general strengths of
PNCs, hyperbranched polyamidoamine (PAMAM) dendrimer has its own featured advantages as
anticancer therapeutics carrier:[28, 29] (i) good water solubility that enhances water solubility of
hydrophobic anticancer drugs and peptides; (ii) monodispersity and predictable molecular weight
that ensures consistent pharmacokinetics and pharmacodynamics; (iii) high density of reactive
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surface groups on dendrimer that empowers dendrimer to enhance therapeutics payload and carry
diverse chemical moieties for different purposes at one time;[30-32] (iv) high membranepenetrating potential that enhances the paracellular transport and intracellular uptake of anticancer
therapeutics.[33, 34]
Lungs have a few advantages over invasive and other non-invasive administration routes:
(i) large surface area. It is estimated that there are 300 million of alveolar cells in human lungs,
which thus leads to 80-90 m2 surface area for gas exchange in lungs.[35] Alveolar sacs consist of
only one epithelial monolayer, thus facilitating the rapid translocation of molecules from lungs to
systemic circulation; (ii) reduced enzymatic degradation. Some drugs (e.g. imipramine,[36]
propranolol,[37] and midazolam[38]) can be inactivated by first-pass metabolism which occurs in
digestive system and liver. Drug delivery to lungs is one of alternative routes of medication
administration that avoids first-pass effect; (iii) high local concentration. Drug delivery to the
lungs is especially promising in treating pulmonary disorders such as lung cancer, chronic
obstructive pulmonary disease (COPD), and cystic fibrosis (CF), since high local drug
concentration, rapid therapeutics action and minimization of systemic adsorption allowing for
decreased side effects.

Therefore, oral inhalation (OI), an attractive non-invasive route of

delivering small molecules and macromolecular therapeutics, has drawn more and more attention
as it can reach different pulmonary regions and even systemic tissues.[39, 40] Nebulizers,
pressurized metered-dose inhalers (pMDIs), and dry powder inhalers (DPIs) are three major
categories.[41, 42] pMDIs are a well-developed aerosol technology and widely accepted by
patients due to its portability, straightforwardness in use and enhanced lung deposition of inhaled
therapeutics. pMDIs consist of 60% aerosol products in market. However, most of drugs are not
soluble in propellant-based pMDIs. The surfactants and/or co-solvents are required to disperse
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small drugs. The difficulty in the development of the surfactants restricts the application of pMDIs.
Additionally, environmentally unfriendly propellant also limits the use of pMDIs to some
extent.[43]
Based on the challenges and opportunities discussed earlier, we propose strategies for
treating lung cancers to (i) design polymer-bound DOX conjugates to promote spatial and temporal
release—thus decreasing the plasma concentration of free DOX; (ii) modulate the transport of
DOX across pulmonary epithelium with nanocarrier surface chemistry manipulation; (iii) enhance
the local concentration of DOX in lung tumors upon pulmonary administration, potentially
improving therapeutic efficacy and decreasing systemic exposure of DOX; (iv) develop oral
inhalation (OI) formulations (pMDIs) for the local delivery to the lung tissue. Such strategies are
expected to improve the survival rate and quality of life of the ca. 225,000 people diagnosed with
lung cancer per year.[2]
Within the context, the objectives of this dissertation are:
Objective #1. Investigate effect of PEGylation and route of administration on systemic
and lung regional biodistribution of dendrimer nanocarriers. Chemotherapy is widely used
in the fight against primary lung cancers and lung metastasis.[6, 44-46] However, there are several
limitations in using chemotherapeutics to treat lung cancers. One major challenge is the low
chemotherapeutic concentration found in the lung tumor upon intravenous (i.v.) administration.[6,
7] It is estimated that only a few percent (ca. 2-4%) of the total dose administered i.v. reaches the
lung tumor.[8] Dose limiting toxicity is another major issue in the chemotherapeutic treatment of
lung cancers.[9] This problem is compounded as high i.v. dosages are usually required due to the
poor distribution profile of chemotherapeutics.[8] Nanocarriers have the potential to improve the
biodistribution and pharmacokinetic profiles of various therapeutics including anti-cancer
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drugs.[47-50] Dendrimers are particularly relevant nanocarrier systems as they have a large
number of surface groups amenable to the conjugation of therapeutic molecules and other ligands
that allow for different purposes. Direct delivery of drug to the lungs has attracted much attention
due to enhanced local drug concentration, fast drug action, and low enzymatic degradation in the
lungs. However, a few extracellular barriers that potentially decrease the efficiency of pulmonary
delivery includes bifurcating airways, mucociliary escalator, and alveolar macrophage
phagocytosis. A few studies have focused on the systemic biodistribution of nanocarriers upon
pulmonary administration,[39] including gold nanoparticles,[51] PEGylated polylysine
dendrimers,[52] PEGylated poly(ethylene imine),[53] diethylaminopropylamine-poly (vinyl
alcohol)-poly (lactide-co-glycolide) copolymer [54] and polystyrene nanoparticles.[55]
Meanwhile, PEGylation of PAMAM dendrimer on surface has shown to significantly prolong the
residence of nanocarriers in blood circulation and potentially accumulate nanocarriers in solid
tumors upon i.v. administration. However, the systemic and local biodistribution of PAMAM
dendrimer nanocarriers administered via pulmonary route is still unclear.

Therefore, the

elucidation of systemic and lung regional biodistribution of PEGylated PAMAM dendrimers is the
prerequisite of assessing pulmonary delivery as route of administration for lung cancers. Bare
PAMAM dendrimers and fully PEGylated dendrimers were synthesized and characterized. The
dendrimer nanocarriers were then delivered to the lungs via pulmonary route.

The

pharmacokinetics and systemic biodistribution of both dendrimers were characterized by ex-vivo
imaging and quantified by extracting PAMAM dendrimers from tissues.

Lung regional

distribution in different cell populations were investigated by specific cell-tagged flow cytometry.
As compared, the same dendrimers were injected intravenously to mice and the same experiments
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are performed. Detailed studies regarding the systemic and local biodistribution will be further
described in the following chapters.
Objective #2 Design PAMAM dendrimer conjugates with temporal and spatial
release of doxorubicin for lung cancer treatment. Doxorubicin (DOX) is one of the most
effective anti-cancer therapeutics available in the clinic today for treating a variety of cancers
including lung tumors.[56, 57] The applicability of DOX is limited, however, partly due to its
cardiac toxicity and myelosuppression.[21]

The free DOX in bloodstream that gradually

accumulates in the heart results in increased oxidative stress, down-regulated protein function,
decreased cardiac gene expression, and up-regulated apoptosis of cardiomyocytes, which
eventually leads to lethal cardiomyopathy.[22] To address this issue, we designed a nanocarrierbased strategy to promote the maximization of intracellular delivery of DOX to lung tumor cells,
and at the same time minimization of systemic exposure of DOX. PAMAM dendrimers are
particularly interesting nanocarrier drug delivery systems as they are highly monodispersed
(predictable pharmacokinetics/biodistribution) and can be easily functionalized with therapeutic
agents through linkages that allow for temporal and spatial control of drug release. Therefore,
DOX was conjugated to PAMAM dendrimers with a pH-responsive linker. The linker is only
cleavable at mild acidic environment (e.g. lysosomal pH), but stable at extracellular/physiological
pH condition. The DOX released in acidic subcellular compartments are then migrated to nuclei
to inhibit nuclear DNA synthesis. PEG was also attached to PAMAM-DOX conjugates to prolong
the residence of the conjugate in blood circulation and improve biodistribution. The potency of
acid-labile PAMAM-DOX conjugates against lung tumors were tested on in vitro and in vivo
models, respectively. The details regarding the design of acid-labile PAMAM-DOX conjugates,
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and studies of in vitro and in vivo potency of these conjugates against lung cancers were described
in the following chapters.
Objective #3: Develop pMDI formulations for non-invasive pulmonary delivery of
acid-labile PAMAM-DOX conjugates. Since OI has demonstrated its advantages over systemic
administration in treating pulmonary disorders.

However, the use of pMDI formulations

containing polymeric nanocarriers is still relatively unexploited mainly due to strong aggregation
of PNCs in propellant. To address the issue, co-solvents and/or surfactants are added to improve
dispersibility of PNCs. However, the less volatile/nonvolatile co-solvents and surfactants may
reduce aerosol performance, although drug solubility can be improved. We attached PEG chains
to dendrimer-DOX on surface for improving the dispersibility of dendrimer conjugates in
propellant-based pMDI formulation. Ether bond of PEG has been shown to strongly interact with
HFA propellant, aiding the solvation of drug particles in propellant.[58] The effect of PEG density
and DOX payload was on the stability formulation and aerosol performance were tested. The
addition of biodegradable and biocompatible surfactant were further added to modulate lung
deposition of the pMDI formulation for the delivery to various lung regions.
In Chapter 1, we presented the literature review about polymeric nanocarriers for
chemotherapeutics delivery, extra and intracellular barriers to pulmonary delivery of
chemotherapeutics, and pMDIs for drug delivery via OI administration.
In Chapter 2, we studied the effect of surface PEGylation and routes of administration on
systemic and local biodistribution of PAMAM dendrimers. Generation 3, amine-terminated
PAMAM dendrimer was labeled with Cy3 probes. The surface of the dendrimers was modified
with high grafting density of polyethylene glycol 1000Da (PEG1000). The PEGylation can
significantly change the surface chemistry and surface charge, which modulates the interaction of
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dendrimers with extracellular and intracellular barriers in vivo. The Cy3-labeled dendrimer and
PEGylated dendrimer were delivered to the lungs via pharyngeal aspiration (PA) and also through
tail intravenous injection (IV). The plasma concentration of dendrimer as a function of time was
studied. Major tissues were excised and then imaged for Cy3 fluorescence. To quantify the
biodistribution, dendrimers were extracted from tissue homogenates. Furthermore, cellular uptake
of dendrimer and PEGylated dendrimers were evaluated based on four major lung cellular
populations — myeloid, epithelial, endothelial and ciliated cells. The selected cell populations
were tagged with corresponding primary/secondary antibodies and then analyzed with flow
cytometry. The chapter is based on the manuscript Zhong Q., Merkel O, Reineke J, da Rocha
S.R.P.

The Effect of the Route of Administration and PEGylation of Poly(amidoamine)

Dendrimers on their Systemic and Lung Cellular Biodistribution. To be submitted to Molecular
Pharmaceutics, 2015.
In Chapter 3, we discussed the development of PEGylated, acid-labile PAMAM-DOX
conjugates and their propellant-based aerosol formulations.

A series of PEGylated

poly(amidoamine) dendrimer nanocarriers with acid-labile DOX conjugates were synthesized, and
characterized with 1H NMR for chemical composition, MALDI-TOF for molecular weight, light
scattering for hydrodynamic diameters and surface charge. We employed a two-step PEGylation
strategy to increase the payload of the hydrophobic DOX, while reaching high PEGylation degree
which is expected to improve in vivo pharmacokinetics and biodistribution. We investigated the
impact of pH (neutral and acidic pH), PEGylation density (low, medium and high) and number of
DOX conjugates (low and medium) on the release of DOX from the dendrimer nanocarrier, the
kinetics of carrier uptake, intracellular release kinetics of DOX from the nanocarrier, and toxicity
in an alveolar adenocarcinoma cell line (A549). These dendrimer-DOX conjugates were then
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formulated into HFA-based inhalers, forming a pseudo solution formulations which are confirmed
by light scattering. The effect of PEG density and DOX payload on the stability were assessed by
visualizing the dispersity as a function of time. The aerosol performance of these formulations
were assessed by an in vitro lung model — Andersen Cascade Impactor (ACI). The chapter is
based on the manuscript: Zhong Q., da Rocha S.R.P. Poly(amidoamine) Dendrimer-Doxorubicin
Conjugates: In vitro characteristics and Pseudo-Solution Formulation in Pressurized MeteredDose Inhalers. Submitted to Molecular Pharmaceutics, 2015
The modification of amine-terminated PAMAM dendrimers with PEG provides several
advantages to the dendrimers. Some of them include, lower cytotoxic potential, enhancement
of mucosal transport and increased circulation time. Chapter 4 studied the effect of PEGylation
degree and DOX payload on their ability to modulate transport of PAMAM-DOX conjugates
across polarized pulmonary Calu-3 monolayers.

The role of paracellular pathways in

transepithelial transport of dendrimer-DOX conjugates was also investigated. The PEGylated
PAMAM-DOX conjugates have been readily formulated in HFA-based formulation with the aid
of a trace of ethanol in Chapter 3. We developed another facile co-solvent free method to prepare
pMDI formulation containing PEGylated dendrimer-DOX conjugates.

The lung deposition

position of the aerosol formulations can be modulated by the addition of biodegradable and
biocompatible triblock copolymer. The aerosol performance of these formulations containing
dendrimer conjugates and triblock copolymers were assessed by an in vitro lung model —
Andersen Cascade Impactor (ACI). The chapter is based on the manuscript: Zhong Q., Humia B.,
Punjabi A., da Rocha S.R.P.

Design of Dendrimer-Doxorubicn Conjugates for Transport

Modulation across in vitro Pulmonary Epithelium and Their Solution Formulation in PressurizedMetered Dose Inhalers. To be submitted to Molecular Pharmaceutics, 2015
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In Chapter 5, we assessed the potency of acid-labile dendrimer-DOX conjugates upon
pulmonary delivery with a mouse lung tumor model. Poly(amidoamine) dendrimer (PAMAM)
with doxorubicin (DOX) conjugated via a pH-labile spacer was synthesized for controlled
intracellular release.

We investigated pH impact (pH 4.5 = lysosomal pH and pH 7.4 =

physiological/extracellular pH) on the DOX release from the dendrimer, and cellular uptake
kinetics and cell kill with B16F10 melanoma cells. The in vivo lung tumor model was developed
by injecting B16F10 melanoma intravenously through tail vein of mouse. 3 doses of therapeutics
with 20 μg per dose and one dose every other day were given to tumor-bearing mice through
pharyngeal aspiration (pulmonary administration), as well as intravenous injection (i.v.) as
compared. The lung tumor burdens at terminal point were evaluated by counting the number of
black nodules per lung. The in vivo systemic distribution of the PAMAM-DOX conjugate was
also quantified by extracting DOX from tissue homogenates. The focus were especially placed on
the retention of PAMAM-DOX conjugates in the lungs and accumulation of DOX in heart tissues
as a function of time. The chapter is based on the manuscript: Zhong Q., Reineke J., da Rocha
S.R.P. Conjugation to Poly(amidoamine) Dendrimers and Pulmonary Delivery Enhances the
Antitumor Activity of Doxorubicin in Lung Metastasis. To be submitted to Journal of Controlled
Release, 2015.
In Chapter 6, we discussed the conclusions drawn from this work and future research
suggestions.

1.2 Literature review
1.2.1 Inadequate biodistribution of chemotherapeutics upon i.v. administration
As high enough (therapeutic) doses at the lung tumor site usually cannot be reached without
inducing substantial systemic toxicity.[6] For example, the maximum concentration of CIS
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administered i.v is limited by strong renal toxicity, which may lead to acute renal failure,[59] while
i.v. DOX presents high cardiotoxicity, which may lead to congestive heart failure and death. [60]
The concentration of DOX reaching the lung tumor upon i.v. administration has been determined
to be as low as 2% of the total dose. [8] This low concentration of chemotherapeutic at the tumor
site also contributes to the development of MDR, as cells cancer cells that survive due to low
dosages, may become resistant.[61] Local delivery of chemotherapeutics to the lung tissue is a
promising alternative to i.v. administration in the treatment in lung cancer.
Direct lung administration of therapeutic agents to the lungs via OI therapy offers several
potential advantages, including the delivery of lower dosages compared to i.v., which will lead to
reduced systemic side effects, as well as enhancing tumor exposure by improving the retention of
the therapeutic agents.[62] Clinical trials show that anti-cancer therapeutics delivered to lung
cancer patients as aerosol before surgery appear only in trace concentrations in plasma, and that
the drug concentration can be as high as 15x in tumor compared to normal lung tissue.[63] Preclinical studies show that the relative concentration of chemotherapeutics in the lungs after
pulmonary administration can be 26 fold higher than that after i.v. administration.[64] Inhaled
DOX formulated in lipid vesicles and delivered as aerosol from nebulizers show no dose limiting
toxicity.[65] The toxicity profile of inhaled DOX in patients with metastatic lung cancer shows
pulmonary dose limiting toxicity, but no systemic toxicity.[65]

Ongoing clinical trials on

inhalation chemotherapy for the treatment of primary or metastatic lung cancer with both DOX
also demonstrate the potential of local lung delivery.[66]
1.2.2 Pulmonary extracellular barriers to delivery of therapeutics to/through the lungs
Respiratory airway consists of nose, pharynx, larynx, trachea, bronchi, bronchioles, and
alveoli sacs. Since 17th generation of bronchioles, alveoli appear in the wall of respiratory airways
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and by 20th generation the entire walls ware composed of alveoli —— alveoli ducts. The bronchi
and bronchioles narrow as the generation increases. Finally, alveoli ducts ends in blind sacs at
23rd generation.[67] As the surface area of alveoli is estimated 80-90 m2, lungs are a potentially
excellent place to deliver biopharmaceuticals for treating both local and systemic disorders.
However, some extracellular barriers restrict efficient pulmonary delivery and deposition in deep
lungs, including hyperbranched lung architecture, clearance processes (mucociliary defense) and
macrophage-mediated immune response. The deposition of inhaled particle in lungs is assessed
by aerodynamic diameter. It is defined as d a  d g 

a , where ρ is mass density of the particle,

ρa is unit density (1 g/cm3) and dg is geometric diameter.[68] The particle with da bigger than 10
µm is deposited on bronchial region away from bronchioles and alveolar area, while the particle
less than 1 µm is highly exhalable. Therefore, 1-5 µm is found optimal size for particle to reach
respiratory airways and peripheral lungs.[69] However, most of PNCs used for drug delivery is

13

Figure 1.1 Diagram of the human lungs and particle deposition
based on size.[57]
smaller than 1 µm, hence PNCs formulated into micron-sized particle is necessary for efficient
deposition on respiratory airways and entry into lungs.
The respiratory airways from nose to terminal bronchioles are covered by mucus layer
which is composed of mucin glycoproteins, cells, bacteria, lipids, salts, proteins and cell debris.[70,
71] The miscellaneous components act together to form a nanoscopically heterogeneous
environment to prevent the transport of foreign particulate across respiratory airways.[72] The
PNCs to cross mucus layer are hindered by (i) size-dependent diffusion. It is reported that average
pore size for particle penetration was to be 100 nm;[73-75] (ii) strong electrostatic interaction with
positively and negatively charged components.

Therefore, the PNCs must be shielded by

hydrophilic and neutral macromolecules; (iii) rapid mucociliary clearance. The luminal mucus
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layer of respiratory tract is renewed every 10 to 20 min, leading to efficient clearance of invading
particles.[76]
1.2.3 Pressurized metered-dose inhalers (pMDIs) as oral inhalation for pulmonary delivery
In lung cancer treatment, current route to administer DOX is i.v. injection which results in
non-specific systemic distribution. The non-specific whole body distribution lowers dose level at
pulmonary cancerous lesion, but increases side effect to normal tissues. In contrast, oral inhalation
is a promising non-invasive approach to efficiently deliver anticancer therapeutics to the lungs,
since it may retain high drug dose in pulmonary area and thus lowers side effect.[77] OI technique
can be broken into three major categories: nebulizer, pressurized metered-dose inhalers (pMDI),
and dry powder inhalers (DPI).[41, 42] Generally, nebulizers can produce small particles (2-5 µm)
that penetrate airways, deposit on deep lungs easily, and deliver large doses of aerosol with little
requirement of patient skills. Inconvenience in handling and considerable sedimentation of
particles on oral cavity, larynx, and trachea result in large waste of delivered drugs.[43] pMDIs
are a well-developed aerosol technology and widely accepted by patients due to its portability,
straightforwardness in use and enhanced lung deposition of inhaled therapeutics.

pMDIs

formulations can be divided into two types: solution formulation and suspension formulation. The
drugs completely dissolved in the propellant can be formulated into a solution formulation,[78, 79]
while the drugs practically insoluble is dispersed in the propellant to make a suspension
formulation and create a heterogeneous system.[80-82] Compared to suspension formulation, the
solution formulation of pMDIs can give rise to a homogenous formulation without shaking prior
to use, a larger fine particle dosage [83] and finer residual aerosol.[84] However, many drugs and
PNCs are not readily soluble in propellants, limiting the amount of drugs that can be used in pMDIs
formulations. Cosolvents and surfactants, such as PEG, Span 20, Tween 80 and Pluronic block
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polymer, are widely added to help increase the solubility of the insoluble drugs.[78, 85] However,
aerosol characteristics may be attenuated by the addition of surfactants and/or cosolvents as they
evaporate more slowly in atomized droplets. Therefore, the dispersion of drug crystals in
propellant and difficulties in screening of surfactants and co-solvents significantly limit the use of
pMDIs. Additionally, the transition from ozone-depleting propellant such as chlorofluorocarbon
(CFC) to more environment-friendly substitutes such as hydrofluoroalkanes (HFA) can cause
complicated issues due to the strong effect of thermodynamic properties of propellants on
solubility of drug crystal and PNCs [86].
1.2.4 Doxorubicin as leading anticancer therapeutics in lung cancer treatment
Doxorubicin (DOX) is an anticancer chemotherapeutics that was first isolated from
Streptomyces peucetius in 1967.[87] Today DOX is a leading therapeutic in clinical oncology,
having a broad range of activity against both solid and “liquid” tumors.[88] DOX is used in the
treatment of several cancers, including breast, ovarian, lung, sarcoma, acute lymphoblastic and
myeloid leukemia.[89] DOX is also used in pediatric oncology.[90, 91] Since the discovery of
DOX, thousands of other anthracyclines have been screened for their anticancer properties, but
only few have emerged as clinically relevant.[92] The lasting relevance of DOX in the fight
against malignant tumors is also demonstrated by the fact that DOX shows up in over 1,500 clinical
trials currently listed in the US NIH registry.[93] There are two proposed mechanisms in which
DOX works: (i) inhibition of topoisomerase-II-mediated DNA repair by intercalating DNA; (ii)
generation of free radicals that rupture cellular and subcellular membrane structure.[94, 95] It was
reported that the transport of DOX across cellular membrane was through simple diffusion due to
electrostatic binding to anionic phospholipid on membrane and direct insertion of hydrophobic
chromophore into lipid layer.[95-97] While nuclear DNA is the most studied DOX, DOX has also
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shown to have mitochondrial activity and this action has been shown to promote apoptosis, even
in MDR cells.[98-100] However, the entire mechanism of how DOX interacts with various
processes in the mitochondria is not yet known.[101, 102] Short term incubation of DOX with
cancerous cells brought about rapid changes in mitochondrial function including changes in
mitochondrial redox potentials towards an increased oxidative state, depolarization of the inner
mitochondrial membrane, increased matrix calcium levels, and increased mitochondrial ROS
production.[103] Long-term effects include an inhibition of respiration, ATP depletion, and
increased production of proteins association with cell cycle arrest and cell death.[103] DOX’s
ability to intercalate with DNA may affect the integrity of mitochondrial DNA, which could also
contribute to a decrease in electron transport chain complexes.
1.2.5 Polymeric nanocarriers (PNCs) for targeted intracellular DOX delivery
DOX is an anticancer therapeutics widely used in cancer chemotherapy.

DOX is

administered intravenously in the form of its hydrochloride salt. Since DOX administered via i.v
route is distributed non-specifically in the body, affecting both tumor tissues and healthy tissues.
Such non-specific distribution leads to insufficient dose in tumor and severe toxicity to normal
tissues. More importantly, the damage of DOX to heart tissue can cause life-threatening cardiac
toxicity. To improve therapeutic efficacy of DOX, several drug delivery systems based upon
polymer nanoparticles,[104-109] liposomes,[71, 109, 110] monoclonal antibodies,[111] polymer
conjugates, [34, 112-116] and polymer micelles[117] have been extensively employed. DOX is
either physically encapsulated in or covalently bound to polymeric matrices. Polymer-based DOX
delivery systems, by using both passive and active targeting strategies, can enhance extracellular
or intracellular concentration of DOX in tumor cells whereas avoiding toxicity to normal tissues.
The encapsulation of DOX into liposomes, polymer micelles and polymeric nanoparticles is an
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effective strategy to increase DOX payload, enhance cellular uptake, and improve
pharmacokinetics. The biodistrubtion of liposomal DOX and DOX-entrapped PNCs have shown

Figure 1.2 Schematic representation of intracellular release of
Polymer-DOX conjugates (e.g. polyamidoamine-PAMAM).
The conjugates are internalized by endocytosis into endosomes
and then end up in lysosomes. DOX is released from polymerDOX conjugates with pH-sensitive linkers broken as pH drops
to 5.0-4.5 in lysosomes. Released DOX subsequently moves out
of lysosome towards nucleus.
higher dose level in tumor and inhibition of tumor growth due to EPR effect [118] and specific
targeting.[119] However, they are still flawed on inconsistent drug payload, weak particle stability
and limited controllability of drug release. Therefore, an alternative strategy where DOX is
conjugated to polymer via a labile linkage has been developed. The protruding advantage of the
conjugate is to achieve reliable sustained drug release. In analogous to DOX-entrapped PNCs,
EPR effect and active targeting strategy facilitate polymer-DOX conjugates to accumulate in
tumor vasculature and are internalized to tumor cells by endocytosis (receptor-mediated,
adsorptive, and fluid phase endocytosis). Subsequently, the polymer-DOX conjugates end up in
acidic endosome (pH 6.0-5.0)/lysosome (pH 5.0-4.5) [120, 121] where DOX is released from
polymer by non-specific pH-controlled hydrolysis [23, 113, 122] or specific enzymolysis [123,
124] shown in Figure 1. Of the labile bonds, cis-aconitic spacer,[115, 125] hydrazone,[115, 126]
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and Gly-Phe-Lys-Gly peptide sequence [127, 128] have been mostly used for preparation of
polymer-DOX conjugates.[129] These linkers are sensitive to lysosomal pH or enzymes while are
maintained stable at extracellular environment. Furthermore, the polymer-DOX conjugate also
showed higher cytotoxcity against cancer cells than bare DOX in vivo experiment.[130, 131]
Therefore, the selective intracellular release of DOX can be accomplished by polymer-DOX
conjugates with pH-sensitive or enzyme-degradable linkers.
1.2.6 PEGylation of PNCs help overcome pulmonary extracellular barriers and improve
biodistribution
Apart from controlled intracellular release and effective tumor selectivity, other challenges
of PNCs-based drug delivery systems include limited hydrophilicity, short blood circulation
residence, and strong serum protein binding and particle aggregation. The modification of PNCs
with biocompatible and hydrophilic polymer is an effective strategy to solve those challenges. One
of the most widely accepted polymers for this modification is polyethylene glycol (PEG) which
has been approved by Food and Drug Administration (FDA).[132] It bears an array of attributes:
neutral molecule, very low toxicity, excellent solubility in aqueous solution, non-immunogenicity,
and no detrimental influence on protein conformation or enzymes activities.[133] PEGylation of
PNCs-DOX has been widely studied at both in vitro and in vivo level. The overall charges on
PNCs surface can be significantly masked after PEGyaltion such as PLA–PEG,[134] PAMAMPEG,[34] and polylysine-PEG nanoparticles,[52] leading to weak serum protein binding and
decreased cytotoxicity and immunogenicity. Furthermore, PEGylated PNCs showed prolonged
blood circulation residence, thus resulting in improved pharmacokinetics and less drug
administration frequency. [113, 135, 136] However, PEGylated nanocarriers are also known to be
less efficiently taken up by the cells.[137] Therefore, a balance between overall charges of PNCs,
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size of PEG chains, and PEG density must be modulated in order to maximize the potency of
anticancer therapeutics.
1.2.7 Development of in vivo lung cancer murine model
The in vivo preclinical evaluation of new chemotherapeutics for cancer therapy requires
relevant and appropriate animal models mainly including subcutaneous and orthotopic xenograft
tumor models. Each model has its advantages and disadvantages. Subcutaneous xenografts are
very convenient way to implant tumor cells, and the consequent tumors are palpable and easy to
quantify the tumor growth.

However, orthotopic xenograft models provide an accurate

representation of tumor microenvironment as cells are implanted directly into the organ in which
the disease originates. This allows for a reliable prediction of toxicity and understanding of
microenvironment-dependent responses to selected therapies, thereby leading to more reliable
translation to clinical cases.[138] The most practical orthotopic lung tumor models involves the
endobronchial inoculation of A549 and H460 cell lines into athymic NCr nu/nu mice.[139]
Despite the benefits of orthotopic models, the development of these models are quite timeconsuming and challenging as cells typically conducted endobronchially, requiring precision and
practice. Additionally, once tumors start proliferation, it is more difficult to handle and quantify
their growth than in traditional xenograft models. Besides primary lung cancers, pulmonary
metastasis model is the other widely used model for evaluating therapy in many tumors.
Essentially, all tumors upon intravenous injection can be found in the lungs and the resulting
pulmonary metastatic nodules are technically viewed as an independent primary tumor rather than
a metastasis.[140] B16 melanoma is transplantable tumor that originated from C57BL/6 mice.
The strain F10 of B16 melanoma (B16-F10) characterized by its robust ability to colonize in the
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lungs has been widely used to develop pulmonary metastasis upon intravenous injection of
melanoma cells.[141-143]

1.3 Relevance and Innovation
This work is greatly relevant and innovative in a few aspects. Since DOX is one of the most
important chemotherapy for various lung cancers, the design of advanced DOX delivery system
and its efficient delivery to lungs via OI are very attractive. This is the first time for (i) the
elucidation of systemic and local biodistribution of PAMAM dendrimers via pulmonary delivery
and effect of PEGylation on these aspects; (ii) development of a novel strategy for lung cancer
treatment, which combines pulmonary delivery with PEGylated PAMAM dendrimer with DOX
conjugated via an acid-labile linker. The developed strategy can significantly increase local dose
of DOX in the lungs, while reduce the accumulation of DOX in heart tissues; (iii) polymer
nanocarrier drug delivery system is formulated into propellant-based inhalers, forming a pseudo
solution aerosol formulation.

This research will contribute to designing novel dendrimer

therapeutics delivery system that may be employed in the treatment of lung cancer, as well as
provide a potential platform for other pulmonary disease treatment such as tuberculosis, and
asthma. Finally, the research is also valuable on subsequent formulation in inexpensive inhalation
devices.

21

CHAPTER 2 — The Effect of the Route of Administration and PEGylation
of Poly(amidoamine) Dendrimers on their Systemic and Lung Cellular
Biodistribution
2.1 Introduction
Pulmonary administration is an attractive and effective route for the non-invasive delivery
of small molecule drugs and biomacromolecules for the treatment of lung disorders such as asthma,
chronic obstructive pulmonary disease (COPD) and cystic fibrosis.[144-149] Oral inhalation (O.I.)
also has several notable advantages when compared to intravenous (I.V.) and other non-invasive
administration routes (e.g. nasal and oral) with respect to the systemic delivery of therapeutics
through the lungs that arise due to the large total surface area for drug absorption, the avoidance
of first-pass metabolism and the potentially rapid therapeutic onset.[35, 150]
In spite of the many potential advantages in the local or systemic delivery of drugs to and
through the lungs, there is a notably small number of commercial O.I. products, and only very few
classes of drugs are formulated as O.I..

Those include adrenocorticoid steroids (e.g.

beclomethasone), bronchodilators (e.g. isoproterenol, metaproterenol, albuterol), antiallergics (e.g.
cromoglicinic acid), and inhalable insulin for diabetes (Afrezza®).[151]
There are, therefore, many opportunities for further development in the pulmonary drug
delivery market. Advances in the formulation of portable aerosol systems and the ability to
develop innovative nanotechnologies capable of modulating the interaction between the
therapeutic agents and the local physiological environment [39, 51, 52, 55, 152-154] are both
expected to support and accelerate the development of O.I. formulations. New formulations have
a broad application range such as the many therapeutics that are under clinical trials for local and
systemic delivery to/through the lungs.[57, 155-159]
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Dendrimers represent a promising class of nanocarrier systems for the delivery of small
molecule therapeutics and biomacromolecules.[113, 160-163] Dendrimers are hyperbranched
polymers that are highly monodisperse and possess a high density of functionalizable surface
groups.[31, 164, 165] A particular class of dendrimers, those with a polyamidoamine (PAMAM)
architecture, has received a lot of attention in the literature, particularly those with amineterminated (NH2) surface groups. These dendrimers can be obtained and functionalized with
therapeutics and other ligands and have the ability to efficiently gain access to the intracellular
milieu.[166]

Toxicity [167] and rapid clearance [168, 169] of unmodified NH2 PAMAM

dendrimers have somewhat reduced the excitement towards these carriers. However, surface
modification of such dendrimers with polyethylene glycol (PEG), also called PEGylation, has been
shown to be one effective strategy in the development of dendrimer nanocarriers with reduced
toxicity,[167] improved pharmacokinetic (PK) profiles,[168, 169] and improved aqueous
solubility. The latter becomes a major issue upon conjugation of hydrophobic therapeutics such as
doxorubicin to such nanocarriers.[170, 171]
The tissue distribution and PK of PEGylated PAMAM dendrimers have been extensively
studied in vivo upon I.V. administration, and the results suggest significantly decreased
toxicity,[172] prolonged systemic circulation,[172, 173] and effective accumulation in target
tissues through passive [34] and active targeting strategies.[174] Meanwhile, a few studies have
focused on the systemic biodistribution of nanocarriers upon pulmonary administration,[39]
including gold nanoparticles,[51] PEGylated polylysine dendrimers,[52] PEGylated poly(ethylene
imine),[53] diethylaminopropylamine-poly (vinyl alcohol)-poly (lactide-co-glycolide) copolymer
[54] and polystyrene nanoparticles.[55] However, few attempts have been made on the systemic
distribution of PAMAM dendrimers and their PEGylated counterparts upon pulmonary
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administration. Additionally, the distribution of PAMAM dendrimers amongst different cell types
of the lung upon pulmonary administration has not been reported yet. Such results are of great
relevance for the ability to passively target various tissues by simply tuning the chemistry of the
nanocarriers. This knowledge will help guide the design of such nanocarriers for targeting
different diseases both in terms of systemic distribution and lung cellular distribution. For example,
knowledge on the distribution to lymph nodes may help us design improved vaccine delivery
systems,[175] while alveolar macrophage targeting may provide us a way to develop new
strategies for the treatment of pulmonary tuberculosis.[176, 177]
The goal of this work is to investigate the systemic and local biodistribution of amineterminated PAMAM dendrimers upon lung delivery, and the effect of PEGylation on their
distribution profile. We have selected generation 3, amine-terminated PAMAM (G3NH2) and
1000Da PEG (G3NH2-PEG1000) for this study. The pharmacokinetic parameters of the bare
dendrimer and highly PEGylated dendrimer were investigated in vivo, upon lung delivery and
benchmarked against the profiles obtained upon I.V. administration. The systemic biodistribution
was qualitatively determined by ex vivo imaging, and quantitative characterization was achieved
by tissue extraction of the dendrimer conjugates. The local distribution of dendrimer conjugates
in different pulmonary cell populations was quantified using cell tagging and flow cytometry. The
results help us understand how the chemistry of such carrier systems may be used to target different
tissues and cell populations, and thus serve as a guide for the design of new dendrimer-based
carriers for the spatially and temporally controlled delivery of a variety of therapeutics for the
treatment of lung and systemic disorders upon O.I. administration.
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2.2 Materials.
Generation 3, amine-terminated, poly(amindo amine) (PAMAM) dendrimers (G3NH2),
with 32 -NH2 surface groups and theoretical molecular weight of 6909 was purchased from
Dendritech, Inc (Midland, MI). Cyanine 3 (Cy3) NHS ester was purchased from Lumiprobe
Corporation (Hallandale Beach, FL). Polyethylene glycol 1000Da (PEG1000) succinimidyl ester
(PEG1000-SC) was purchased from NANOCS Inc (New York, NY). Paraformaldehyde solution
4% in PBS, saponin, dispase, and 10 kU heparin sodium salt from porcine intestinal mucosa were
purchased from Sigma-Aldrich (St Louis, MO). Sodium phosphate (dibasic, anhydrous) and
sodium phosphate (monobasic, monohydrate) were purchased from EMD Chemicals, Inc
(Gibbstown, NJ). Deuterium oxide (D2O, D: 99.9%) was purchased from Cambridge Isotope
Laboratories (Andover, MA). Rat anti-mouse CD16/CD32 monoclonal antibody (Fc blocker) was
provided by Thermo Fisher (Waltham, MA). PerCP-Cy5.5 labeled anti-CD45 (30-F11) and PElabeled anti-CD31 were purchased from EBioscience (San Diego, CA).

A primary anti-

prosurfactant protein C antibody (pro-SPC) (1:100) and a primary anti-tubulin antibody (1:100)
were obtained from abcam (Cambridge, United Kindom). Alexa Fluor®647 F(ab’)2 goat antimouse IgG secondary antibody (1:100) and pacific blue F(ab’)2 goat anti-mouse IgG secondary
antibody (1:100) were purchased from Life Technologies (Grand Island, NY). Falcon cell strainers
with mesh size 100 µm were obtained from Thermo Fisher Scientific (Waltham, MA). Ultrapure
deionized water (DI H2O) was obtained with the Barnstead NANOpure DIamond System (D11911)
from Thermo Fisher Scientific (Waltham, MA).

Amicon® Ultra 15 centrifugal filters

(MWCO=3kDa) were purchased from EMD Millipore (Billerica, MA).

Thin layer

chromatography (TLC) Silica gel 60 F254 plastic sheet was purchased from Merck KGaA
(Darmstadt, Germany). All reagents were used as received unless otherwise specified.
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2.3 Methods
2.3.1 Cy3 labeling of PAMAM dendrimer (G3NH2-Cy3)
G3NH2 (27.2 mg, 3.94 µmol) was dissolved in 3.0 ml phosphate buffer solution (0.2 M,
pH 8.4). A 0.5 ml dimethylsulfoxide (DMSO) of Cy3 NHS ester (7.29 mg, 12.35 µmol) was added
dropwise to the above aqueous buffer. The reaction mixture was stirred for 2h at 4oC and another
4h at room temperature.

The unreacted Cy3 was removed using centrifugal filter device

(MWCO=3kDa) until TLC showed no free Cy3 in the product. The product was lyophilized and
then stored at 4oC for further use. The resulting structure of the G3NH2-Cy3 (number of Cy3
conjugated to the dendrimer) was determined using proton nuclear magnetic resonance (1H NMR)
and mass-assisted laser desorption/ionization-time of flight (MALDI-TOF). 1H NMR (DMSO_d6,
ppm) spectra and peak assignment and MALDI spectra are provided in the Figure S1 of
Supplemental Information in Appendix 1. The ratio of Cy3 to dendrimer was also determined
using UV spectrometry. The UV spectra of Cy3-labeled dendrimer were recorded using Varian
Cary® 50 UV-Vis spectrometer (Santa Clara, CA). The concentration of Cy3 was calculated using
Beer-Lambert law A = ɛbc to quantify the ratio, where molar absorbtivity ɛ at 555 nm is 150,000
L∙mol-1∙cm-1, path length of quartz cuvette b is 1 cm, and c is concentration of sample with mol∙L1

as unit. The result was compared with the data from 1H NMR and MALDI.

2.3.2 Synthesis of PEGylated PAMAM dendrimers (G3NH2-PEG1000-Cy3)
The resulting Cy3-labeled G3NH2 (15.2 mg, 1.84 µmol) was dissolved in 3.0 ml phosphate
buffer (0.2 M pH 8.0). A 1 ml anhydrous p-dioxane of PEG1000-SC (56.2 mg, 55.2 µmol) was
added to the above aqueous buffer. The reaction was stirred for 2h at 0oC, and another 4h at room
temperature. The unreacted PEG1000 was removed using a centrifugal filter device (MWCO =
3kDa). The resulting PEGylated dendrimer (G3NH2-PEG1000-Cy3) was lyophilized and then
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stored at 4oC for further use.

1

H NMR (DMSO_d6, ppm) spectra and peak assignment, and

MALDI spectra are provided in the Supplemental Information in Appendix 1.
2.3.3 Size and Surface Charge of the Conjugates.

conjugates were measured using a Malvern NanoCS Zetasizer (Malvern Instruments;
Worcestershire, UK). The sample (1.0 mg/ml) was dissolved in DI H2O. The aqueous suspension
was equilibrated for 120 s before measurement, and the Mitoschi model was used as scattering

calculated using the built-in software.
2.3.4 Pulmonary administration of the dendrimer conjugates
Pulmonary delivery of the bare and PEGylated Cy3-labeled dendrimers was performed
using the pharyngeal aspiration (P.A.) technique.[55] Briefly, male balb/c mice (25 g, 10-12 weeks
old) were deeply anesthetized with 2.5% v/v isoflurance/oxygen and then placed on a tilted board
in a supine position. The tongue was held gently in extension while a 50 µl saline solution of
G3NH2-PEG1000-Cy3 (4.09 mg/ml) or G3NH2-Cy3 (1.03 mg/ml) conjugate – same total G3NH2
concentration - was gradually dripped in the pharynx region with a micro syringe. The tongue was
continuously held until after a few breaths. As the whole solution was administered, the mice were
left under anesthesia for 5 min and returned to the cage for monitoring of rapid recovery. The P.A.
technique has comparable effectiveness to intratracheal instillation, while less invasive, and also
allows for the delivery of high dosages.[178]
2.3.5 Pharmacokinetics (PK) of the administered dendrimer conjugates
After the administration of dendrimer conjugates, blood samples were collected at
predetermined time points (0.25, 0.5, 1, 3.25 and 6.5 h). A volume of 80 µl of blood collected
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from tail vein was mixed with 20 µl of heparin saline (10 U/ml). The mixture was centrifuged at
5000 rpm for 45 s, and the plasma obtained was pulsed into a flat bottom 96-well plate for Cy3
fluorescence determination using BioTek Synergy HT multi-code microplate reader (Winooski,
VA, US).
2.3.6 Systemic biodistribution of the administered dendrimer conjugates
The mice were sacrificed 6.5 h after the administration of the conjugates. This time point
is based on our previous experience where we measured the PK profile for G3NH2 in the same
model by using the same route.[168] The various tissues were excised and washed with saline,
including axillary lymph nodes (ALN), bronchial lymph nodes (BLN), cervical lymph nodes
(CLN), mesenteric lymph nodes (MLN), thymus, brain, heart, liver, lungs, kidneys, stomach and
spleen. The residual saline was wiped off using a filter paper, and the excised tissues were
immediately used for analysis. We bench-marked our studies by delivering the same dose of
dendrimer conjugates I.V. through the tail vein. These mice were sacrificed, harvested and
samples analyzed in the same manner as the pulmonary study groups.
2.3.7 Ex-vivo imaging of excised tissues
The excised tissues were visualized using a Carestream In Vivo Xtreme (Rochester, NY,
US) imaging system (Excitation/Emission: 555/571 nm). The exposure time was set to 30 s.
Visible light and Cy3 fluorescence images were taken and overlaid using the manufacturer's
software.
2.3.8 Quantification of dendrimer conjugates in tissues
The excised tissues were fully homogenized using a Cole-Parmer LabGEN 7 Series
Homogenizer (Vernon Hills, IL) in a 3 ml aqueous solution of 3 N sodium hydroxide (NaOH) and
the dendrimer conjugates were then extracted for 72 h at room temperature in darkness. The
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extracted dendrimer conjugates were collected by centrifugation (14,000 g, 10 min) at 4°C. The
amount of dendrimer conjugates in each tissue was quantified according to established calibration
curves in the corresponding tissue. Briefly, the tissue was spiked with a known amount of G3NH2Cy3 or G3NH2-24PEG1000-Cy3 and the extracted as described above. The fluorescence intensity
was plotted as a function of the amount of G3NH2-Cy3 or G3NH2-24PEG1000-Cy3.[179]
2.3.9 Single cell staining for pulmonary cellular biodistribution of the nanocarriers
Pulmonary myeloid cells, alveolar epithelial cells, endothelial cells and ciliated airway
epithelial cells were stained by probe-labeled antibodies and then analyzed with flow cytometry
following a reported method with modifications (See Supplemental Information in Appendix
1).[180] Briefly, the excised lungs were ground gently and incubated with dispase and DNase to
break extracellular matrix. The resulting homogenate was filtered with 100 µm nylon cell strainers.
The obtained cells were fixed with 4% paraformaldehyde solution and then incubated with 0.15%
saponin buffer for permeabilization at 4oC. Subsequently, the cells were incubated with Fc-blocker
for 20 min and then stained with the probe-labeled antibodies against CD45, CD31, pro-SPC and
β-tubulin for another 25 min at 4oC in darkness. The stained cells were analyzed with a BD
Bioscience BD LSR II Analyzer (San Jose, CA, US).

Data analysis was performed with

TREESTAR FlowJo software (Ashland, OR, US). Cells were sorted in two ways: those that
contained and those that did not contain internalized dendrimer conjugates. Secondly, from those
that contained dendrimer conjugates, the fraction of myeloid (CD45), (alveolar) epithelial (proSPC), endothelial (CD31) and ciliated (β-tubulin) cells was determined. Studies were performed
for both G3NH2-Cy3 and G3NH2-PEG1000-Cy3 conjugates, so that the effect of chemistry could
also be assessed.
2.3.10 Statistical analysis
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Graphpad Prism 5 was used to perform the statistical analysis. Data were compared using
Student’s t test. Means were considered statistically significantly different with a *p value <0.05.

2.4 Results and discussion

Figure 2.1 Schematic diagram of the synthesis of the Cy3-labled, PEGylated dendrimer
conjugates. The Cy3 terminology is dropped in the results and discussion part. For
simplicity, the conjugates are referred to G3NH2 and G3NH2-mPEG1000, where m is the
number of PEG 1000Da graft moieties – the number of Cy3 is the same for all conjugates.
r.t. = room temperature
2.4.1 Synthesis of PEGylated dendrimer conjugates
Table 2.1 Characterization of the Cy3-labeled, PEGylated dendrimer conjugates (G3NH2 and
G3NH2-24PEG1000). Molecular weight (MW), number of PEG grafts (m), size
(hydrodynamic diameter, HD), and zeta potential (ζ) as determined by MALDI, 1H NMR, UV
spectrometry and light scattering (LS).

Compound

MW

m

n
HD±s.d (nm)

ζ±s.d (mV)

0

+3.8±1.3

+18.8±5.0

3.3

2.8

+5.1±1.4

+24.5±6.9

3.3

2.8

+9.9±3.6

-3.7±5.0

(Da)

MALDI

NMR

MALDI NMR

G3NH2 (as received)

6900

0

0

0

0

G3NH2

8285

0

0

3.1

G3NH2-24PEG1000

33312

24.5

23.9

3.1

UV
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Both Cy3 labeling and PEGylation were performed using a primary amine/NHS ester
chemistry, resulting in the formation of an alkyl amide bond in each case, which is a bond known
to be stable under both in vitro and in vivo conditions.[181] The synthetic route is shown in Figure
2.1. The first step in the preparation of the conjugates was to label G3NH2 with Cy3 before
PEGylation to guarantee the same number of Cy3 molecules on both the non-PEGylated and
PEGylated dendrimers. The 1H NMR with peak assignments and the MALDI spectra are shown
in the Supporting Information in Appendix 1. The NMR peaks at 7.614-7.163 ppm, 6.476 ppm,
1.509 ppm, and 1.353 ppm indicate successful conjugation of Cy3 to G3NH2. Similarly, the
molecular weight shift in MALDI from 6900 Da to 8285 Da after Cy3 tagging, also confirm the
successful conjugation of Cy3. The UV spectrometry is also used to quantify the ratio of
conjugated Cy3 to dendrimer due to the Cy3 absorption at 555 nm. As shown in Table 2.1, an
average of ca. 3 Cy3 molecules was conjugated per dendrimer as determined (in close agreement)
by 1H NMR (3.3), MALDI (3.1) and UV spectrometry (2.8).
Subsequently, dendrimers with a high PEG density were prepared by reacting G3NH2-Cy3
with PEG1000 succinimidyl ester. The 1H NMR peak at 4.02 ppm revealed the successful
conjugation of PEG1000 to dendrimer-Cy3 with an amide bond. 1H NMR and MALDI were also
used for quantification of PEG1000 density, revealing an average of 23.9 and 24.6
PEG1000/dendrimer, respectively.
The size and surface charge of bare dendrimer and PEGylated dendrimer conjugates were
determined by light scattering (LS). Compared to the bare dendrimer, the size of G3NH2-Cy3
increased only slightly to 5.1 nm, while at high PEG density the HD of the dendrimer increased
dramatically, to nearly 10 nm. This increase may be attributed to the stretching of the densely
packed layer of PEG1000.[182] The surface charge of G3NH2-3Cy3 was seen to be even more
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cationic than the bare dendrimer due to the introduction of tertiary amines of Cy3, which have a
stronger electron donating capacity. Even though a primary amine from the dendrimer was used
up in the conjugation of each Cy3 molecule, two tertiary amines were brought into the conjugate
per Cy3. In contrast, the surface charge of the dendrimer was reversed upon PEGylation, resulting
good agreement with a
previous report.[168] These two carriers are thus different in two very important ways: their
surface charge (one is positive and the other negative/neutral) and their size (PEGylated dendrimer
is twice as big as non-PEGylated). The PEGylation of the nanocarriers is expected to prolong their
residence in systemic circulation and reduce nanocarrier toxicity.[168, 169, 183] The surface
charge of the conjugates and their size is also expected to impact their transport across the
extracellular/apical barriers of the lung tissue,[39, 41, 168, 184] whose gap junctions are in the
order of 3 nm.[185, 186]
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Figure 2.2 Plasma concentration (Cp) as a function of time after administration of
G3NH2 and G3NH2-24PEG1000 via (a) pharyngeal aspiration (P.A.) and (b)
intravenous injection (I.V.) (n=3 per group). The statistical analysis was performed
between G3NH2 and G3NH2-24PEG1000 with Student’s t-test (*p < 0.05, **p < 0.01,
and ***p < 0.001).
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For simplicity, in the following discussion “Cy3” will no longer be mentioned when
describing the conjugate structures – the conjugates will be referred to simply as G3NH2 or
G3NH2-PEG1000.
2.4.2 Plasma concentration profiles of dendrimer conjugates administered via pulmonary
and I.V. routes.
The plasma concentration-time profiles of the bare dendrimer (G3NH2) and highly
PEGylated dendrimer (G3NH2-PEG1000) following pulmonary (P.A.) and intra-venous (I.V.)
administration are summarized in Figure 2.2.
The plasma concentration of dendrimer conjugates delivered via the pulmonary route
(Figure 2.2a) is seen to increase soon after administration. For G3NH2-24PEG1000, it levels off
at 3.25 h post administration (plasma concentration not statistically different at 3.25 h and 6.5 h),
while for G3NH2, a peak is reached at 3.25 h (plasma concentration at 6.5h significantly lower
than at 3.25 h). The plasma concentration of the PEGylated dendrimer was 6-fold higher than that
of the bare dendrimer (peak concentration: 0.6±0.2 µg/ml vs 3.8±0.4 µg/ml or 2.1±0.6% vs
13.2±1.7% of overall dose). The plasma concentration of the G3NH2 conjugates administered I.V.
decreased quickly, reaching 1.1±0.3 µg/ml (3.8% of overall dose) at 6.5 h post administration as
can be seen in Figure 2.2b. However, the plasma concentration of the highly PEGylated dendrimer
G3NH2-24PEG1000 decreased only slightly within the same time remaining at 76% of the
delivered dose. At 6.5 h the plasma concentration of the PEGylated dendrimer is 19.5-fold higher
than that of bare dendrimer (21.6±1.5 µg/ml vs 1.1±0.3 µg/ml). A similar plasma concentrationtime profile was also found for PEGylated polylysine dendrimers of 11kDa, 22kDa and 78kDa,
upon delivered to the lungs via intratracheal instillation.[52]
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The effect of PEGylation on plasma concentration is in line with previous results for
PAMAM dendrimers and other polymeric nanoparticles.[34, 173, 187] The plasma concentration
and in vivo biodistribution of the dendrimer conjugates is mainly affected by its absorption,
distribution, metabolism and elimination.[169] Surface charge, size and surface functionality of
the dendrimer conjugates determine their interaction with serum proteins and blood cells, uptake
into target and non-target organs, and potential routes of elimination. It has been demonstrated
that PEGylation can neutralize surface charge of cationic polymers [125, 174] and reduce the
binding affinity of proteins to nanocarriers,[188-191] which attenuates plasma protein adsorption,
opsonization, phagocytosis and stimulation of immune cells.[30, 172, 191, 192] Therefore, the
blood circulatory residence of PEGylated dendrimers was significantly prolonged.
In contrast to I.V. administration, dendrimer conjugates administered via pulmonary route
need to cross several extracellular barriers to enter the local/systemic blood circulation. These
extracellular barriers include the fast-renewing mucus gel layer and ciliated epithelial cells on the
airways, resident alveolar macrophages, lung surfactant and the alveolar epithelial cells in the deep
lungs.

The significantly different plasma concentration profiles for G3NH2 and G3NH2-

24PEG1000 suggest that their charge and/or size have a significant impact on how they interact
with the extracellular barriers before they reach systemic circulation.

We have previously

observed that even though dendrimers are much smaller than the mucus mesh size (ca. 100 nm),[72]
they may be retained in the mucus layer depending on their charge. Cationic dendrimers interact
with the mucus environment much more strongly, and thus take longer to traverse the mucus layer
compared to neutral/negatively charged PEGylated dendrimers.[72, 168] The increase in size of
the PEGylated conjugates may in principle also have an effect as the tight junctions of the epithelial
barriers strongly modulate the transport of molecules as a function of time – for example,
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macromolecular therapeutics with sizes < 40-50kDa (HD: 5-6 nm nm) are known to be peak in
systemic circulation in a matter of minutes,[179] while those larger molecules peak in systemic
circulation upon lung delivery over periods of hours, days, or weeks.[67] However, in vitro results
show that even highly PEGylated dendrimers can interact with the tight junctions of the pulmonary
epithelium, and thus modulate their way across, reducing the impact of their size,[168] at least
within the size range being investigated and discussed here.
The impact of the dendrimer size can perhaps more strongly affect the route of elimination
upon reaching systemic circulation. The HD of the non-PEGylated dendrimer (5.1 ± 1.4 nm) is
smaller than the size limit (ca. 6 nm) in which nanoparticles are quickly eliminated from blood
circulation, and it can thus be eliminated by the kidneys (glomerular filtration),[193] while those
nanocarriers larger than 6 nm, as for example G3NH2-24PEG1000 (HD = 10.9±3.6 nm), cannot
be eliminated by kidneys, but accumulate in liver and spleen through the mononuclear phagocyte
system (MPS), which is a relatively slow process.[49, 194] However, the hydrophilicity imparted
by the PEGylation reduces or delays MPS processing [190, 195] and prolongs systemic
circulation.[168] Thus, once the dendrimers are absorbed systemically, the PEGylation prevents
glomerular filtration (due to their size) and also reduces MPS processing (due to their
hydrophilicity).
2.4.3 Systemic biodistribution of the dendrimer conjugates delivered via the pulmonary
and intra-venous (I.V.) routes.
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The effect of the administration route and PEGylation on the systemic distribution of
dendrimer conjugates was investigated in this work. Mice were sacrificed 6.5 h after P.A. or I.V.
administration, and the major organs were excised, including lymph nodes, thymus, heart, lungs,
stomach, spleen, liver and kidneys.
ALN BLN

CLN

Ex vivo imaging was used to qualitatively assess the

MLN Thymus Lungs Heart Spleen Stomach Brain Kidneys Liver

Blank

G3NH2
(I.V.)
G3NH2-24PEG1000
(I.V.)

G3NH2
(P.A.)
G3NH2-24PEG1000
(P.A.)

Figure 2.3 Ex vivo biodistribution of G3NH2 and G3NH2-24PEG1000
delivered via pharyngeal aspiration (P.A.) or I.V., determined 6.5 h after
administration (n=3 per group). ALN: axillary lymph nodes; BLN:
bronchial lymph nodes; CLN: cervical lymph nodes; MLN: mesenteric
lymph nodes. The tissues that are enlarged for better visualization in the
figure are ALN, BLN, CLN and MLN. Liver is shrunk instead for better
visualization. The inset is the scale bar of fluorescne intensity.

biodistribution of the dendrimer conjugates in these tissues. The results, using representative
tissues, are summarized in Figure 2.3.
Quantitative assessment of the concentration of the conjugates was performed by
fluorescence spectroscopy by recovering the tagged dendrimers from the various tissues as
discussed in Materials and Methods. The results, in terms of % of (total) Dose, as a function of
route of administration and conjugate chemistry are summarized Figure 2.4. The results are also
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summarized in terms of the mass dendrimer / mass tissue – they are shown in Figure S4 Supplemental Information in Appendix 1.
The results demonstrate that administration route (compare Figure 2.4a and 2.4b) and
chemistry of the conjugates (comparing G3NH2 and G3NH2-24PEG1000 in Figure 2.4a and
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conjugate chemistry, however, is observed to be much less pronounced following I.V. delivery
when compared to P.A. administration. It can also be observed that the amount of conjugate found
in the lungs is much higher when they are administered via. P.A. than compared to I.V. delivery,
as expected. While 83.4±7.3% of the injected dose for G3NH2 and 67.7±7.4% of injected dose
for G3NH2-24PEG1000 are present in the lungs 6.5 h hours post P.A. administration, only 1.6 ±
0.5 % G3NH2 and 0.9 ± 0.4 % G3NH2-24PEG1000 can be found in the lungs at the same time
when administered I.V. The lung retention upon P.A. delivery is also impacted by the chemistry
of the nanocarriers. The positively charged G3NH2 is retained longer in the lungs, while the
PEGylated dendrimer translocates to systemic circulation and leaves the lungs to a higher extent.
These results suggest the potential of the dendrimer nanocarriers for the targeting of lung diseases
when combined with oral inhalation formulations as the chemistry of the conjugates can be used
to modulate the transport of therapeutics across the pulmonary epithelium. The potential in using
such nanocarrier systems is supported by our recent results where we demonstrate that dendrimer
nanocarriers can be formulated in portable oral inhalation devices,[184] and those can be used for
the delivery of small molecules [146, 184] or biomacromolecules such as nucleic acids.[144, 163]
We also observed that the dendrimers administered via P.A. show up in significant
quantities in the lymph nodes (LN), while no accumulation is observed upon I.V. administration.
In fact, on a mass/tissue basis (Figure S4), the mass of conjugates found in the LN upon P.A. is
second only to the lungs. It can also be observed that the chemistry of the conjugates plays a major
role in terms of their biodistribution to the LNs upon P.A. delivery. The PEGylated dendrimer
appears in significantly greater concentrations in the bronchial lymph nodes (BLN) and cervical
lymph nodes (CLN), and in the thymus as well compared to the non-PEGylated conjugates.
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Charge effects on biodistribution have been reported for solid nanoparticles.[39, 194]
Neutral (polystyrene-polyacrylate) and hydrophilic (PEG20kDa) organic nanoparticles smaller
than 38 nm and with PEG ligands were rapidly translocated to mediastinal lymph nodes, while
anionic and cationic charged nanoparticles readily adsorbed on endogeneous protein in the lungs.
When polystyrene nanoparticles ranging from 50 to 900 nm are administered to the lungs, the
highest nanoparticle deposition (35 – 50% of extrapulmonary distribution) was also detected in
the lymph nodes 3 h after pulmonary administration.[55]
These results point to a strategy for passively targeting the lymph nodes with dendrimers
upon delivery via P.A., which may prove relevant for the development of various dendrimer-based
therapies, including pulmonary vaccination (e.g. influenza,[196] tuberculosis,[145] HPV
infection[197]) and diseases of the lymphatic system such as metastasis (e.g. breast cancers [198]).
No obvious fluorescence was found in the major organs responsible for elimination of the
dendrimers such as liver, spleen and kidneys at 6.5 h post administration when the conjugates were
delivered via P.A.. In contrast, significant quantities of the conjugates are detected in liver, spleen
and kidneys when the conjugates were administered intravenously.

In that case, greater

concentrations of the non-PEGylated dendrimers are cleared/found in the kidneys (32.8±8.8%),
spleen (5.3±2.5%) and liver (7.0±3.7%) when compared to the than PEGylated conjugates (2.7±1.2%
in kidneys, 2.9±1.7% in liver, and 2.7±1.6% in spleen). These results are in excellent agreement
with the PK results discussed above. In fact, the accumulation of bare dendrimer in the kidneys
may be underestimated to some extent since previous studies showed PAMAM dendrimers can be
detected in urine 2 h after I.V. injection.[199] The distribution of dendrimer in both kidneys and
liver/spleen revealed renal excretion and MPS are able to play roles in dendrimer elimination.
Noticeably, the kidneys showed the greatest fluorescence in the case of bare dendrimer,
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demonstrating that the bare dendrimer was mainly eliminated renally due to its small size (5.1
nm).[49] However, the PEGylated conjugates show no preferable accumulation site at 6.5 h.
2.4.4 Lung cellular biodistribution of the dendrimer conjugates administered via
pulmonary route.
The internalization of the dendrimer conjugates in selected lung cell types upon P.A. was
also assessed. Four typical pulmonary cell populations were selected to be tagged during the flow
cytometry experiments, namely myeloid, endothelial, alveolar epithelial and airway ciliated
epithelial cells. The characteristic receptors of these cells are CD45 on myeloid cells, CD31 on
endothelial cells, lung pro-surfactant protein C (pro-SPC) on alveolar epithelial type II cells, and
cilia layer on apical side of airway epithelial cells. Cilium is a microtubule-based cytoskeleton
that is constructed by β-tubulin in combination with α-tubulin.

Therefore, ciliated airway

epithelium has much higher levels of β-tubulin than other cells do. The flow cytometry results are
summarized in Figure 2.5 – representative dot plots are shown in the Supplemental Information
in Appendix 1– Figure S3.
The flow cytometry results (inset in Figure 2.5) indicate that G3NH2 is found internalized
in 32.8±3.6% of the pulmonary cells upon P.A. delivery, while the % of the cells that had
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internalized G3NH2-24PEG1000 was 27.9±2.7%. While no statistically significant difference was
found when comparing the average for both groups, a lower percentage of internalization of the
PEGylated dendrimer would be in agreement with the fact that PEGylation has been shown to
decrease the rate and extent of internalization within this time frame - as shown in vitro,[168, 183].
This observed trend also confirms that the PEGylated dendrimers seem to be transported into
systemic circulation faster (PK results) and are found at a lower concentration in the lungs
(biodistribution results).
Myeloid cells, including monocytes, granulocytes, dendritic cells and macrophages, were
observed to internalize the largest fraction of dendrimers when compared to all other cells. While
the specific cell subpopulation was not determined, these results suggest that such dendrimer
conjugates would be able to target cells that are relevant in the treatment of medically important
diseases such as tuberculosis,[145] and in vaccine delivery applications.[196] It is also observed
that the cell populations interact differently with the different chemistries. For example, while
37.2% of the cells that internalized G3NH2 were myeloid type, the preference of myeloid cells
was lower towards G3NH2-24PEG1000. As a matter of fact, the percentage of all cells (based on
cell type) that had internalized G3NH2-24PEG1000 was lower than the percentage of cells that
internalized G3NH2. This was not true for endothelial cells, where 20.4% contained G3NH224PEG1000, compared to only 6.0% for G3NH2. These results support the view that the
PEGylated dendrimers can more efficiently transport across the epithelial barrier of the pulmonary
epithelium, and gain access to the endothelial layer, where they are internalized, while at the same
being able to evade internalization by myeloid cells.
In addition, the dendrimer nanocarriers can be also significantly internalized by alveolar
epithelial cells (G3NH2 vs. G3NH2-24PEG1000 = 22.9±3.7% vs. 16.1±4.5% of those cells
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internalizing dendrimer nanocarriers) and ciliated airway epithelium (G3NH2 vs. G3NH224PEG1000 = 12.4±4.2% vs. 8.3±1.8% of those that internalized dendrimer). These results show
that highly positively charged bare dendrimers are entrapped by or interacts with the epithelial
layer to a larger extent than their PEGylated counterparts. The internalization of dendrimer
nanocarriers by alveolar/airways epithelial cells implies its potential for drug delivery to the
diseases that cause acute/chronic dysfunctional respiratory tract and lungs such as pneumonia
(usually in alveolar sacs), and asthma (airways and lungs).
Combined, the biodistribution, PK and lung cellular distribution results shown here provide
us with clues that can help formulate a reasonable hypothesis as to why the dendrimer conjugates
are so effectively drained into the lymph nodes upon P.A. While big particles (> 500 nm) require
the activation of antigen-presenting cells (e.g. dendritic cells, B cells) to be trafficked to lymph
nodes,[55] dendrimer nanocarriers with hydrodynamic diameters < 10 nm tend to rapidly
translocate across pulmonary epithelium from airway/alveolar luminal surface to septal
interstitium, followed by rapid accumulation to lymph nodes. This step doesn’t need to activate
antigen-presenting cells (APCs). It is believed that the passive pathway may play a major role in
targeting dendrimer nanocarriers to lymph nodes.[200] Although APCs would rather phagocytize
large particles than small ones, the abundance of APCs in the respiratory tract and lungs can also
effectively take up smaller carriers such as dendrimers. The macrophages and dendritic cells
activated by the phagocytosis of dendrimer nanocarriers migrate via lymph flow to
tracheabronchial and bronchiolar lymph nodes including bronchial-associated lymphatic tissue
(BALT), and are eventually carried into draining lymph nodes.[152, 201, 202] In addition, the
routing of dendrimer nanocarriers to lymph nodes is dictated by their surface chemistry.

2.5 Conclusions
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In this work we investigated the effect of the surface chemistry (PEGylated vs. nonPEGylated) and the route of administration (pulmonary delivery vs. intravenous injection) on the
systemic tissue biodistribution and local (lung) cellular distribution of G3NH2 dendrimers. The
results show that both have a strong impact on how the dendrimers interact with the physiological
environment. Biodistribution results show much greater accumulation of dendrimer nanocarriers
in lungs and a variety of lymph nodes upon pulmonary delivery, for both PEGylated and nonPEGylated dendrimers when compared to I.V. administration. PEGylation is seen to further
promote the passive targeting of dendrimers to lymph nodes upon pulmonary administration.
Upon systemic delivery, PEGylation was seen to increase circulation times, as expected, with very
little lung or lymph node accumulation.

PEGylation also helps modulated the uptake of

dendrimers by different lung cell populations. The results shown here suggest that both the
pulmonary route of administration and dendrimer chemistry combined can be used to passively
target tissues of great interest, and can thus be used as guiding principles in the development of
dendrimer-based drug delivery strategies for medically relevant diseases including lung ailments,
pulmonary vaccination, and malignant metastases among others.
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cytometry histograms of selected cell populations are also included. These information can be
found Appendix A.
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CHAPTER 3 — Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In
vitro characteristics and Pseudo-Solution Formulation in Pressurized MeteredDose Inhalers
3.1 Introduction
Cancer is the second most common cause of death in the United States.[2, 203] An
estimated 1.7 million new cases are diagnosed yearly, with ca. 600 thousand cancer deaths.[204]
Among the many types of malignant tumors, lung cancers are of great relevance as they are the
leading cause of cancer death among both men and women.[1, 205] More people die of lung
cancer than colorectal, breast, pancreatic, and prostate cancers combined.[2]
Chemotherapy is widely used in the fight against primary lung cancers and lung
metastasis.[6, 44-46] However, there are several limitations in using chemotherapeutics to treat
lung cancers. One major challenge is the low chemotherapeutic concentration found in the lung
tumor upon intravenous (i.v.) administration.[6, 7] It is estimated that only a few percent (ca. 24%) of the total dose administered i.v. reaches the lung tumor.[8] Dose limiting toxicity is another
major issue in the chemotherapeutic treatment of lung cancers.[9] This problem is compounded
as high i.v. dosages are usually required due to the poor distribution profile of
chemotherapeutics.[8]
Doxorubicin (DOX) is a leading therapeutic in clinical oncology, having a broad range of
activity against both “liquid” and solid tumors,[88] including lung cancers.[6, 57, 206] Since the
discovery of DOX, thousands of other anthracyclines have been screened for their anticancer
properties, but only few have emerged as clinically relevant.[92]

In spite of its immense

acceptability, however, DOX causes a series of side effects, of particularly relevance being its
toxicity to the cardiac tissue.[207-209]

While DOX-induced cardiomyopathy is clinically

manageable, it is associated with 50% mortality in those patients that develop congestive heart
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failure during treatment,[210, 211] thus limiting the range of applicability of this powerful
therapeutic. The ability to efficiently deliver DOX locally to the lungs, and to improve DOX’s
biodistribution by minimizing its concentration in the cardiac tissue may, therefore, represent an
important step forward in the use of such a relevant anti-cancer therapeutic in the treatment of lung
cancers.
Nanocarriers have the potential to improve the biodistribution and pharmacokinetic
profiles of various therapeutics including anti-cancer drugs.[47-50] Dendrimers are particularly
relevant nanocarrier systems as they are highly monodisperse,[31] have a large number of surface
groups amenable to the conjugation of therapeutic molecules and also other agents and ligands that
allow for the enhancement of the properties of the nanocarriers such as increased aqueous
solubility upon conjugation of hydrophobic therapeutics[30] (as is the case for DOX), and
enhanced pharmacokinetic and biodistribution profiles,[169] as well as the tagging of imaging
agents for theranostics,[199, 212] among others. Particularly relevant to this work is the fact that
we have also recently shown that the chemistry of generation 3, amine-terminated PAMAM
dendrimers (G3NH2) can be used to modulate their interaction with the pulmonary epithelium both
in vitro and in vivo,[168] and can thus be potentially used to improve therapeutic outcomes of
DOX.
Based on the challenges and opportunities discussed above, the goal of this work was to
evaluate the interaction of PAMAM dendrimer-DOX conjugates with an in vitro lung cancer
model, and to develop portable oral inhalation (OI) formulations for the local delivery of the DOX
conjugates to the lungs. More specifically, we propose to synthesize and characterize G3NH2DOX conjugates with an intracellular degradable linker and varying densities of PEG 1000Da, and
to evaluate the kinetics of cellular internalization, intracellular DOX release and organelle
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colocalization, and cell kill on A549 cells – a model of the alveolar epithelial human
adenocarcinoma. Moreover, we also propose to develop HFA-based pMDI formulations of the
G3NH2-DOX conjugates with aerosol characteristics conducive to deep lung deposition of DOX.

3.2 Materials
Generation 3, amine-terminated, poly(amido amine) (PAMAM) dendrimer (G3NH2, 32 NH2 surface groups, theoretical molecular weight = 6909) was purchased from Dendritech, Inc
(Miland, MI, USA). PEG1000Da succinimidyl ester (PEG1K-SE) was purchased from NANOCS
Inc (New York, NY, USA). Doxorubicin hydrochloride salt (DOX) was purchased from LC
Laboratories (Woburn, MA, USA). Cis-aconityl anhydride, succinic anhydride, triethylamine
(TEA), 2, 5-dihydoxybenzoic acid (2, 5-DHB), ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) and N-hydroxylsuccinimide (NHS) were purchased from Sigma-Aldrich (St Louis, MO,
USA). 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) was purchased
from Life Technologies (Grand Island, NY, USA). Deuterated dimethylsulfoxide (DMSO_d6)
was purchased from Cambridge Isotope Laboratories (Andover, MA, USA). Ultrapure deionized
water (DI H2O, Ω=18.0-18.2) was sourced from a Barnstead NANOpure DIamond System
(D11911), equipment purchased from Thermo Fisher Scientific (Waltham, MA, USA).
1,1,1,2,3,3,3-heptafluoropropane (HFA227) with trade name Dupont™ FM-200® and 2H, 3H
perfluoropentane (HPFP) with trade name Vertrel™ XF were purchased from Dupont
(Wilmington, DE, USA). A549 human lung cancer cell line was purchased from American Type
Culture Collection (Manassas, VA, USA). Spectra®Por dialysis membrane (MWCO = 3000Da)
was purchased from Spectrum Laboratories, Inc (Rancho Dominguez, CA, USA). Amicon® Ultra
15 centrifugal filter device (MWCO = 3000Da) was purchased from EMD Millipore (Billerica,
MA, USA). Thin layer chromatography (TLC) Silica gel 60 F254 plastic sheet was purchased from
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Merck KGaA (Darmstadt, Germany).

All reagents were used as received unless specified

elsewhere.

3.3 Methods
3.3.1 Synthesis and characterization of acid-labile, PEGylated PAMAM-DOX conjugates
(G3NH2-mPEG-nDOX).
As shown in Figure 1, DOX was reacted with cis-aconityl anhydride in basic aqueous
solution to obtain cis-aconityl DOX. Acid-labile, PEGylated conjugates were synthesized via two
different routes: Direct PEGylation or Two-step PEGylation. In the Direct PEGylation approach,
cis-aconityl DOX was first conjugated to G3NH2 using EDC/NHS chemistry.

PEG was

subsequently conjugated to G3NH2-nDOX to obtain the final product G3NH2-mPEG-nDOX.
Various PEG densities (m = 0, 9 and 21) were achieved by reacting different ratios of PEG-SE to
G3NH2-nDOX. The Two-step PEGylation strategy was required in order to achieve higher
payloads of DOX (in this particular case for n = 7), as G3NH2-nDOX becomes too hydrophobic
and crashes out of solution for n > 3. In the Two-step PEGylation strategy, G3NH2 is first prePEGylated at a low/medium PEG density. Cis-aconityl DOX is subsequently conjugated (to a
high/desired payload) to the pre-PEGylated dendrimer using EDC/NHS chemistry. Finally,
additional PEG is conjugated onto the pre-PEGylated dendrimer-DOX conjugates, so as to achieve
the desired/final PEG density. Proton nuclear magnetic resonance (1H NMR) was recorded using
Mercury 400 spectrometer (Agilent Technologies, Inc. Santa Clara, CA, USA). The molecular
weight (MW) of the various intermediates and final products was determined by electrospray
ionization (ESI) mass spectrometry using a ZQ-Waters TERS/Micromass spectrometer (Waters
Corporation. Milford, MA, USA) and matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) using a Bruker Daltonics UltrafleXtreme mass spectrometer (Bruker Corporation.
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Billerica, MA, USA). Hydrodynamic diameter (HD) and zeta potential (ζ) were determined using
Zetasizer Nano ZS (Malvern Instruments Ltd. Malvern, Worcestershire, UK). Solvated diameter
(SD) was also determined using the Zetasizer Nano ZS, but in that case in HPFP (non-aqueous
solvent). Detailed procedures for these measurements are described in Supplemental Information
S1, and all synthetic details of the conjugates are also described in Supplemental Information S2
in Appendix 2.
3.3.2 Synthesis and characterization of non-labile, PEGylated PAMAM-DOX conjugates
(G3NH2-mPEG-nDOXNL).
The non-labile G3NH2-mPEG-nDOXNL conjugates were synthesized via the same
strategy—direct PEGylation and two-step PEGylation—as described in Section 3.1. The only one
difference is that DOX was first reacted with succinic anhydride in non-aqueous solution.
3.3.3 Culture of A549 Cells.
Human lung alveolar adenocarcinoma epithelia cells (A549), passages 10 to 15, were
plated in 75 cm2 cell culture flask at a density of 104 cells/mL, and cultured with Dulbecco’s
Modified Eagle’s Medium (DMEM, Life Technologies) supplemented with 10% Fetal Bovine
Serum (FBS, Atlanta Biologicals) and penicillin (100 U/ml)-streptomycin (100 µg/ml) (Pen-Strep.
Life Technologies). The cells were grown in Thermo Scientific™ CO2 incubator (Thermo Fisher
Scientific) at 37 oC and 5% CO2. The medium was exchanged every two days and the cells were
split when they reached ca. 80% confluence.
3.3.4 In vitro release of acid-labile G3NH2-mPEG-nDOX and acid-non-labile G3NH2mPEG-nDOXNL conjugates.
In vitro release was determined at both pH 7.4 and 4.5, representing the extracellular physiological
pH and the lysosomal pH, respectively. A 2 mL of phosphate buffer saline (PBS, 1X, pH 7.4) or
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citrate buffer (0.01 M, pH 4.5) containing free DOX or the conjugates (all with 0.38 µmol DOX
or equiv.) was added to a dialysis membrane (MWCO = 3000Da), and the system immersed in 30
mL PBS or citrate buffer. The in vitro release studies were performed in MaxQ thermostatic water
bath shaker (Thermo Fisher Scientific), preset to 37.0 ± 0.2 °C. A 0.1 mL solution from outside
the dialysis bag was sampled at predetermined time points, and the concentration of DOX
determined using a Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek Instruments, Inc.
Winnooski, VT, USA), at 490 nm. The samples were returned after each time point. These
experiments were run in triplicate. The cumulative release of DOX from G3NH2-mPEG-nDOX
and G3NH2-mPEG-nDOXNL was plotted as a function of time.
3.3.5 Cell kill of acid-labile G3NH2-mPEG-nDOX and acid-non-labile G3NH2-mPEGnDOXNL conjugates.
The ability of DOX, G3NH2-mPEG, G3NH2-mPEG-nDOX, and G3NH2-mPEG-nDOXNL
conjugates to kill A549 lung cancer cells was assessed using the MTT assay. A series of
concentrations were sterilized by filtering sample-laden DMEM (no phenol red) through 0.22 µm
sterile syringe filter (VWR Internationals. Radnor, PA, USA).

1×104 cells/well (n=8 per

concentration) were seeded in tissue culture treated 96-well plate (VWR Internationals) with
DMEM (no phenol red). The medium was removed after 24 h, and 100 µL of the sample-laden
DMEM (no phenol red) was pulsed to each well. The samples were incubated with cells for 72 h
or 144 h. The sample-laden medium was then removed from each well. The cells were washed
with PBS (1X, pH 7.4) twice. 100 µL of fresh DMEM (no phenol red) and 10 µL of MTT PBS
solution (5 mg/ml) were added to each well. After 4 h (37 oC, 5% CO2), 75 µL of medium was
removed, and 60 µL DMSO was added into each well to dissolve formazan crystal. The cells were
allowed to sit in the incubator (37 oC, 5% CO2) for another 2 h. Finally, the absorbance of each
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well was recorded at 540 nm using Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek
Instruments, Inc).
3.3.6 Cellular internalization of acid-labile G3NH2-mPEG-nDOX conjugates by A549 cells.
3×105 A549 cells/well were seeded in 24-well plates 24 h before the experiment. A 0.5 mL sterile
Hanks Balanced Salt Solution (HBSS, 1X, pH 7.4) of free DOX or G3NH2-mPEG-nDOX
conjugates (0.1 µM DOX equivalent) was added to each well and then incubated with cells for
different lengths of time (0.5, 1, 1.5, 2, 3, 4 and 5 h. n=3 per time point). The cellular
internalization was ceased at each time point by replacing sample-laden HBSS with cold blank
HBSS. The cells were detached with 0.2 mL 0.25% trypsin-0.53 mM EDTA solution (Life
Technologies). The detached cells were pelletized by centrifugation at 350 g. The cell pellet was
resuspended in 0.5 mL blank HBSS (4 oC) and immediately analyzed for DOX fluorescence using
flow cytometry (BD LSR II Analyzer, BD Bioscience. San Jose, CA, USA). At least 10,000 events
were counted for statistical significance. Median fluorescence intensity (MFI) was plotted as a
function of time to evaluate the effect of dendrimer chemistry (PEG density and DOX payload) on
cellular internalization.
3.3.7 Intracellular release and nuclear colocalization of DOX from acid-labile G3NH2mPEG-nDOX conjugates.
2×105 cells were seeded on a cover slide, which was placed in a 24-well plate. After 24 h, a 0.5
mL DMEM (no phenol red) solution of the acid-labile G3NH2-mPEG-nDOX conjugates (4 µM
DOX equivalent) was incubated with the cells for 48 h. The sample-containing medium was then
thoroughly removed by washing the cells with PBS (1X, pH 7.4) three times. Nuclei were then
stained with Hoechst 33342 (Life Technologies) for 10 min and excess dye was thoroughly washed
away with PBS three times. The cells were fixed with 4% paraformaldehyde PBS solution (Sigma-
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Aldrich) at 4 °C for 20 min and then mounted for imaging. The fixed cells were imaged with Zeiss
LSM 780 Confocal Laser Scanning Microscope (Carl Zeiss Microscopy. Oberkrochen, Germany).
To evaluate the intracellular release of DOX from acid-labile G3NH2-mPEG-nDOX conjugates as
a function of time (and the free DOX control), the DOX or conjugate-laden medium was incubated
with cells for different lengths of time (24, 48, 96 and 144 h, with n=3 per time point). The
Pearson’s correlation coefficient (PCC) was calculated as a function of time using the Leica LAS
AF Lite software (Leica Microsystems. Buffalo Grove, IL, USA). The results were compared with
free DOX.

Colocalization of the non-labile conjugates was also qualitatively assessed by

rendering the 3D confocal images of A549 cell incubated with the G3NH2-mPEG-nDOXNL
conjugates, and stained with nuclear stain.
3.3.8 Preparation and characterization of the pMDI formulations
3.3.8.1 Physical stability of acid-labile G3NH2-mPEG-nDOX conjugate formulation in
HFA227 propellant.
A predetermined amount of G3NH2-mPEG-nDOX conjugates and anhydrous ethanol were
weighed into pressure proof glass vial (West Pharmaceutical Services. Exton, PA, USA).
Subsequently, the glass vial was crimped manually using 63 µL metering valves (Bespak. Norfolk,
UK). HFA227 propellant (4 mL) was added to the sealed glass vial with the help of a manual
syringe pump (HiP 50-6-15) and a home-made high pressure filler. The resulting formulation was
placed in VWR P250D low energy sonication bath (VWR Internationals) for 30 min, which was
set to 180 W and 0-5 oC. The physical stability of the formulations was evaluated by visually
monitoring the dispersion as a function of time after sonication.
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3.3.8.2 Particle size measurement.
The solvated diameters (SD) of G3NH2-mPEG-nDOX conjugates were determined using
light scattering (LS). Briefly, the aqueous solution of G3NH2-mPEG-nDOX conjugate was
filtered with 0.22 µm syringe filter (VWR Internationals) and then lyophilized. HPFP was also
filtered with 0.22 µm syringe filter (VWR Internationals) to remove any impurities in solvent. The
purified G3NH2-mPEG-nDOX conjugate (0.2 mg DOX equivalent) was added to 1 mL HPFP with
the help of anhydrous ethanol (0.37 % v/v). The HPFP was added and then sonicated at 0-5 oC for
30 min. The SD of the conjugate in HPFP was determined using Zetasizer Nano ZS (Malvern
Instruments). The average SD and standard deviation (s.d.) were calculated based on at least three
measurements.
3.3.8.3 Aerosol performance of the pMDI formulations.
The in vitro aerosol characteristics of G3NH2-mPEG-nDOX pMDI formulations were
determined with Andersen Cascade Impactor (CroPharm, Inc. Milford, CT, USA) fitted with a
USP induction port. All measurement was operated at a flow rate of 28.3 L/min, 25 oC and 75%
relative humidity.[163] The pMDI formulations were prepared as described above and several
shots were fired to waste. Subsequently, 10 shots were released into an Anderson Cascade
Impactor (ACI) with 10 s interval between shots. The run was promptly stopped 10 s after the last
shot. The ACI was dissembled carefully. Actuator, induction port, eight plates and filter
membrane were thoroughly rinsed with 10 mL DI H2O each. The concentration of the G3NH2mPEG-nDOX conjugates collected in the aqueous solutions was measured at 490 nm using Cary
50 UV-Vis spectrometer (Agilent Technologies. Santa Clara, CA, USA). The mass of the
conjugates deposited on the actuator, induction port, and each plate were calculated relative to an
established calibration curve. The following aerosol parameters were calculated: respirable
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fraction (RF), fine particle fraction (FPF), mass median aerodynamic diameter (MMAD),
geometric standard deviation (GSD) and recovery. The RF is defined as the ratio of mass of
particles collected on Stage 0 to filter to the mass of particles released into the ACI. The FPF is
defined as the ratio of mass of particles on Stage 3 to filter, to the mass of particles on Induction
port to Filter. The MMAD represents the median of the distribution of airborne particle mass with
respect to aerodynamic diameter. MMAD is usually reported along with the GSD, which
characterizes the variability of the particle size distribution. GSD is defined as the square root of
the ratio of 84.13% over 15.87% particle size distribution. Further details on the calculation of
MMAD and GSD has been previously reported.[80] The recovery is calculated by dividing
collected dose (mass of particles in actuator, induction port, stage 0-7 and filter) by theoretical
dose (concentration × volume per puff × puff number).

3.4 Results and Discussion
3.4.1 Synthesis and characterization of acid-labile G3NH2-mPEG-nDOX and non-labile
G3NH2-mPEG-nDOXNL conjugates.
DOX was conjugated to generation 3, amine-terminated PAMAM dendrimers (G3NH2)
through an acid-labile cis-aconityl spacer. After forming two amide bonds with DOX and G3NH2,
cis-aconityl anhydride has one free carboxyl group (-COOH) left, which can readily catalyze the
cleavage of its neighboring intra-molecular amide bond at acidic conditions (i.e. pH < 5), and thus
release conjugated DOX – not the pro-drug but DOX itself.[213]
Two synthetic strategies were developed for synthesis of PEGylated PAMAM dendrimers
containing different DOX payloads: direct PEGylation for low DOX payloads, and two-step
PEGylation for high DOX payloads, as shown in Figure 3.1.
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In the direct PEGylation strategy, cis-aconityl DOX was first conjugated to G3NH2,
followed by PEGylation. However, the maximum payload that can be obtained before the
conjugate becomes water insoluble is ca. 3.3 DOX. Therefore, an alternative strategy is required
in order to prepare G3NH2-DOX conjugates with higher DOX payloads. The way we approached
the problem was to first prepare G3NH2 with an initial loading of PEG1000, and only then
conjugate the hydrophobic DOX. For a pre-PEGylated G3NH2 with 7PEG1000, we observed that
up to 8.8 DOX molecules can be conjugated before the nanoconstruct becomes water insoluble.
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Figure 3.1 Synthesis of the PEGylated, generation 3, amine-terminated PAMAM dendrimer
(G3NH2) conjugated with DOX. DOX conjugated via an acid-labile linker: G3NH2-mPEG-nDOX;
DOX conjugated via a non-labile linker: G3NH2-mPEG-nDOXNL.
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Based on these observations, it seems that a further increase in DOX payload can be
achieved by initially conjugating higher number density of PEG1000. Using this approach, in
order to achieve the final / desired PEG density (if greater than 7PEG100), a second round of
PEGylation is needed. This two-step PEGylation strategy is a viable approach to achieve both
high degree of PEGylation and high DOX payload.
We also attempted another strategy in which high PEGylation preceded DOX conjugation,
so as to avoid a two PEGylation strategy. However, only 4.4 DOX can be conjugated to G3NH222PEG1000, leading to the failure to achieve high DOX payload. A similar strategy in which
PEGylation precedes DOX conjugation has been also reported in an earlier work. High density of
peripheral PEG, however, was not attempted (20 PEG out of 64 surface groups) in these reports.[34,
125] However, we will show later that in our work high PEGylation densities are required for the
formulation of these nanoconstructs in pMDIs.
In summary, the synthesis of PEGylated PAMAM with low DOX payload (i.e. 3-4
DOX/G3NH2) can be performed independently of the sequence of DOX and PEG conjugation,
while the conjugates with high DOX payload (> 7-9 DOXs/G3NH2) need to follow the conjugation
sequence: 1st PEGylation  DOX conjugation  2nd PEGylation.
As described for the acid-labile counterparts, the acid-non-labile conjugates with low and
high payloads were synthesized via direct PEGylation or two-step PEGylation, with cis-aconityl
spacer replaced by succinic linker. The disappearance of free carboxyl group in succinic spacer
renders the conjugates stable under both acidic and neutral conditions (G3NH2-mPEG-nDOXNL).
The

acid-labile

G3NH2-mPEG-nDOX

and

non-labile

G3NH2-mPEG-nDOXNL

conjugates were characterized by 1H NMR, MALDI, and ESI. The ESI (m/z) peaks at 700.2016
([cis-aconityl DOX+H]+), 722.1509 ([cis-aconityl DOX+Na]+), and 738.1769 ([cis-aconityl
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DOX+K]+) confirm the successful reaction between DOX and cis-aconityl anhydride, while
666.1815 ([succinic DOX+Na]+) and 682.1591 ([succinic DOX+K]+) were assigned to succinic

Figure 3.2 Example of (a) 1H NMR spectra of PEGylated G3NH2
dendrimer with acid-labile DOX conjugates (G3NH2-3DOX and
G3NH2-21PEG-7DOX). Inset: chemical structure of G3NH2mPEG-nDOX. Spectral shifts for all compounds are provided in
Supplemental Information S2 in Appendix 2, and (b) MALDI
spectra of a PEGylated G3NH2 dendrimer with acid-labile DOX
conjugates (G3NH2-21PEG-7DOX) and the intermediates
synthesized via two-step PEGylation strategy.
DOX (Supplemental Information in Appendix 2). The 1H NMR peaks at 6.397 ppm (-CH=C- of
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aconityl spacer), 4.025 to 3.936 ppm (-CH2- in PEG) and characteristic peaks of DOX (see
Supplemental Information in Appendix 2) indicate that DOX was successfully conjugated to
dendrimer to form G3NH2-mPEG-nDOX – Figure 3.2a. In Figure 3.2b we show an example of
MW change of the conjugates prepared in the two-step approach (G3NH2-21PEG-7DOX), as
monitored by MALDI-TOF. Results for the all other materials are provided in Supplemental
Information in Appendix 2.

Table 3.1 Molecular weight (MW), number of PEG1000 grafts (m), number of doxorubicin
(DOX) conjugates (n), hydrodynamic diameter (HD), and zeta potential (ζ) of the PEGylated,
generation 3, amine-terminated PAMAM dendrimer (G3NH2) conjugates. DOX conjugated
via an acid-labile linker: G3NH2-mPEG-nDOX; DOX conjugated via a non-labile linker:
G3NH2-mPEG-nDOXNL. Results obtained by 1H NMR, MALDI, and light scattering (LS)
at 25oC. s.d. = standard deviation.

The PEG density, DOX payload, and MW of acid-labile G3NH2-mPEG-nDOX and acidnon-labile G3NH2-mPEG-nDOXNL conjugates were quantified and are summarized in Table 3.1
along with their hydrodynamic diameter (HD) and zeta potential (ζ).
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A series of dendrimers linked with 3 DOX through a pH labile bond or stable bond (control)
and varying PEG1000 density were prepared. Another system with 7 DOX was also prepared to
compare the effect of DOX loading. The HD is seen to increas upon PEGylation and DOX
conjugation, with sizes ranging from 4.0 to 11.3 nm. At low DOX density, the HD is dominated
by the PEG density, as all dendrimers with the same PEG density have similar HD, except for
G3NH2-10PEG. G3NH2-10PEG’s small HD may be related to the fact that PEG can more easily
form strong bonds with the protonated terminal amine groups of G3NH2, and thus assume a more
collapsed configuration.[182, 214] The addition of 7DOX to the dendrimer with high PEG density
seems to have an impact on the overall size, albeit not statistically significant.
We can also observe that the ζ of the nanocarriers decreases from a large positive value for
the conjugates with no PEG, to negatively charged at high PEG density – note here that this is the
case in spite of the fact that not all surface groups have been modified with PEG, and thus
protonated amines are still expected to be present. This effect may be related to the fact that ether
oxygen from PEG can strongly interact with the protonated surface amines, thus shielding the
surface charge of the nanocarriers.[182, 215] The presence of the extra carboxyl group of the acidlabile DOX linker also helps decrease the overall charge of the dendrimer, as can be observed by
comparing for example G3NH2

2-

high PEG densities.[168]
Sizes and charges are some of the most relevant parameters in the design of nanocarriers
for drug delivery applications, as these properties dictate how the dendrimer nanocarriers interact
with the physiological environment, and thus their fate, including bioavailability,
pharmacokinetics and pharmacodynamics.[30, 169] The next step in our work was to evaluate the
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success of the acid-labile DOX conjugation strategy, by determining the release at relevant
physiological pHs.
3.4.2 In vitro release of DOX from acid-labile G3NH2-mPEG-nDOX and non-labile
G3NH2-mPEG-nDOXNL conjugates at extracellular physiological and lysosomal pH

Figure 3.3 In vitro release profiles of DOX from the acid-labile (G3NH2-mPEG-nDOX) and
non-labile (G3NH2-mPEG-nDOXNL) conjugates at (i) lysosomal pH = 4.5: (a) and (b); (ii)
physiological pH = 7.4: (c) and (d), all at 37 oC.

The DOX released from the acid-labile G3NH2-mPEG-nDOX conjugates and the effect of
PEG density on the release of DOX were investigated at pH 7.4 (extracellular physiological pH)
and 4.5 (lysosomal pH). The release profiles were compared to that of the acid-non-labile G3NH2mPEG-nDOXNL conjugates and free DOX, the controls. The results are summarized in Figure
3.3.
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As shown in Figure 3.3 (b and d), only very small amounts of conjugated DOX are released
from the acid-non-labile G3NH2-mPEG-nDOXNL conjugates at either physiological or acidic pH
conditions (<4%). In contrast, the release of DOX from G3NH2-mPEG-nDOX is shown to be a
strong function of pH. While small (<9%) amounts of DOX are released from G3NH2-mPEGnDOX at pH 7.4, when G3NH2-mPEG-nDOX is in contact with an acidic medium, > 80-85%
DOX is released from the acid-labile conjugates. Based on the released profile of free DOX, we
expect the losses of up to ca. 7% of DOX (lack of recovery) due to interactions of DOX with the
dialysis bag and to a lesser extent due to photobleaching.
The rate and total amount of DOX released from the acid-labile conjugates is also seen to
be a function of the PEGylation density of G3NH2-mPEG-nDOX. An increase is PEG density is
seen to retard the release of DOX. At 50 h, for example, the % release of DOX for G3NH2-21PEG3DOX is only 47.6%, while that for G3NH2-3DOX is 80.3%. The effect of PEGylation can be
explained by the increased steric hindrance for proton access to initiate the degradation of the acidlabile linker and also by providing a prolonged diffusion of released hydrophobic DOX out of
hydrophilic PEG coating layer.[214]
In summary, the acid-labile PEGylated PAMAM-DOX conjugates showed the potential of
being stable at extracellular physiological pH, while a sustained DOX release in conditions
mimicking intracellular acidic compartments is achieved. It was also shown that the release of
DOX can be further modulated by tailoring the peripheral PEG density. The crucial advantage
from acid-labile linker is the potential to decrease the concentration of free DOX in plasma by
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promoting drug release intracellularly, thus diminishing DOX potential toxicity in general and
cardiotoxicity in particular, which may lead to congestive heart failure and death.
3.4.3 Kill of lung adenocarcinoma cells with acid-labile G3NH2-mPEG-nDOX and nonlabile G3NH2-mPEG-nDOXNL conjugates.
The cytotoxicity of the various DOX conjugates and controls, including free DOX, free

Figure 3.4 Cell kill of (a) G3NH2 and PEGylated dendrimers (G3NH2-mPEG), (b) acidnon-labile conjugates (G3NH2-mPEG-nDOXNL), and (c) acid-labile conjugates (G3NH2mPEG-nDOX), as determined by the MTT assay after 72 h incubation with A549 cells. (d)
Cell kill of acid-labile conjugates (G3NH2-mPEG-nDOX) determined by the MTT assay
after 144 h incubation with A549 cells. Free DOX is used as control. Results denote mean
± s.d. (n=8).
dendrimer, and free dendrimer-PEG conjugates was assessed by MTT assay on A549 cells. The
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results are summarized in Figure 3.4. Corresponding IC50 values are listed in Supplemental
Information Table S1 in Appendix 2.
Neither PAMAM (PEGylated or non-PEGylated) nor acid-non-labile G3NH2-mPEGnDOXNL showed strong toxicity against A549 cells within the concentration range and incubation
time investigated – Figure 4a. Their IC50 values could not be detected in the measured range. The
toxicity of bare G3NH2 was similar to that of G3NH2-3DOXNL (Figure 3.4b), demonstrating that
the toxicity of the conjugates containing non-labile DOX was mainly induced by the peripheral
NH2 groups of the dendrimers.
In contrast, free DOX and acid-labile conjugates induced significant cell kill on alveolar
cancer cells. In Figure 3.4c it can be observed that the profiles for free DOX and acid-labile DOX
are similar, but free DOX is seen to have higher activity at lower concentration. This is to a large
extent related to the fact that free DOX can quickly diffuse through the cell bilayer[104, 216] and
reach the nucleus, while DOX from the nanocarriers only starts to be released after internalization
and traffic to the lysosomes, where the liable bonds will be broken – allowing DOX to finally reach
the nucleus.[217, 218] After cleavage, the diffusion of DOX out of lysosome is also a timeconsuming process as the base form of weak bases (e.g. DOX) can readily diffuse across internal
membrane of lysosome, while their cationic forms (major form of weak bases in lysosomes)
diffuse very slowly across the membrane.[219] This effect can be seen to be dominant, as the cell
kill profiles for free DOX and conjugated DOX are seen to be much closer to each other at 144 h
post exposure to the dendrimer-DOX conjugates. Another possible reason for the reduced toxicity
of conjugated DOX is related to the isomerization during the conjugation of cis-aconityl DOX to
dendrimer (cis-aconityl to trans-aconityl DOX),[220] which may result in the failure of original
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DOX release from the dendrimer conjugates – a pro-drug is released instead. The reduced toxicity
of polymer-bound DOX conjugates is consistent with previously published results.[34, 221]
In summary, the conjugation of DOX to dendrimer nanocarriers promotes the control of its
release, both temporally and also spatially (intracellular/low pH), and further control can be
achieved upon PEGylation. The cell kill curves reflect this temporal controlled release, with DOX
toxicity of the conjugates progressively becoming more similar to free DOX profile, as the DOXdendrimer bonds are slowly broken down upon cellular internalization and transport of the carriers
to acidic compartments, and finally diffusion of DOX to reach the nucleus. The impact of
PEGylation density on cell kill is small, and becomes negligible at long incubation times, a very

Figure 3.5 Synthesis of the PEGylated, generation 3, amine-terminated PAMAM dendrimer (G3NH2)
conjugated with DOX. DOX conjugated via an acid-labile linker: G3NH2-mPEG-nDOX; DOX
conjugated via a non-labile linker: G3NH2-mPEG-nDOXNL.
favorable result as the interaction of the carriers in vivo can be controlled by changing the
PEGylation density/surface characteristics of the nanocarriers, [222, 223] and so can its behavior
in HFA-propellants used in pMDI formulation, as will be shown later.
3.4.4 Cellular internalization of acid-labile G3NH2-mPEG-nDOX conjugates
The kinetics of cellular internalization of the acid-labile G3NH2-mPEG-nDOX conjugates
in A549 cells was evaluated by flow cytometry, by measuring the median fluorescence intensity
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(MFI) of DOX internalized within the cells as a function of time, for a period of 5 h. The results
are summarized in Figure 3.5.
It can be observed from Figure 3.5a that the rate and extent of internalization of DOX
within 5h is enhanced upon conjugation to G3NH2. The rate of internalization of DOX in G3NH23DOX is 4.7 times greater than free DOX, and the total internalization is statistically different and
about 1.6 times as high as free DOX at the end of 5 h. The difference in extent of internalization
of free DOX and conjugated DOX is seen to decrease as a function of time. PEGylation is seen to
decrease the rate and extent in cellular internalization of conjugated DOX – Figure 3.5a. It is
interesting to note, however, that at the highest PEG density (G3NH2-21PEG-3DOX), the rate and
extent of internalization of conjugated DOX is not much different than free DOX, and the means
(MFI and rate) are not statistically different at later time points when compared to the same
conjugates.
It has been reported that hydrophobic DOX is taken up through passive diffusion and that
the diffusion rate is determined by the concentration gradient and interaction with the lipid
bilayer.[216, 224] Dendrimer nanocarriers are internalized through different endocytic pathways
such as receptor-mediated endocytosis,[217, 225, 226] macropinocytosis,[226] and non-specific,
adsorptive endocytosis.[225, 227, 228] The difference in internalization rate of PAMAM-DOX
conjugates can be attributed to changes in surface charge. G3NH2readily adsorbed and quickly saturates the negative plasma membrane.[227] As a consequence,
rapid internalization and uptake plateau (1.5 h after incubation) are observed. The uptake plateau
may also reveal the equilibrium of internalization and exocytosis of those conjugates. The nonspecific, adsorptive endocytosis is faster and less energy-dependent than other endocytic pathways
due to its electrostatic interaction.[217]
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density of PEG. The interaction between the negatively charged G3NH2-mPEG-nDOX and the
plasma membrane is thus attenuated, leading to a slowdown in internalization. However, it is
important to note that the long-term cytotoxicity studies suggest that high DOX internalization is
achieved for all carrier systems, as similar IC50 concentrations are observed independent of the
PEGylation density.
We also investigated the impact of the DOX loading of the conjugates on the rate and extent
of internalization of DOX. The results from Figure 3.5b show that the rate and extent of
internalization of the dendrimer with the higher payload (G3NH2-21PEG-7DOX) is not
statistically different from that for the dendrimer with lower payload (G3NH2-21PEG-3DOX),
indicating that PEGylation dominates the rate and extent of internalization at short times, which is
reasonable considering that there are 21PEG and only 7/3DOX per dendrimer, and both impart
negative charged characteristics to the dendrimer.
In summary, conjugating DOX to dendrimer nanocarriers enhances their rate and extent of
cellular uptake, at least at early times. Cellular internalization of dendrimer-DOX conjugates can
be further modulated by PEG density, while the DOX payload on the periphery of the conjugates
does not affect uptake when at high PEG densities.
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3.4.5 Intracellular release and colocalization of DOX from acid-labile G3NH2-mPEGnDOX conjugates

Figure 3.6 (a) Selected confocal images of A549 cells contacted with free DOX, acid-labile
G3NH2-3DOX and acid-non-labile G3NH2-3DOXNL conjugates. (b) Cross section of 3D
rendered confocal image of acid-labile G3NH2-3DOX and acid-non-labile G3NH2-3DOXNL
conjugates. Image (a) and (b) were obtained 48 h after A549 cells were incubated with the
samples. Blue color represents nuclei, red color for DOX, and pink color for DOX co-localized
with nuclei.
The intracellular colocalization of free DOX, and DOX from the acid-labile G3NH2-3DOX
and acid-non-labile G3NH2-3DOXNL conjugates in A549 cells was determined by confocal
microscopy. As shown in Figure 3.6a (“Overlay” column), the red fluorescence of DOX in the
case of free DOX (first row) and of the DOX from the G3NH2-DOX conjugate (second row) was
highly superposed with the blue staining of the nucleus (Hoechst 33342), revealing significant
colocalization of DOX with the nuclei of A549 cells, the target organelle.

Perinuclear

colocalization of DOX from G3NH2-DOX indicates that not all DOX had been released at that
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time. No red fluorescence from DOX was observed in the nuclei for acid-non-labile G3NH23DOXNL (third row).
The 3D rendering of the confocal layers for G3NH2-3DOX and G3NH2-3DOXNL shown
in Figure 3.6b further confirms the ability of the conjugates to gain intracellular access, to be
trafficked through an acidic pathway, thus releasing the DOX conjugated through the acid labile
bond to G3NH2, and finally to co-localize with the nucleus. These results support the cell kill
experiments shown in Figure 3.5. We can also observe that DOX in G3NH2-3DOXNL does not
gain access to the nucleus as is not released due to the presence of a pH stable bond between DOX
and the dendrimer, and the fact that the dendrimer-DOX conjugate seems to be too large to
passively cross the nuclear pores.

Figure 3.7 Pearson’s Correlation Coefficient (PCC) of
DOX free and from acid-labile G3NH2-mPEG-nDOX
conjugates as a function of incubation time. PCC was
determined by confocal microscopy, and calculated based
on the colocalization of blue-stained nuclei and red DOX.
These qualitative observations are complemented by quantitative results of the
colocalization of DOX (red fluorescent pixels from the confocal slices) with the nucleus (blue
fluorescent pixels) as a function of incubation time, upon determination of the Pearson’s
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Correlation Coefficient (PCC) for those fluorescent signals. A PCC = 1 represents complete
correlation, while a PCC = 0 represents no correlation.[229] The PCC values for DOX:nucleus
for G3NH2-mPEG-nDOX conjugates, and for free DOX (control) are summarized in Figure 3.7.
The PCC of free DOX is seen to reach 0.87, which represents very high correlation, and
this happens at early times - 24 h due to fast colocalization of free DOX within the nucleus. The
PCC is seen to level off after ca. 48 h. The PCC for DOX:nucleus in the experiments with the
acid-labile G3NH2-mPEG-nDOX conjugates is also seen to be very high at 0.7, indicating strong
nuclear colocalization, with a maximum PCC happening at 144 h. However, the maximum PPC
for the conjugated DOX is smaller than that seen for free DOX. This lower maximum PCC may
be attributed to the isomerization of the conjugates and the fact that there are many potential
endocytic pathways for internalization of the conjugates. As cis-aconityl DOX is conjugated to
PAMAM dendrimer, cis-aconityl spacer may isomerize to trans-aconityl form.[220]

The

PAMAM-DOX conjugates with cis-aconityl spacer releases free DOX, whereas the counterparts
with trans-aconityl spacer gives rise to aconityl DOX due to the cleavage of amide bond between
G3NH2 and linker. The aconityl DOX is not able to get into nucleus due to the loss of the NH2
group, which is the driving force of DOX to reach the negatively charged DNA.[96] In addition,
the conjugates that are internalized by certain endocytic pathways that do not lead to the acidic
lysosomes (i.e. caveolae-mediated endocytosis) will have a retarded rate of release for DOX.[230]
The PCC curves are also impacted by PEGylation. They are supported by the cellular
internalization (Figure 3.5) and controlled release (Figure 3.3) results that show a slowdown in
uptake and release as the PEG density increases. The DOX loading is shown not to affect the PPC
curves – see curves for G3NH2-21PEG-3DOX and G3NH2-21PEG-7DOX. Finally, it is worth
pointing out that the rate of increase in PCC with time is also slower in the case of the conjugates

70
– compared to free DOX, but it is not clear whether a plateau has been reached at the terminal
point of the experiment, which may suggest that higher PCCs for DOX from the conjugates may
be achieved.
3.4.6 Physical stability of the acid-labile G3NH2-mPEG-nDOX conjugates in HFA
Propellant.
Once the efficacy of the DOX conjugation strategy was assessed in vitro, we developed a
strategy to formulate dendrimer-DOX conjugates in pMDI formulations for local lung delivery.
We are particularly interested in pMDIs due to the many advantages of such portable inhalers,
including ease of use and the fact that they are the least expensive OI devices in the market
today.[231-233]
We started by investigating the impact of PEGylation and DOX loading on the
dispersibility / pseudo-solubilization of the G3NH2-mPEG-nDOX conjugates in HFA277, one of
the propellants approved by the FDA for formulation in pMDIs.[234] The stability of the
formulations was assessed by visually monitoring the dispersion of G3NH2-mPEG-nDOX
conjugates in HFA227 as a function of time after sonication.[58] In order to improve the
solubilization/dispersion of the conjugates, a small amount of ethanol (EtOH) cosolvent was added.
EtOH is an excipient commonly used in commercial pMDI products, usually at much higher
concentrations - up to ca. 15% v/v in commercial formulations [235] However, because the
presence of large amounts of EtOH is known to negatively impact aerosol quality in pMDIs,[78,
233, 236] we kept the EtOH concentration to a minimum. The physical stability results of the
formulations are summarized in Figure 3.8.
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We can observe that the dispersibility / pseudo-solubilization of the G3NH2-mPEG-nDOX
conjugates is dramatically impacted by the presence of PEG1000. As the PEG1000 density
increases, so does the dispersibility of the conjugate, with the conjugate having 21PEG1000

Figure 3.8 Dispersion of acid-labile G3NH2-mPEG-nDOX in HFA227 propellant as a function of
time after sonication. Conditions were: 0.2 mg/mL DOX equivalent; 0.37% anhydrous ethanol (v/v
relative to the propellant), at 25oC.
showing excellent dispersibility in HFA227. Our previous ab initio calculations and chemical
force microscopy results have revealed that ether-containing functionalities (e.g. -CH2CH2O-) can
be well solvated in HFA propellants as the ether oxygen atom can strongly interact with the dipole
of the propellant.[237] The precise conformation of the PEG layer around the dendrimer when the
system is dispersed in HFA propellant is still unclear. However, we speculate that some of the
segments of the PEG chain may protrude into the propellant, thus acting as a stabilizer as they
strongly interact with HFA molecules (HFA-ether complexes),[237] whereas the rest of domains
cover the dendrimer surface to form a compact architecture, so as to reduce attractive forces among
the dendrimer nanocarriers.[182] Therefore, it is likely that the conjugates in propellant HFA227
take on a core-shell conformation in which PAMAM and DOX consist of the core and PEG chains
are situated in the outer shell layer. We also see that at high PEG1000 density the increased
payload of HFA-phobic DOX does not affect the dispersibility of the conjugate in the propellant.
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It is believed that 7 peripheral DOX molecules can be still thoroughly coated by an abundance of
grafted PEG chains.
In order to further clarify the nature of the pseudo-solutions/dispersions of the conjugates
in HFA, we determined their solvated diameters (SD). We use an HFA that is liquid at ambient
conditions and a model liquid propellant — 2H,3H perfluoropentane (HPFP).[81, 238] The results
are summarized in Table 3.2.
Table 3.2 Solvated diameter (SD) of the PEGylated (m), generation 3,
amine-terminated PAMAM dendrimer (G3NH2) conjugates with DOX
measured in the model propellant HPFP. DOX conjugated via an acid-labile
linker (G3NH2-mPEG-nDOX). Results determined by light scattering (LS)
at 25oC and 0.2 mg/mL DOX equivalent. n.p. = not present; % in parenthesis
= volume fraction within that diameter range.
SD ± s.d.
Conjugate
Peak A

Peak B

G3NH2-3DOX

0.5 ± 0.1 µm (13.3%)

6.1 ± 2.8 µm

G3NH2-9PEG-3DOX

0.7 ± 0.1 µm (15.1%)

4.2 ± 1.2 µm

G3NH2-21PEG-3DOX

26.1 ± 7.8 nm (100%)

n.p.

G3NH2-21PEG-7DOX

38.3 ± 11.6 nm (100%)

n.p.

At low/no PEG1000 density, the G3NH2-mPEG-nDOX conjugates formed large, micronsized aggregates, which indicates the lack of dispersibility in HFAs. However, upon increasing
density of PEG1000 to 21, no micron-sized aggregates can be found. The SDs of the highly
PEGylated conjugates were around 30-40 nm. These sizes may represent aggregates of a few
conjugates only, or even a single dendrimer conjugate whose SD in HPFP (26 nm for G3NH221PEG-3DOX) turns out to be a few times larger than their HD (SD in water – 10 nm G3NH221PEG-3DOX) - which are reported in Table 3.1.
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3.4.7 Aerosol characteristics of pMDI formulations of acid-labile G3NH2-mPEG-nDOX
conjugates.
While good dispersibility was found for the PEGylated conjugates, the results discussed

Figure 3.9 (a) Structure diagram of an Andersen Cascade Impactor (ACI) and correlation of stages
in ACI to anatomical regions of the lungs. (b) Aerosol characteristics of the pMDI formulations
containing acid-labile conjugates (G3NH2-mPEG-nDOX) in HFA227 propellant at 0.2 mg/mL DOX
equivalent and 0.37% anhydrous ethanol v/v relative to propellant, as determined using ACI at 25
o
C. AC, IP, 0-7 and F denote actuator, induction port, Stage 0-7 and filter, respectively.
before do not address the aerosol quality of the resulting formulations. Andersen Cascade
Impactor (ACI) is widely used as an in vitro lung model to determine drug deposition in the lungs.
The correlation of stages to anatomical pulmonary regions are summarized in Figure 3.9a. Stage
3 and higher represent the lower respiratory tract and deep lung deposition. The effect of PEG
density on the aerosol performance of pMDI formulations of G3NH2-mPEG-nDOX conjugates
was evaluated and are summarized in Figure 3.9b and Table 3.3.
Formulations were prepared at the same conditions as in the physical stability studies
discussed earlier - HFA227 propellant at 0.2 mg/mL DOX equivalent and 0.37% v/v EtOH. It can
be observed from Figure 9b that the fraction of DOX (in the conjugate) deposited on stages 3-F
increase dramatically at the high PEG density (21PEG1000) compared to no PEG and 9PEG1000.
The mass deposition on each stage is summarized in Supplementary Information Table S2 of
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Appendix B. The mean mass aerodynamic diameter (MMAD), and the geometric standard
deviation (GSD) of the formulations were determined from the ACI results and are summarized in
Table 3.3, along with the respirable fraction (RF) and fine particle fraction (FPF), which represent
respirable dose of the formulation and the dose deposited on low respiratory and deep lung area,
respectively.
While the MMAD for all conjugates fall within the optimum range (5.0-0.5µm), the GSD
is much smaller for the highly PEGylated conjugates. More importantly, the RF and FPF for the
conjugates with 21PEG1000 (both low and high DOX payload) are much higher than those for
G3NH2-3DOX and G3NH2-9PEG-3DOX, the conjugates that showed low dispersibility of the
propellant. The RF and FPF for G3NH2-21PEG-3DOX was found to be 82.0% and 78.1%,
respectively. For comparison, most of marketed formulations have RF<45%[239-241] of emitted
dose and FPF<55%.[163] The RF of the formulation is even higher than HFA-based solution
formulations of small molecules (RF: ca. 60-80%) containing soluble excipients.[239, 242] The
recovery for the formulations containing G3NH2-21PEG-3DOX and G3NH2-21PEG-7DOX is
much higher than that of the poorly dispersed counterparts. We believe that the loss of the
delivered dose of the formulation containing highly PEGylated conjugates is mainly from small
particles with exhalable size range (aerodynamic diameter < 0.5 µm), whereas the strong
aggregation of non-PEGylated/low PEGylated conjugates in propellant (big aggregates may not
be puffed out) causes the relatively low recovery rate for those nanocarrier systems.
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One interesting aspect of this study is the fact that pMDI formulations containing
dendrimer conjugates with such small SD – thousand fold smaller than the optimum aerosol
diameter - between 0.5to 5 µm,[243] are capable of generating corresponding aerosols with such
exceptional quality.
Table 3.3 Median mass aerodynamic diameter (MMAD), geometric standard deviation (GSD),
respirable fraction (RF), fine particle fraction (FPF) and recovery (%) of the pMDI formulation
containing the PEGylated (m), generation 3, amine-terminated PAMAM dendrimer (G3NH2)
dendrimers conjugated with DOX via an acid-labile linker (G3NH2-mPEG-nDOX). Aerosol
results determined using the Andersen Cascade Impactor (ACI), at 25oC. Formulation containing
0.2 mg of DOX equivalent per mL of propellant and anhydrous ethanol at 0.37% v/v relative to the
propellant. Propellant is HFA227.
Conjugates

MMAD (µm) GSD (µm)

RF (%)

FPF (%)

Recovery (%)

G3NH2-3DOX

4.5 ± 1.9

6.6 ± 2.4

31.8 ± 3.9 16.1 ± 1.8

65.7 ± 6.4

G3NH2-9PEG-3DOX

3.3 ± 0.8

3.9 ± 1.4

33.1 ± 5.9 29.7 ± 3.7

69.2 ± 7.1

G3NH2-21PEG-3DOX

1.2 ± 0.1

1.9 ± 0.1

82.0 ± 4.8 78.1 ± 4.3

86.9 ± 4.7

G3NH2-21PEG-7DOX

1.2 ± 0.1

1.6 ± 0.1

75.4 ± 3.0 70.8 ± 5.4

84.6 ± 5.5

We propose here a mechanism to explain the results, a schematic diagram of which is
shown in Figure 3.10.

In Figure 3.10a, the pseudo-solution of the G3NH2-mPEG-nDOX

conjugates in HFA propellant is shown – this picture is supported by the SD and physical stability
results discussed above. Upon depressing the actuator, droplets containing G3NH2-mPEG-nDOX
and propellant are formed. As the HFA227 propellant evaporates – Figure 3.10b, the polymer
concentration within the droplets increases and it eventually crosses the phase boundary illustrated
in Figure 10c – from a single phase to a phase-separated system. Micron-sized particles made of
phase-separated G3NH2-mPEG-nDOX are formed with the appropriate aerosol diameter for deep
lung deposition - Figure 3.10b (iii).
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Figure 3.10 Schematic diagram of the proposed
mechanism for the formation of the micron size
aerosol particles from the nanometer size
conjugates. (a) Acid-labile G3NH2-mPEG-nDOX
are solvated as individual particles or
nanoaggregates of a few molecules in liquid
HFA227 in pMDI at its saturated pressure. (b) As
the aerosol forms, the conjugates are (i) initially
fully solvated; (ii) as the propellant evaporates, the
dendrimer solution phase separates, forming
dendrimer nuclei that continue to increase in size to
form particles until; (iii) the propellant completely
evaporates.
(c) Phase separation as the
concentration of dendrimer conjugates increases
upon evaporation of propellant at ambient pressure.

3.5 Conclusion
In this work we demonstrated the ability of G3NH2-DOX conjugates to effectively kill
A549 cells, an in vitro model of alveolar adenocarcinoma. We also developed a novel strategy for
the formulation of the conjugates in pMDIs, consisting in forming a pseudo-solution of the
nanocarrier/polymer-drug conjugates in the propellant, which can be achieved upon surface
modification of the nanocarrier with a moiety that has high affinity to HFA. DOX was conjugated
to G3NH2 through a pH sensitive bond, which was shown to be a suitable strategy to provide a
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sustained intracellular release, while being very stable at extracellular physiological conditions.
We showed that the release profile of DOX at low pH can be further modulated by the number
density of PEG conjugated onto the G3NH2 surface. PEGylation is used to enhance the aqueous
solubility of the conjugate at high DOX payloads, and also to promote the formation of the pseudosolution in the propellant HFA of pMDIs. The impact of PEG is also observed on the rate and
extent of internalization of the dendrimer-DOX conjugates in A549 cells at short times (up to 5h).
Nuclear colocalization studies indicate that the dendrimer-DOX conjugates are not only taken up
by A549 cells, but the DOX released colocalizes with its target organelle, the nucleus, very
efficiently. Interestingly, PEGylation does not affect the ability of the conjugates to kill the
adenocarcinoma cells, as all conjugates show similar IC50’s at the same DOX equivalent loading
at long incubation times. Highly stable pseudo-solution of the G3NH2-nDOX conjugates were
formed at high PEG densities, as the dipole of HFA can interact very strongly with the ether oxygen
of the PEG layer covering the drug-dendrimer conjugate, and thus promote its pseudosolubilization. The aerosol characteristics of the resulting pMDI formulations were shown to be
exceptional, with respirable fractions as high as 82%. The relevance of the aerosol study goes
beyond the formulation of DOX, as other small molecule therapeutics have similar potential to be
formulated in pMDIs as dendrimer-drug pseudo solutions using the strategy discussed here.
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3.7 Supplemental information
Description of synthesis and characterization of the acid-labile and acid-non-labile
PEGylated dendrimer-DOX conjugates/structures including 1H NMR, ESI, MALDI-TOF and LS.
The IC50 of free DOX and various PEGylated dendrimer-DOX conjugates and aerosol mass
deposition in ACI of pMDI formulation containing dendrimer-DOX conjugates are also provided.
This material is available in Appendix B.
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CHAPTER 4 — Design of Dendrimer-Doxorubicin Conjugates for
Transport Modulation across in vitro Pulmonary Epithelium and their
Solution Formulation in pMDIs
4.1 Introduction
Of all malignant tumors, lung cancers hold great relevance as it is the leading cause of
cancer death for both men and women throughout the world.[2] The mortality of lung cancer is
higher than that of colorectal, breast and prostate cancers combined. 5-year survival rate of lung
cancers after initial prognosis is only 16.6% since most of patients are diagnosed at late phase, thus
limiting surgical treatment in the alleviation of lung cancers.[244] Therefore, chemotherapy is
widely used as a tool to treat lung cancers. However, limited progress has been made by
chemotherapy in the fight against lung cancers. One of major challenges is low therapeutic
concentration found in lung tumors upon systemic administration (e.g. intravenous and
intraperitoneal injection).[8] Therefore high dosage of drug with strong systemic adverse effects
is required due to poor distribution to lung tumors.
The lungs as a portal of entry for regional [245, 246] and even systemic [247, 248] drug
delivery is often characterized by enhanced bioavailability, which is to some extent associated with
long drug retention, large respiratory surface area (ca. 100 m2),[249] low enzymatic degradation
of drugs in lung tissues, fast action of drug, reduced systemic adverse effect, and thin cellular
barriers for entry of drugs to blood circulation.[250] Several anatomical barriers that entrap drugs
administered through pulmonary route include bifurcated bronchi, epithelial layers with viscous
mucus, fast-renewed mucociliary clearance, and alveolar macrophage.[251] One major challenge
in pulmonary drug delivery is limited transport across respiratory epithelial barriers, which
attenuates drug distribution in lung tissues and even its entry to systemic circulation. For example,
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tight junction with small pore size (ca. 0.5-2 nm),[185] junctional protein complex that regulates
paracellular transport,[185] and transmembrane drug transporters in charge of transcytosis.[186]
Oral inhalation (OI) has showed its great promise not only for regional administration of
therapeutics to the lungs, but also as a promising noninvasive route to systemic circulation through
the lungs.[245, 252]

Pressurized-metered dose inhalers (pMDIs) have been seen the most

promising OI technique due to its portability, ease of use and reliable dosage delivery. However,
the biggest challenge for pMDIs formulation is that few drugs are soluble, even with the aid of cosolvents or surfactants, in propellants used for pMDIs.[78] The addition of co-solvents and
surfactants help solubilize and disperse drugs to in propellants, making a drug suspension that is a
heterogeneous system. In contrast, solution formulation gives rise to a homogenous system
characterized by a larger fine particle dosage [83] and finer residual aerosol,[84] which leads to
efficient delivery of drug to low respiratory tract and deep lung areas. Additionally, the fraction
of nonvolatile components added to both solution and suspension formulation can modulate
aerosol performance of pMDI formulations.
Doxorubicin (DOX), as a leading chemotherapeutics, has been widely used for treating
many cancers including lung cancers. Fast clearance and severe cardiac toxicity, however, limit
its application in some patient populations.

Dendrimer nanocarriers (DNCs) have been

successfully explored for targeted and controlled delivery of DOX in cancer treatment.[33, 125,
253] Polyamidoamine (PAMAM) is a hyperbranched synthetic dendrimer with monodispersity,
highly controlled size, and multivalent surface groups.[30, 31] By attaching different ligands, the
multifunctional surface groups of PAMAM dendrimer could be potentially used to (i) target tumor
cells,[170] (ii) modulate cellular uptake,[254] (iii) facilitate transepithelial transport,[41, 42, 192]
and (iv) deliver therapeutics to subcellular organelles.[170] However, amine-terminated PAMAM
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dendrimer showed generation-dependent toxicity and hemolysis.[255] PEGylation has been an
effective strategy to help DNCs improve pharmacokinetics,[173, 256] reduce toxicity,[170, 257]
and escape mucus entrapping.[72] Recent study showed an additional significant attribute of PEG
as ligand for pulmonary administration: the modulation of in vitro transepithelial transport of
DNCs across airway epithelium and in vivo entry of DNCs to systemic circulation.[256]
Based on those challenges and opportunities of pulmonary route for lung cancer treatment,
the work was to design DNCs for controlled intracellular delivery of DOX that can modulate the
transport across pulmonary epithelium, as well as to develop facile DNC-laden pMDI formulation
with superior aerosol performance. To achieve this goal, DOX was conjugated to generation 3
amine-terminated PAMAM dendrimer with varying peripheral PEG density via an acid-labile cisaconityl spacer.

The effects of PEGylation degree and DOX payload on in vitro release,

cytotoxicity, and transepithelial transport were investigated on airway epithelial cancer cell model
(Calu-3). The PEGylated PAMAM-DOX conjugates were directly formulated in portable pMDI
with HFA227 propellant. The effect of PEGylation degree on physical stability, particle size and
aerosol characteristics was also evaluated with scanning electronic microscopy, dynamic light
scattering and Andersen Cascade Impractor (ACI). The deposition of the conjugates in different
pulmonary regions was modulated by adjusting conjugate concentration in pMDI formulation.
Broadly, this work is of great relevance because to our best knowledge it is for the first time that
polymeric nanocarrier-based drug delivery system has been formulated into propellant-based
solution pMDI formulation which holds aerosol performance superior to current marketable pMDI
products and formulations in literatures.
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4.2 Materials
Generation 3 amine-terminated poly(amindo amine) (PAMAM) dendrimer (G3NH2, 32 NH2 surface groups, theoretical molecular weight = 6909) was purchased from Dendritech, Inc
(Miland, MI, USA). Doxorubicin hydrochloride salt (DOX) was purchased from LC Laboratories
(Woburn, MA, USA). Polyethylene glycol succinimidyl ester, 1000Da (PEG1000-SE) was
purchased from NANOCS, Inc (New York, NY, USA). Polyethylene glycol 1000Da (PEG1000),
cis-aconityl anhydride, sodium hydroxide (NaOH), stannous octoate (95%), 4% paraformaldehyde phosphate buffer saline and mucin from porcine stomach (type III, bound sialic acid
0.5-1.5 %) were purchased from Sigma-Aldrich (St Louis, MO, USA). D, L-lactide was a gift
from Purac Biomaterials (Amsterdam, Netherland).

Pierce® BCA Protein Assay Kit was

purchased from Thermo Fisher Scientific (Waltham, MA, USA). Dulbecco’s Modified Eagle’s
Medium (DMEM) and penicillin (10,000 U/mL)-streptomycin (10,000 µg/mL) were purchased
from Life Technologies (Grand Island, NY, USA). Fetal bovine serum (FBS) was purchased from
Atlanta Biologicals, Inc (Flowery Branch, GA, USA). Deuterated dimethlsulfoxide (DMSO_d6)
was purchased from Cambridge Isotope Laboratories (Andover, MA, USA). Ultrapure deionized
water (DI H2O) was obtained from a Barnstead NANOpure DIamond System (D11911) from
Thermo Fisher Scientific (Waltham, MA, USA). Calu-3 human lung adenocarcinoma epithelial
cell lines were purchased from American Cell Collection (Manassas, VA, USA). Amicon® Ultra
15 centrifugal filter device (MWCO = 3000Da) was purchased from EMD Millipore (Billerica,
MA, USA). Costar Transwell® Permeable Support (pore size: 0.4 µm; surface area = 0.33 cm2)
was purchased from Corning Incorporated (Corning, NY, USA). Thin layer chromatography (TLC)
Silica gel 60 F254 plastic sheet was purchased from Merck KGaA (Darmstadt, Germany). All
reagents were used as received unless otherwise stated.
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4.3 Methods
4.3.1

Synthesis of acid-labile PEGylated PAMAM-DOX conjugates (G3NH2-mPEG-nDOX, m=0,
9, 21, and n=3, 7).

The synthesis of the acid-labile (cis-aconityl), PEGylated DOX-dendrimer conjugates used
in this work has been discussed in detail in Chapter 2. All the products were characterized with
proton nuclear magnetic resonance (1H NMR), matrix-assisted laser desorption/ionization-time of
flight (MALDI-TOF), and light scattering (LS). The characteristics of the various conjugates are
summarized in Table 1.
4.3.2

Cell kill ability of acid-labile G3NH2-mPEG-nDOX conjugates against Calu-3 cells.

The ability of free DOX and G3NH2-mPEG-nDOX conjugates in killing the human lung
adenocarcinoma Calu-3 cell was assessed using the MTT assay. Approximately 1×104 cells/well
(n=8 per concentration) were seeded in tissue culture treated 96-well plates (VWR Internationals.
Radnor, PA, USA) with DMEM (no phenol red). The medium was removed after 24h and 100 µl
of the free or conjugated DOX solution in DMEM (no phenol red) was pulsed to each well. The
samples were incubated with the cells for 72h. The sample-laden medium was then removed from
each well. The cells were washed with PBS (1X, pH 7.4) twice. 100 µl of fresh DMEM (no
phenol red) and 10 µl of MTT PBS solution (5 mg/mL) were added to each well and incubated for
4h (37 oC, 5% CO2). Subsequently, 75 µl medium was removed from each well and 60 µl DMSO
was added back into the wells to dissolve the formazan crystal. The cells were incubated (37 oC,
5% CO2) for another 2h. Finally, the absorbance of formazan at 540 nm was recorded using a
Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek Instruments, Inc. Winooski, VT, USA).
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4.3.3 In vitro transport of G3NH2-mPEG1000-nDOX conjugates across polarized Calu-3
monolayers
4.3.3.1 Cell growth on Transwell® inserts.
Approximately 5×104 Calu-3 cells (passage 10-20) were seeded on the apical compartment
of each insert, which was placed onto 24-well plates with 0.2 mL DMEM (20% FBS, 100 U/mL
penicillin and 100 µg/mL streptomycin). The basolateral compartment of each insert was filled
with 0.6 mL DMEM (20% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin). The cells
were grown for 48h (37 oC, 5% CO2) and the medium was removed from the apical side at that
time. The cells were allowed to grow at the air-liquid interface (AIC). The medium in the
basolateral compartment was changed every 2 days. The transepithelial electrical resistance
(TEER) of the cell were monitored every day, to assess the formation of confluent and polarized
monolayers.[256] TEER measurements were performed with a chopstick electrodes (STX-2) and
EVOM voltometer (World Precision Instruments. Sarasota, FL, USA) as reported previously.[256]
The actual monolayer TEER was obtained by subtracting the EVOM reading of a blank insert from
that of cell-laden insert, and normalizing for the surface area of the insert (0.33 cm2).
4.3.3.2 In vitro transepithelial transport.
In vitro transport was conducted as the TEER of cell monolayer started leveling off at ca.
450 Ω (ca. 11 days). The TEER was measured prior to the addition of free DOX or G3NH2mPEG1000-nDOX conjugates. HBSS (1X, pH 7.4) was added to apical (0.2 mL) and basolateral
(0.6 mL) compartments of the insert and the TEER was again measured as described above. The
obtained TEER was used as that at t = 0h. Subsequently, the inserts were moved to the next well
and the blank HBSS in apical compartment was replaced with 0.2 mL HBSS with 50 nM (DOX
equivalent) of free DOX or G3NH2-mPEG1000-nDOX conjugates (n=6 per sample). The TEER
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was measured after 1 h (the conjugate-laden HBSS in the apical compartment was used rather than
blank HBSS) and the insert was then moved to a new well. TEER measurement and insert
movement were repeated. The process was terminated at 5h post pulsing free DOX or the DOX
conjugates. A 0.1 mL HBSS solution was taken from each of the basolateral compartment to
determine the DOX concentration (fluorescence, with Biotek Synergy 2 Multi-Mode Microplate
Reader). The transport from apical to basolateral side (AB) was represented by apparent
permeability (Papp AB), calculated as Papp 

F
, where F is the flux or rate of change of
A  C0

cumulative mass transported from apical to basolateral direction, A is the area of the insert and C0
is the initial concentration of free DOX or DOX in the conjugates. Subsequently, the HBSS at the
apical side of the monolayer was recovered to determine the remaining amount of DOX in the
apical side of the chamber. After that, 3 inserts from each sample (n=6) were used to monitor
TEER recovery of the cell monolayer over time when free DOX or conjugated DOX was removed,
while the other 3 inserts were used for determining the extent of internalization as described next.
The cell monolayer was washed with fresh HBSS twice and 0.2 mL DMEM was added to apical
side. The TEER was measured at 24, 48 and 72 h after the terminal transport point.
4.3.3.3 Internalization during in vitro transport.
The cell monolayers on the other 3 wells were washed with 4 oC blank HBSS thrice. The
cell monolayer on each insert was detached by 0.2 mL 0.25% trypsin-EDTA solution and was then
lysed overnight using 0.5 mL Triton-X100 aqueous solution (0.5% by weight). The supernatant
collected by centrifuging the lysate was measured for DOX fluorescence analysis. The uptake of
free DOX or conjugates was normalized to cellular protein content using BCA protein assay. To
perform a mass balance, the mass of the samples that were (i) internalized, (ii) transported in AB
direction, or (iii) retained at apical side was summed up and compared to the total initial mass.
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4.3.4 Transport of G3NH2-mPEG1000-nDOX conjugates across mucus
The transport of the conjugates across an artificial mucus layer was also studied to
deconvolute the impact of the mucus and that of the polarized cell layer on the transport of the
nanocarriers. The synthetic mucus gel was composed of mucin (23 mg/mL) and buffer (85 mM
NaCl, 20 mM HEPES, pH 7.3).[256] The mucus was shaken at 4 oC overnight. A 30 µL mixture
of free DOX or conjugates (50 nM DOX equivalent, n=3 per sample) and mucus gel (ca. 900 µm
thick) was pulsed onto the apical side of each insert which were placed onto a 24-well plate. The
basolateral compartment was filled with 0.6 mL HBSS-HEPES (1X, pH 7.4, HEPES 0.1 mM).
The insert was moved every hour to a new well and the transport assay was terminated at 5h. The
solution from the basolateral side (0.1 mL) was analyzed for DOX fluorescence to quantify the
extent to which the free DOX or DOX from conjugates transport across the mucus layer.
4.3.5 Preparation and Characterization of the pMDI Formulations
4.3.5.1 Synthesis of the polylactide-PEG-polylactide (LAn-EOm-LAn) tri-block copolymer.
The LAn-EOm-LAn tri-block copolymer was prepared as reported previously, with small
modifications.[258] Briefly, PEG1000Da (1 g, 1 mmol) was reacted with D, L-lactide (10 g, 0.183
mol) with 0.1% wt/wt stannous octoate as catalyst. The reaction was stirred under N2 atmosphere
at 145oC for 1h. The resulting copolymer was dissolved in 3 mL dichloromethane and then
precipitated with 100 mL cold methanol. The product was isolated by centrifugation and dried
completely under reduced pressure. The resulting LAn-EOm-LAn tri-block copolymer, where n
and m are the number of repeat units, was characterized with 1H NMR and MALDI-TOF.
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4.3.5.2 Preparation of pseudo-solution formulation containing G3NH2-21PEG1000-3DOX
conjugate.
G3NH2-21PEG1000-3DOX (0.2 mg DOX equivalent per mL HFA227) with varying
concentrations of copolymer stabilizer LAn-EOm-LAn (0, 0.12 and 0.53 mM) were added into
pressure proof glass vials (West Pharmaceutical Services. Exton, PA, USA). The glass vials were
placed onto a hot plate (60 oC) for a few seconds (Method A) or trace amounts of anhydrous ethanol
(0.37% v/v relative to HFA227 propellant) was added to the conjugate and copolymer mixture
(Method B). The glass vial was immediately crimped manually using 63 µl metering valve
(Bespak. King’s Lynn, Norfolk, UK). HFA227 propellant (4 mL) was filled to the sealed glass
vial using a manual syringe pump (HiP 50-6-15) and a home-made high pressure filler. The
formulation was sonicated for 30 min at 0-5 oC in a sonicating bath (P250D, VWR International),
set to 180 W.
4.3.5.3 Solvated diameter (SD) of pseudo-solutions in HFAs.
The SD of G3NH2-21PEG1000-3DOX conjugate was determined in 2H, 3H
perfluoropentane (HPFP), a model for propellant HFA that is liquid at ambient conditions, using
Nano ZS Zetasizer (Malvern Instrumetns Ltd. Malvern, Worcestershire, UK). Briefly, the
aqueous solution of the conjugate was filtered with 0.22 µm syringe filter (VWR Internationals)
and then lyophilized carefully. G3NH2-21PEG1000-3DOX conjugate (0.2 mg DOX equivalent
per mL HPFP) was dissolved in HPFP with the aid of anhydrous ethanol (0.30 % v/v relative to
HPFP). The HPFP was sonicated at 0-5 oC for 30 min. Average size and standard deviation (s.d.)
of over 14 repeats are reported here.
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4.3.5.4 Aerosol performance of the pseudo-solution formulations.
The aerosol characteristics of the formulations were determined with an Andersen Cascade
Impactor (ACI, CroPharm, Inc. Milford, CT, USA) fitted with a USP induction port at a flow rate
of 28.3 L/min, 25oC and 75% relative humidity.[82] The pMDI formulations were prepared as
described above. Several shots were fired to waste. Subsequently, 20 shots were released into the
ACI with 10s interval between each shot. Air flow was maintained 10s after the last shot. The
actuator, induction port, plate on each stage and nylon filter membrane were thoroughly rinsed
with 10 mL acetone each. 3 mL sample-containing acetone solution was used for measuring UV
absorption of DOX at 494 nm using Cary 50 UV-Vis spectrometer (Agilent Technologies. Santa
Clara, CA, USA). The mass of the conjugate was determined according to an established
calibration curve. The measurements were performed in triplicate (n=3). The respirable fraction,
representing respirable dose of the formulation, was calculated following Equation 1. Fine particle
fraction, denoting the dose deposited on low respiratory and deep lung, was calculated following
Equation 2. Mass median aerodynamic diameter (median of the distribution of airborne particle
mass with respect to aerodynamic diameter) and geometric standard deviation (variability of
particle size distribution) were calculated as reported previously.[80]

RF =

Stage 0 to Filter
Actuator + Induction port + Stage 0 to Filter

FPF =

Stage 3 to Filter
Induction port to Filter

Eq. 1

Eq. 2

4.4 Results and discussion
4.4.1 Physiochemical properties of acid-labile G3NH2-mPEG-nDOX conjugates
The synthesis and characterization of the acid-labile G3NH2-mPEG-nDOX conjugates
have been discussed in detail in Chapter 2. Briefly, we synthesized acid-labile G3NH2-mPEG-
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nDOX conjugates with varying PEG density (low = 0, medium = 9 and high = 21) and DOX
payload (low = 3 and medium = 7). Two PEGylation strategies were developed for dendrimers
containing different DOX payloads: direct PEGylation for low DOX payloads, and two-step
PEGylation for high DOX payloads. In direct PEGylation, DOX was conjugated to generation 3
amine-terminated PAMAM dendrimer via an acid-cleavable cis-aconityl spacer. The PAMAMDOX conjugates were then covalently attached with varying density of PEG1000Da. For the
dendrimer conjugates carrying high DOX payload, DOX was conjugated to the dendrimers that
have been PEGylated aforehand (PAMAM-xPEG1000; x = average 7 PEG1000 per dendrimer),
and followed by second PEGylation step to achieve high density of PEGylation.
Both 1H NMR and MALDI-TOF demonstrated the successful conjugation of DOX and
PEGylation. The hydrodynamic diameters (HD) and zeta potentials of G3NH2-mPEG-nDOX
conjugates measured with light scattering (LS). That is, 4.0±2.3 nm and +6.3±3.5 mV for G3NH23DOX, 6.9±3.2 nm and -2.1±4.3 mV for G3NH2-9PEG-3DOX, 9.6±4.9 nm and -6.6±2.7 mV for
G3NH2-21PEG1000-3DOX, and 11.3±4.3 nm and -10.5±6.1 mV for G3NH2-9PEG-7DOX. The
in vitro release of DOX from the conjugates determined at pH 7.4 and pH 4.5 showed DOX (8085%) is released from dendrimer conjugates only at acidic pH (lysosomal pH), while is stable at
extracellular/physiological conditions (<8 % DOX is released). Additionally, the rate at which
DOX is released decreases as PEGylation degree increases. Therefore, the intracellular release of
DOX in reponse to pH drop potentially decrease the concentration of free DOX in plasma, thus
reducing systemic adverse effects.

01

90
4.4.2 Cytotoxicity of acid-labile G3NH2-mPEG-nDOX conjugates
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Figure 4.1 Viability of Calu-3 cells 72 h post incubation
with varying concentrations of bare dendrimer, free DOX
or acid-labile conjugates (G3NH2-mPEG1000-nDOX, with
m = 0, 9, or 21 and n = 3 or 7), as determined by the MTT
assay. Results denoted as mean ± s.d. (n=6). The inset of
IC50 values of the free DOX (DOX) various conjugates at
72 h incubation. The IC50 values were obtained with nonlinear regression Log(inhibitor) vs. Response (variable
slope).
The cytotoxicity of the various dendrimer-DOX conjugates and controls (free DOX) was
assessed by MTT assay on Calu-3 cells. As shown in Figure 4.1, free DOX and acid-labile
conjugates induce significant cell kill on airway epithelial cells. The cell kill profiles for free DOX
and acid-labile dendrimer-DOX conjugates follow similar trend, but free DOX have greater
potency at 72 h incubation (see both profiles and IC50 values). As discussed in Chapter 2, we
believe the cytotoxicity of the acid-labile conjugates could be comparable to that of free DOX as
incubation time was prolonged and the impact of PEGylation was negligible at long incubation
times. The stronger time-dependent cell kill is mainly related to the sustained release of DOX
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from dendrimer conjugates and different cellular uptake pathways for free DOX and acid-labile
DOX.
4.4.3 In vitro transport of acid-labile G3NH2-mPEG-nDOX conjugates across polarized
pulmonary epithelial monolayer
Our recent work has shown surface chemistry of generation 3, amine-terminated PAMAM
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Figure 4.2 Apical to basolateral (AB) transport of
free DOX and DOX from acid-labile G3NH2mPEG1000-nDOX conjugates across polarized Calu3 cell monolayers as a function of time (n=6).
Statistical significance was calculated with respect to
free DOX by one-way ANOVA Dunnett’s test
(*p<0.05).
dendrimers (G3NH2) can be used to modulate their interaction with the pulmonary epithelium both
in vitro and in vivo,[168] and thus be potentially used to improve permeability of DOX across
pulmonary epithelial barriers. In this work, we studied the effect of PEGylation degree and DOX
payload on the transport of acid-labile G3NH2-mPEG-nDOX conjugates across epithelial
monolayer with an in vitro Calu-3 cell monolayer model — upper airway cancer cell line.[184]
The G3NH2-mPEG-nDOX conjugates are pulsed to apical side of cell monolayer and the amount
of the conjugate collected at basolateral side are measured. The results are plotted in Figure 4.2.
It is observed that the dendrimers with medium (9 PEG) and high (21 PEG; *p<0.05 at 4.5 and 5.5
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h with respect to free DOX) PEGylation degree transport more DOX from apical to basolateral
side (A  B) of cell monolayer than free DOX, while non-PEGylated dendrimer transports less
DOX in A  B direction. Additionally, the amount of DOX collected at basolateral side increases
as PEGylation degree increases. The cumulative mass of DOX transported in A  B direction
slightly increases as DOX payload increases, but no statistical significance is observed.
We also calculate overall apparent A  B permeability (Papp A  B) of free DOX and
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Figure 4.3 Apparent permeability (Papp) of G3NH2mPEG1000-nDOX conjugates across Calu-3 cell
monolayer (n=6). Papp was determined at 5 h post
incubation of the cell monolayer with the conjugates,
with the transport being from the apical to basolateral
(AB) side. Statistical significance was calculated
with respect to free DOX by one-way ANOVA
Dunnett’s test (*p<0.05).
G3NH2-mPEG-nDOX conjugates. Papp A  B is a measure of ease with which substances are
transported across epithelial layers. Our results (Figure 4.3) show Papp A  B of free DOX is
2.0×10-6 cm/s, which lies between G3NH2-3DOX and G3NH2-9PEG-3DOX. Papp A  B values
of highly PEGylated dendrimer-DOX conjugate are significantly higher than that of free DOX.
Both Papp A  B and cumulative mass of DOX at receiving side demonstrate PEGylation and
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varying DOX payload could modulate the transepithelial transport of dendrimer-DOX conjugates
across pulmonary epithelial layers.
It has been reported that the DOX translocates across polarized epithelial monolayer is
through transcellular pathway (e.g. transcytosis) in which DOX molecules are taken up by
epithelial cells on apical side and then dropped off on basolateral side.[259, 260] The transport of
DOX through paracellular pathway hasn’t been reported in literature. In contrast, dendrimer
nanocarriers are able to cross epithelial barriers via paracellular route in conjunction with
transcytosis.[42, 184, 218] and the rate of transport is affected by their size and surface chemistry.
To understand the role of paracellular pathway in transepithelial transport of dendrimer-DOX
conjugates, electrophysiological behavior of cell monolayer is evaluated by measuring the TEER
value in the course of transport. The TEER values are summarized in Figure 4.4. Only a limited
reduction (ca. 10%) is observed in the case of free DOX, demonstrating no obvious opening of
intercellular tight junction proteins (e.g. actins and occludins) and good integrity of Calu-3 cell
monolayer. It thus corroborates the fact that paracellular pathway plays little/no role in the
transepithelial transport of DOX across pulmonary epithelial layer.[259] On the other hand, it is
evident that dendrimer-DOX conjugates have pronounced impact on TEER of Calu-3 cell
monolayer (ca. up to 40-60% decrease in the course of transport experiment), indicating the
significant opening of intercellular tight junction, which is a robust evidence of paracellular
transport.[261] Additionally, the TEER decreases as PEG density increases, demonstrating the
highly PEGylated dendrimer can have stronger interaction with tight junctional proteins. The
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opening of tight junction This is in accordance with the findings in Bharatwaj’s work.[256] The
TEER values of Calu-3 monolayer are reversible upon removal of dendrimer-DOX conjugates
from apical side. As seen in Figure 4.4, all TEER values return to ca. 90% of their original values
within 48 h. The reversibility of the TEER values revealed Calu-3 cells are not damaged
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Figure 4.4 Variation in transepithelial electrical resistance
(TEER) across polarized Calu-3 monolayer grown on
Transwell® inserts during the 5 h in vitro transport experiments
(n=6), and up to 36h after the completion of transport
experiment (n=3) – after washing of the apical side of the
monolayer where the conjugates had been pulsed.
significantly as the G3NH2-mPEG-nDOX conjugates transport across.[41, 184]. Therefore, the
combined results indicate PEG chains on dendrimer surface may promote the paracellular transport
of dendrimer-DOX conjugate by interacting with intercellular tight junction and the interaction
has no permanent damages on calu-3 monolayer.
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On top of surface chemistry impact, the change on surface charge introduced by
PEGylation should be considered.

As discussed earlier, non-PEGylated dendrimer-DOX

conjugate (G3NH2-3DOX) were positively charged, whereas moderately (G3NH2-9PEG100090
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Figure 4.5 Transport of the acid-labile G3NH2mPEG1000-nDOX conjugates across the synthetic
mucus layer as a function of time. Statistical
significance was calculated with respect to free
DOX by one-way ANOVA Dunnett’s test
(*p<0.05).
3DOX) and highly (G3NH2-21PEG1000-3DOX and G3NH2-21PEG1000-7DOX) PEGylated
dendrimer-DOX conjugates are near-neutral or slightly negative. The tight junctional opening by
surface charge of dendrimers is ranked in the sequence: positive > negative > neutral.[41] The
sequence is obtained based on the transport study on intestinal epithelial models (e.g. Caco-2 cell
line). However, these intestinal cell monolayer models do not have mucus gel layer covered on
apical side. The mucus layers on the top of respiratory epithelial monolayer (e.g. Calu-3 cell line)
are able to trap invading nanocarriers, especially positively charged and hydrophobic particulates.
Mucus is viscoelastic gel layer covering the organs and tissues that expose to external environment,
such as lungs, stomach and vagina. Mucus gel is made up of crosslinked mucin fiber, lipids, salts,

96
proteins, nucleic acids and cellular debris.[72] The thickness of respiratory mucus layer ranges
from 5 to 55 µm.[262, 263] The respiratory mucus can entrap inhaled particles and bacteria due
to the presence of size-limiting pores, hydrophobic domains and polyvalent adhesion. The
particulate-entrapped mucus gel is the rapidly cleared by mucociliary escalator and fast renewed
mucus.[72, 264]
To study the retention of G3NH2-mPEG-nDOX conjugates by mucus layer, we use
synthetic human mucin gel to mimic mucus layer on cell monolayer. As shown in Figure 4.5, free
DOX, G3NH2-21PEG1000-3DOX and G3NH2-21PEG1000-7DOX show similar capability to
escape mucus trapping. Dendrimer-DOX conjugates with low PEG density transport across mucus
gel at a much smaller rate. The similar trend is also reported our recent study and Schipper’s work
investigating the transport of deacetylated chitosan across mucus-covered intestinal epithelial
cells.[265] G3NH2-3DOX is positively charged, while G3NH2-21PEG1000-3DOX and G3NH221PEG1000-7DOX are negatively charged. A large amount of anionic charges (e.g. carboxyl and
sulfate groups) in glycosylated domains of mucin fibers can significantly immobilize cationic
dendrimers (G3NH2-3DOX), while negatively charged dendrimers can relatively cross the mucus
layer easily.[266-268]
At the end of transport experiment, we also calculate amount of dendrimer conjugates left
in apical side of cell monolayer and internalized into Calu-3 cells. As seen in Figure 4.6, most of
free DOX and dendrimer-DOX conjugates remain in apical side of cell monolayer (65-80% of
added samples). Approximately, 6.4% G3NH2-3DOX has been internalized by Calu-3 cells at
terminal point (5.5 h), whereas PEGylated dendrimer-DOX conjugates have reduced
internalization (4.4% for G3NH2-9PEG1000-3DOX, 3.2% for G3NH2-21PEG1000-3DOX, and
2.5% for G3NH2-21PEG1000-7DOX). These results in combination with cumulative mass
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transported across cell monolayer allow us to perform an overall mass balance study.
Approximately, an average of 85% of added samples can be recovered. The 15% of the conjugates
in loss may be attributed to a few factors including the presence of conjugates adhered to cell
debris after lysis and the adsorption of conjugates to surfaces of the inserts.[256]
110

% of conjugates

100

Transported
Internalized
Recovered

90
80
70
60
20
10

X
O
10
00
-7
G

PE
21

21

2-

2G

3N

H

H
3N
G

D

D
G

PE

EG
9P
2H

3N
G

10
00
-3

D
10
00
-3

3D
2H
3N
G

O

X
O

X
O

X
D
O

X

0

Figure 4.6 Mass balance of DOX conjugates during the
in vitro transport experiments. The mass transported
from apical to basolateral side (AB), the mass
internalized into Calu-3 cells, and the mass retained on
apical side were determined for the mass balance.
In summary, the transport of DOX across pulmonary epithelial epithelium can be
significantly enhanced upon its conjugation to dendrimers and PEGylation. The significantly
reduced TEER value and very limited internalization of dendrimer conjugates reveal that
paracellular pathways play a vital role in the transport of PEGylated dendrimer-DOX across
pulmonary epithelium.
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4.4.4 Pseudo solution pMDI formulations of acid-labile G3NH2-mPEG-nDOX conjugates
In Chapter 2, we have reported that the pseudo solution formulation of acid-labile G3NH2mPEG-nDOX conjugates in pMDIs can be readily prepared with a trace of cosolvent (ethanol).
The physical stability and aerosol characteristics of the pMDI formulations improve significantly
as the PEG density increases. In this work, a facile cosolvent-free preparation for the pMDI
formulation was also developed (Method A). We selected the G3NH2-21PEG1000-3DOX as
model conjugate.

A predetermined amount of conjugates (0.2 mg DOX per mL HFA227

propellant) was added to pressure proof glass vial and then slightly melted at ca. 60 oC for a few
seconds. Propellant HFA227 was subsequently added to the conjugates. The molten PEGylated
dendrimer conjugates are found well solvated by propellant even without sonication. The pMDI
formulation of G3NH2-21PEG1000-3DOX was also prepared with cosolvent method reported
earlier (Method B). The solvation diameters (SDs) of the pMDI formulations prepared by both
methods are determined using light scattering (LS). We use an HFA that is liquid at ambient
conditions and a model liquid propellant — 2H, 3H perfluoropentane (HPFP).[81, 238] The
measurement showed SDs of the formulation from Method A and Method B are similar: 27.3±8.5
nm vs. 26.1±7.8 nm, revealing that Method A can also prepare PEGylated dendrimer-DOX
conjugates into pseudo solution pMDI formaution. The size may represent aggregates of a few
conjugates only, or even a single dendrimer conjugate whose SD in HPFP (26-28 nm for G3NH221PEG1000-3DOX) turns out to be less than 3 times larger than their HD (SD in water – 10 nm
G3NH2-21PEG1000-3DOX).
To further understand thermal properties of G3NH2-m21PEG1000-nDOX conjugate,
differential scanning calorimetry (DSC) was used to monitor their molten behaviors and the results
were plotted in Figure 4.7 (a). The melting point (mp) of G3NH2-21PEG1000-3DOX is 45.72 oC,
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which is similar to that of PEG (mp of pure PEG: 46.72 oC). Since G3NH2 dendrimer
is an

Exothermic
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amorphous polymer without melting point, PEG chains on surface are mainly responsible for
melting behavior of the conjugate. It is believed that the molten PEG chains covering on dendrimer
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Stagesby Method A and B are summarized in Figure 4.7 (b). The mass
deposition on each stage is summarized in Supplementary Information Table S1.

The

formulations prepared by Method A and B showed similar the deposition fraction of the conjugates
on ACI, mainly on from Stage 4 to 7 which corresponds to deep lung regions. Respirable fraction
(RF), fine particle fraction (FPF), mass median aerodynamic diameter (MMAD), geometric
standard deviation (GSD) and recovery are calculated according to the deposition data and listed
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in Table 4.1. The RF and FPF are two major parameters to assess the efficiency of the pMDI
formulation for pulmonary delivery.[82] RF (85.2±5.8%) and FPF (81.9±4.5%) of the formulation
from Method A are slightly greater than those of Method B (RF: 82.0±4.8%; FPF: 78.1±4.3%),
but no statistical significance is found. The FPFs obtained from both methods are much higher
Table 4.1 Median mass aerodynamic diameter (MMAD), geometric standard deviation (GSD),
respirable fraction (RF) and fine particle fraction (FPF) of the pMDI formulations containing
acid-labile G3NH2-21PEG1000-3DOX conjugate and LA46-EO23-LA46 triblock copolymer
surfactants, as determined by Andersen Cascade Impactor (ACI). The formulations were
prepared with Method A (no ethanol) and contained 0.2 mg DOX equivalent per mL HFA227
propellant and varying concentrations of LA46-EO23-LA46 copolymer (0, 0.12 and 0.53 mM).
Statistical significance was performed with respect to the pMDI formulation with 0 mM LA46EO23-LA46 prepared by Method A using one-way ANOVA Dunnett’s test with *p<0.05,
**p<0.01, and ***p<0.001. † denotes the formulation was prepared by the Method B,
formulations containing anhydrous ethanol at 0.37% v/v relative to HFA227 propellant.
LA46-EO23-LA46

MMAD (µm)

GSD (µm)

RF (%)

FPF (%)

Recovery (%)

0†

1.2±0.1

1.8±0.1

82.0±4.8

78.1±4.3

86.9±4.7

0

1.3±0.1

1.9±0.1

85.2±5.8

81.9 ±4.5

84.0±5.9

0.12

2.3±0.3**

1.9±0.1

82.4±6.6

68.7±5.8*

84.5±7.2

0.53

3.0±0.5***

2.2±0.1

79.2±8.9

58.4±6.1**

78.7±6.4

than those of commercial HFA-based suspension pMDIs (30-55% on average)[81, 269] and HFAbased solution formulations (60-80% on average).[239, 242] Additionally, the MMAD and GSD
are similar for both methods, falling within the optimum range of aerodynamic diameters (5.00.5µm). The recovery for both formulations is similar. We believe that the loss of the delivered
dose of the formulation containing G3NH2-21PEG1000-3DOX is mainly from small particles with
exhalable size range (aerodynamic diameter < 0.5 µm). It is noted that micronized particles are
formed from pseudo solution pMDI formulation of nano-sized particles with propellant molecule
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vaporizing. A phase separation mechanism for micronized particle formation is proposed in
Chapter 2.
In summary, the pseudo solution of formulation of highly PEGylated dendrimer-DOX
conjugates can be also prepared with a facile cosolvent-free method. The formulation prepared
with this method shows superior aerosol properties and is conducive to deep lung deposition.
4.4.6 Deposition-tunable pMDI formulation of G3NH2-mPEG-nDOX conjugates by the
addition of triblock copolymer LAn-EOm-LAn
It is observed in Figure 4.7 (b) that ca. 70% of the G3NH2-21PEG1000-3DOX conjugate
deposited on Stage 5 to 7 which corresponds to deep lung areas including terminal bronchioles and
alveolar sacs. Therefore, the formulation tends to deliver chemotherapeutics to peripheral lung
cancers.[270] However, some primary and secondary airway malignancies occur on upper (e.g.
trachea) and lower respiratory (bronchi, primary and secondary bronchioles) tracts.[271, 272] As
is well known, the addition of non-volatile excipients to pMDI formulations can increase their
MMADs due to reduced vapor pressure of the propellant, thus leading to increased deposition of
particles in central lung area.[78, 273] In this work, we selected triblock copolymer LAn-EOmLAn as nonvolatile excipients to adjust aerosol characteristics as experimental work and
computational simulation has shown biocompatible polylactide homopolymers and copolymers
are soluble excipients in HFA propellant,[58, 274, 275] which won’t change the nature of pseudo
solution of highly PEGylated dendrimer-DOX conjugates. Wu and da Rocha reported the
copolymers with longer lactide (LA) repeat units are more capable of partitioning interaction
between drug molecules.[58] Therefore, the LAn-EOm-LAn copolymer with long PLA block was
synthesized via ring opening polymerization of D, L-lactide (LA) with hydroxyl PEG (HOPEG1000-OH) as macromolecular initiator.[258] The 1HNMR and MALDI-TOF of resulting
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LAn-EOm-LAn copolymer (Figure 4.8) show the ratio of LA unit to PEG chain is 92:1 and the
molecular weight is 7561.61Da. The triblock copolymer will be denoted as LA46-EO23-LA46 from
here. The G3NH2-21PEG1000-3DOX conjugate was mixed with LA46-EO23-LA46 copolymer and
then heated slightly before HFA227 filling.
We studied the effect of PLA46-PEG-PLA46 concentration on the solvation diameters of
the pMDI formulations by LS. The results show the SDs of the formulations range from ca. 26 to

(a)

MWPLA-PEG-PLA = 7561.61

(b)
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Figure 4.8 1H NMR and MALDI spectra of LA46-EO23-LA46 triblock copolymer..
31 nm (PLA46-PEG-PLA46 concentration — 0 mM: 26.1±7.8 nm; 0.12 mM: 30.3±10.9 nm;
28.6±7.8 nm) and are not affected by the concentration of PLA46-PEG-PLA46 within 0 – 0.53 mM.
This reflects the addition of LAn-EOm-LAn copolymer does not affect the nature of solution
formulation. The solvation diameter of LA46-EO23-LA46 copolymer in HPFP is not detected with
LS, possibly due to the random coiled conformation of linear polymer. It is thus believed that
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LAn-EOm-LAn copolymer is not able to form strong interaction with PEGylated dendrimer
conjugate.
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Figure 4.9 Effect of the concentration of LA46-EO23-LA46 triblock
copolymer on the aerosol characteristics of the pMDI formulations
of G3NH2-21PEG1000-3DOX in HFA227 (0.2 mg DOX
equivalent per mL propellant). The formulation was prepared by
Method A.
The effect of the concentration of LA46-EO23-LA46 on the aerosol characteristics of the
pMDI formulations is determined with ACI and the lung deposition is plotted in Figure 4.9. It is
obviously observed that the deposition of G3NH2-21PEG1000-3DOX on lower stages increases
as the concentration of PLA46-PEG-PLA46 copolymer increases. The ratio of the deposition of
conjugates on Stage 2-4 to Stage 5-7 (F2-4/5-7) was 0.22 (15.0%:67.0%) for 0 mM, 1.24
(40.0%:32.1%) for 0.12 mM, and 1.94 (51.9%:26.7%) for 0.53 mM. According to the correlation
of ACI stage to anatomical lungs, Stage 2 to 4 corresponds to lung anatomical regions such as
trachea, primary and secondary bronchi, while Stage 5 to 7 corresponds to deep lung area including
terminal bronchioles and alveoli. The shift of lung deposition to lower stages of ACI reveals the
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formulation with LA46-EO23-LA46 as excipient is capable of delivering PEGylated dendrimer
conjugates to upper respiratory tract.
The aerosol parameters of these pMDI formulations are summarized in Table 1.
As the concentration of PLA46-PEG-PLA46 increases, the RF of these pMDI formulations
decreases slightly, while the FPF decreases with statistical significance. However, the lowest FPF
is still greater than that of commercial HFA-based pMDI formulations (30-55% on average).[82]
The MMAD of these formulations increases from 1.3 µm to 3.0 µm with the concentration of
LA46-EO23-LA46 increasing from 0 to 0.53 mM, which remain in the optimal range of particle size
for oral inhalation (5-0.5 µm). The trend of change of FPF and MMAD with the addition of
nonvolatile soluble excipient is in accordance with published results.[78]
In summary, the pseudo solution formulation of PEGylated dendrimer-DOX conjugate is
tunable in terms of cancerous sites in the lungs by adjusting the concentration of PAL-PEG-PLA
copolymer. For broad relevance, the PEGylated PAMAM dendrimers via oral inhalation can be
used as a platform for delivering therapeutics of interest to treat other pulmonary disorders.

4.5 Conclusion
In this work, a series of PEGylated PAMAM dendrimers with acid-labile DOX conjugated
have been synthesized. The conjugates were maintained stable at physiological condition (e.g.
blood circulation), while were capable of releasing free DOX at acidic compartment (e.g. lysosome)
causing comparable cytotoxicity to free DOX against lung cancer epithelial cell line (calu-3). In
vitro transport of G3NH2-mPEG-nDOX conjugates across polarized lung epithelia model
indicated the apparent transport of apical to basolateral side increased as PEG density increased,
whereas cellular uptake rate declined due to attenuated interaction upon PEGylation.

The

significant reduction in TEER showed paracellular pathway played a vital role in sending the
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conjugates across epithelial monolayer. Different from other epithelial cells (e.g. intestinal or
colorectal epithelia), mucus gel layer secreted by airways epithelial cells withheld a large amount
of conjugates. However, high degree of PEGylation can help the conjugates effectively escape
from mucus entrapping—thus enhancing transcellular transport rate. The G3NH2-mPEG-nDOX
conjugates can be readily formulated into HFA-based pMDIs with two different methods: heating
method and co-solvent aiding method, forming solution formulations.

The pMDI solution

formulations prepared by the two methods had very excellent physical stability and aerosol
characteristics (high RF and FPF, and low MMAD and GSD). Considering cancerous lesions of
the lungs and respiratory tract, the aerosol deposition was tunable by adjusting the concentrations
of biodegradable LAn-EOm-LAn triblock copolymers.

Therefore, all combined results

demonstrated that the acid-labile PEGylated PAMAM-DOX conjugates administered locally by
oral inhalation are promising for treating lung adenocarcinoma. Broadly, the pMDI solution
formulation containing PEGylated PAMAM dendrimers is also promising platform for treating
other pulmonary disorders.
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CHAPTER 5 — Conjugation to Poly(amidoamine) Dendrimers and
Pulmonary Delivery Enhances the Antitumor Activity of Doxorubicin in
Lung Metastasis
5.1 Introduction
Cancer is the second most common cause of death for both men and women in the United
States, second only to heart diseases.[276] Amongst the many malignant tumors, lung cancers are
the leading cause of death. More patients die from lung cancers than breast, pancreatic, and
prostate cancers combined.[2] Although curative surgery is the first choice in the clinic for treating
primary lung tumors, chemotherapy plays a vital role in inhibiting tumor growth after surgery,
partly due to the high rates of recurrence.[277, 278] Additionally, the lungs are the most common
site for metastasis for almost all other primary tumors.[279] Metastatic tumors are also associated
with more than 90% of cancer-related deaths.[280] The development of new strategies that can
help improve chemotherapeutic outcomes during the treatment of lung metastasis have, therefore,
a significant potential societal impact.
One of the major challenges limiting the success of chemotherapeutic treatment in lung
metastasis is the low concentration of anticancer agents in the lung tissue and lung tumor. Upon
systemic administration, such as intravenous injection (i.v.), only a few percent of the total dose
(TD) (< 4%) actually reaches the tumor site.[8] Because of typical systemic toxicity of anti-cancer
therapeutics, increasing the overall administered dose so as to reach therapeutic local concentration
of chemotherapeutics is usually not a viable strategy.[9] The study of the effectiveness of new
chemotherapeutic strategies that consider local lung delivery are, therefore, also of great potential
relevance as they promote local drug concentration while decreasing systemic exposure.
Doxorubicin (DOX) is one of the most effective anti-cancer therapeutics available in the
clinic today [281] and has been widely used alone or in combination to treat a variety of malignant
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cancers including lung tumors.[56, 57] DOX induces the apoptosis of cancer cells by intercalating
itself to DNA double helix and thus inhibiting the progression of enzyme topoisomerase II. Other
mechanisms include the production of high level reactive oxygen species (ROS) and cellular
membrane disruption.[95] The applicability of DOX is to some extent limited, however, due to
its damage to the cardiac tissue.[21] The accumulation of DOX in the heart results in increased
oxidative stress, down-regulated protein function, decreased cardiac gene expression, and upregulated apoptosis of cardiomyocytes, which eventually leads to lethal cardiomyopathy.[22]
There are, therefore, tremendous opportunities in the development of strategies that will
enhance the local concentration of DOX in the lung tissue, while maximizing its intracellular
delivery to lung tumor cells, and at the same time minimizing the systemic concentration of free
DOX.

Nanocarriers are uniquely suited in this aspect, as they can be used to modulate the

pharmacokinetics (PK) and biodistribution of therapeutic agents.[282]

Dendrimers are

particularly interesting drug carrier systems as they are highly monodispersed (predictable
PK/biodistribution) and can be easily functionalized with therapeutic agents through linkages that
allow for temporal and spatial control of drug release. Dendrimer can also be modified with
various ligands to control their interaction with the physiological environment and can also
promote their cellular internalization.[31, 167, 212]
Based on the challenges and opportunities discussed earlier, the goal of this study was to
investigate the effect of the conjugation of DOX to dendrimer and of the local administration of
the carrier system to the lung tissue on the efficacy of DOX in reducing the metastatic lung tumor
burden. We conjugate DOX to carboxyl-terminated, generation 4, poly(amidoamine) dendrimer
(G4COOH) nanocarriers through an intracellularly-triggered (pH-responsive) drug release linker.
We evaluated the impact of pH on the release kinetics of the conjugates – both at extracellular
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physiological pH (7.4) and intracellular pH (lysosomal, 4.5). The ability of the conjugates gain
access to and to kill B16F10 mouse melanoma cells was also investigated using flow cytometry
and MTT assay.

A mouse model of lung metastasis (from melanoma B16F10 cells) was

established and the efficacy of the G4COOH-DOX conjugates in reducing the metastatic lung
tumor burden and rate of survival was investigated. The effect of conjugation was assessed by
comparing the results of the studies above to free DOX, while the impact of the local lung delivery
was determined by comparing the effectiveness of the conjugates and free DOX delivered via
pharyngeal aspiration (locally) and intra venous (i.v.). The potential of the conjugation of DOX
to G4COOH and the pulmonary delivery route are also discussed in terms of the tissue distribution
of the carriers, particularly to the lungs (target) and the cardiac tissue (to be avoided).

5.2 Materials
Generation 4, carboxyl-terminated, poly(amidoamine) dendrimer (G4COOH) was
purchased from Dendritech, Inc (Miland, MI, USA). Doxorubicin hydrochloride (DOX) was
purchased from LC Laboratories (Woburn, MA, USA). N-methylmorpholine (NMM) and isobutyl
chloroformate (IBCF) were purchased from VWR Internationals (Radnor, PA, USA). Tert-butyl
carbamate (TBC), trifluoroacetic acid (TFA), triethylamine (TEA), 2, 5-dihydroxybenzoic acid (2,
5-DHB), and 4% paraformaldehyde PBS solution were purchased from Sigma-Aldrich (St Louis,
MO, USA). Phosphate buffer saline (PBS, 1X), Dulbecco’s Modified Eagle’s Medium (DMEM),
penicillin (10,000 U/mL)-streptomycin (10,000 µg/mL), and trypsin-EDTA solution (0.25%
trypsin and 0.53 mM EDTA) were purchased from Life Technologies (Grand Island, NY, USA).
Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA, USA).
Deuterated dimethylsulfoxide (DMSO_d6) was purchased from Cambridge Isotope Laboratories
(Andover, MA, USA). Ultrapure deionized water (DI H2O, Ω=18.0-18.2) was sourced from a
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Barnstead NANOpure DIamond System (D11911), equipment purchased from Thermo Fisher
Scientific (Waltham, MA, USA). All anhydrous organic solvents including dimethylsulfoxide
(DMSO), dimethylformamide (DMF), dichloromethane (DCM), and methanol (MeOH) were
bought from VWR International (Radnor, PA, USA).

Spectra®Por dialysis membrane

(MWCO=3kDa) was purchased from Spectrum Laboratories, Inc (Rancho Dominguez, CA, USA).
Amicon® Ultra 15 centrifugal filter device (MWCO=10kDa) was purchased from EMD Millipore
(Billerica, MA, USA). Thin layer chromatography (TLC) Silica gel 60 F254 plastic sheet was
purchased from Merck KGaA (Darmstadt, Germany). All reagents were used as received unless
otherwise noted.

5.3 Methods
5.3.1 Cell culture
Mouse melanoma cell line (B16F10), passage 5 to 10, was kindly gifted by Dr. Haipeng
Liu, Department of Chemical Engineering and Materials Science at Wayne State University.
B16F10 cells were seeded in a Corning® 75 cm2 U-Shaped Canted Neck Cell Culture Flask
(Corning Life Sciences. Tewksbury, MA, USA), and cultured with DMEM supplemented with
10% FBS and penicillin (100 U/mL)-streptomycin (100 µg/mL) (Pen-Strep). The cells were
grown in a Thermo Scientific™ CO2 incubator (Thermo Fisher Scientific) at 37 oC and 5% CO2.
The medium was exchanged every two days and the cells were split as they reached ca. 70-80%
confluence.
5.3.2 Animals for in vivo experiments
All animal experiments were performed in accordance with the guidelines of the
Institutional Animal Care and Use Committee at Wayne State University. Male C57BL/6 mice
(6-8 weeks, 20-22 g) were purchased from Charles River Laboratories (Wilmington, MA, USA).
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The mice were housed under a 12 h light/dark cycle, allowed food and water ad libitum, and
acclimatized for 1 week prior to any experiment.
5.3.3 Synthesis and characterization of dendrimer-DOX conjugates with an acid-labile
bond (G4COOH-nDOX)
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Figure 5.1 Synthesis of the generation 4, carboxyl-terminated PAMAM dendrimer
(G4COOH) conjugated with acid-labile DOX (G4COOH-nDOX). NMM = Nmethylmorpholine; IBCF = isobutyl chloroformate; TFA = trifluoroaetic acid; DCM =
dichloromethane.
The synthetic route of the G4COOH-nDOX conjugate is shown in Figure 5.1. All the
intermediates and final products were characterized with proton nuclear magnetic resonance (1H
NMR) for chemical composition and mass-assisted laser desorption/ionization-time of flight
(MALDI-TOF) for molecular weight. The hydrodynamic diameter (HD) and zeta potential () of
the intermediates and final products were measured with light scattering (LS). The methods for
instrumentation can be found in Supporting Information in Appendix 4.
G4COOH (78.3 mg, 3.80 µmol) was mixed with NMM (117.98 µL, 1.07 mmol) and IBCF
(133.64 µL, 1.02 mmol) in 8 mL DMSO/DMF (v/v, 10/90). The system was stirred at 0 oC for 5
min, and then TBC (32.1 mg, 0.243 mmol) was added to the above mixture.[113] The reaction
was further stirred at 0 oC for 30 min and continued at room temperature for 48 h. The organic
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solvent was completely removed under reduced pressure. The product was redissolved in 0.1 M
phosphate buffer solution with pH value being adjusted to around 10. The product (G4COOHmTBC) was purified with centrifugal filtration (MWCO=10kDa) and the product collected in filter
was lyophilized for 24 h. 1H NMR (ppm, DMSO_d6): δ 9.52 (s, 32.30H, -NHBoc in TBC), 8.67
(s, 29.58H, -NHCO- in TBC), 7.89-7.70 (m, 156.84H, -NHCO- in G4COOH), 3.06 (m, 372.38H,
-CONHCH2- (He) in G4COOH), 2.63-2.56 (m, 328.45H, -NCH2- (Hd) and -COCH2CH2CO (Hjr3)
in G4COOH), 2.41 (m, 126.38H, -CH2N- (Hb,c) in G4COOH), 2.29 (m, 150.53H, CH2CH2CONHNH- (succinic methylene, Hjr2) in G4COOH), 2.18 (m, 248.00H, -CH2CO- (Ha) in
G4COOH), 1.36 (m, 305.54H, -(CH3)3 in TBC). MALDI-TOF m/z (Da): 20531.79.
The resulting G4COOH-mTBC (84.34 mg, 4.10 µmol) was dissolved in 5 mL TFA/DCM
(80/20, v/v) and stirred at 0 oC for 30 min. The TFA was immediately removed under reduced
pressure. The product was treated with 0.1 M phosphate buffer solution (pH 10). The product
(G4COOH-mHyd) was purified with centrifugal filtration (MWCO=10kDa) and the conjugate
collected in the filter was lyophilized for 24 h. 1H NMR (DMSO_d6, ppm): δ 9.02 (s, 19.06H,
NH2NHCO- in hydrazide), 8.03 (m, 175.56H, -NHCO- in G4COOH), 3.05 (m, 258.24H, CONHCH2- (He) in G4COOH), 2.620 (m, 188.96H, -NCH2- (Hd) and -COCH2CH2CO- (Hjr3) in
G4COOH), 2.41 (m, 87.18H, CH2N- (Hb,c) in G4COOH), 2.23 (m, 151.22H, -CH2CONHNH2
(succinic methylene (Hjr2) in G4COOH), 2.18 (m, 248.00H, -CH2CO- (Ha) in G4COOH).
MALDI-TOF m/z (Da): 17780.33.
DOX (20 mg, 34.48 µmol) was dissolved in 40 mL anhydrous MeOH with a trace amount
of TFA as catalyst (1.32 µL, 17.32 µmol). The G4COOH-mHyd (18.67 mg, 1.05 µmol) was added
to the above organic mixture and the reaction was monitored with TLC until the reaction was
completed. The MeOH was completely removed under reduced pressure. The product was
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purified with centrifugal filtration (MWCO=10kDa) and the solution was monitored repeated for
ending of centrifugal process. The product (G4COOH-nDOX) was lyophilized for 24 h. 1H NMR
(DMSO_d6, ppm): δ 9.02 (s, 20.41H, NH2NHCO- in hydrazide), 8.05 (m, 167.13H, -NHCO- and
Ar-H in G4COOH and DOX), 5.26 (s, 11.99H, -CH- in DOX), 4.89 (d, 12.72H, -CH- in DOX),
4.570 (m, 24.72H, -CH2OH in DOX), 4.17 (s, 11.02H, -CH- in DOX), 3.94 (s, 35.23H, -OCH3 in
DOX), 3.05 (m, 255.54H, -CONHCH2- (He) in G4COOH), 2.620 (m, 217.26H, -NCH2- (Hd) and
-COCH2CH2CO- (Hjr3) in G4COOH), 2.41 (m, 109.82H, CH2N- (Hb,c) in G4COOH), 2.29 (m,
152.93H, -CH2CONHNH2 (succinic methylene (Hjr1,

jr2)

in G4COOH), 2.18 (m, 248.00H, -

CH2CO- (Ha) in G4COOH), 1.86 and 1.65 (d, 23.96H, -CH2- in DOX), 1.12 (s, 36.10H, -CH3 in
DOX). MALDI-TOF m/z (Da): 23860.59.
5.3.4 In vitro release of DOX from the G4COOH-nDOX conjugate
In vitro release of DOX was determined at both pH 7.4 and 4.5 that represent extracellular
physiological pH and the lysosomal pH, respectively. A 2.0 mL of PBS (10 mM, pH 7.4) or citrate
buffer (10 mM, pH 4.5) containing free DOX or G4COOH-12DOX conjugate (both with 1 µmol
DOX or equivalent) was added to a dialysis bag (MWCO=3kDa), and the dialysis bag was
immersed in 30 mL same medium as inside the bag. The in vitro release was performed by gently
shaking the system at 37.0 ± 0.2 °C and in darkness. A 0.1 mL buffer solution from outside the
dialysis bag was sampled at predetermined time points, and the absorption of DOX was determined
using a Biotek Synergy 2 Multi-Mode Microplate Reader (Biotek Instruments, Inc. Winooski, VA,
USA), at 490 nm and the amount of DOX was calculated with respect to an established calibration
curve.

These experiments were run in triplicate.

The samples were returned after each

measurement. The cumulative release of DOX from the conjugate was plotted as a function of
time.
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5.3.5 Cell kill (in vitro) of the G4COOH-nDOX conjugate
The ability of the G4COOH-12DOX conjugate to kill B16F10 melanoma cells was
assessed using the MTT assay. The results benchmarked against free DOX as control. Briefly,
sample-laden DMEM (no phenol red) was sterilized through 0.22 µm syringe filter (VWR
Internationals). 10,000 B16F10 cells were seeded in each well of tissue culture treated 96-well
plate (VWR Internationals) 24 h ahead of the experiment. The DMEM in each well was replaced
with a 100 µL of the sample-laden DMEM (no phenol red). The medium was removed after 48h,
and the cells were washed twice with 100 µL PBS (10 mM, pH 7.4). 100 µL of fresh DMEM (no
phenol red) and 10 µL of MTT (5 mg/mL in PBS) were added to each well. After 4 h incubation
at 37 oC and 5% CO2, 75 µL medium was removed and 60 µL DMSO was then added. The cells
were allowed to sit in the incubator (37 oC, 5% CO2) for another 2 h. Finally, the absorbance of
each well was recorded at 570 nm. The cell viability of B16F10 cells was plotted as a function of
free- or dendrimer-conjugated DOX concentration (n=8 per concentration).
5.3.6 Cellular internalization of the G4COOH-nDOX conjugate by B16F10 cells
3×105 B16F10 cells/well were seeded in Costar® 24-well cell culture plate (Corning Life
Science. Tewksbury, MA, USA) 24 h prior to the experiment. A 0.5 mL sterile Hanks Balanced
Salt Solution (HBSS, 1X, pH 7.4) containing free DOX or G4COOH-12DOX (1 µM DOX or
equivalent) was added to each well and then incubated with cells for different times (0.5, 1, 1.5, 2,
3, 4 and 5 h. n=3 per time point). The cellular internalization was terminated at each time point
by washing the cells with cold HBSS (1X, pH 7.4). The cells were detached with 0.2 mL trypsinEDTA and were then pelletized by centrifugation at 350 g. The collected cells were resuspended
in 0.5 mL cold HBSS and immediately analyzed for DOX fluorescence with BD LSR II Analyzer
with excitation/emission=488/590 (BD Bioscience. San Jose, CA, USA). At least 10,000 events
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were counted for statistical significance. Median fluorescence intensity (MFI) was plotted as a
function of time to evaluate the cellular internalization of free DOX and dendrimer conjugates.
5.3.7 Efficacy of free and dendrimer-conjugated DOX in treating lung metastasis
A 200 µL PBS containing 2×105 B16F10 cells were implanted to each mouse through tail
vein to develop the lung metastasis model. At 5, 7 and 9 days post tumor implantation (DPI5,
DPI7 and DPI9), 50 µL PBS containing free DOX or G4COOH-nDOX (20 µg of DOX equivalent
per dose) was administered to each mouse via either pharyngeal aspiration (p.a. = lung delivery)
or i.v. injection, which served as the control in terms of route of administration. The mice were
deeply anesthetized with 2.5% v/v isoflurance/oxygen and then placed on a slant board in a supine
position. The tongue was gently extended and a 50 µL sample-laden PBS was gradually dripped
in the pharynx region with a Hamilton®900 series syringe (Hamilton Company. Reno, NV, USA).
The tongue was not returned until after a few breaths. The mice were gently returned to the cage
and monitored during a few minutes for recovery. The mice were observed daily for behaviour
(e.g. diet, drinking, and motion) and body weight. The mice were euthanized at DPI17 or prior to
terminal point if necessary. The terminal point criteria include weight loss of 20% or more,
obvious signs of illness in addition to the tumor, inability to move freely or significant quivering,
and inability to eat/drink properly. The nodule numbers in the lungs of each mouse were carefully
counted (The lung metastases at late stages are characterized by large patches of nodules, so it’s
inappropriate/unlikely to count nodule number exactly at that phase). Kaplan-Meier survival
curves were drawn by plotting survival rate as a function of DPI. The lungs of each mouse were
also weighed out to evaluate tumor burden. These combined parameters are used to evaluate
antitumor efficacy of free DOX and DOX-conjugated dendrimer conjugates. The cohort given
with PBS was used as positive control group. We used 6 mice per cohort for statistical analysis.
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5.3.8 Systemic distribution of the G4COOH-nDOX conjugate
As the mice were euthanized, the blood was collected by cardiac puncture and principle
organs were excised for quantifying systemic distribution of DOX. The excised tissues are lungs,
heart, liver, spleen, kidneys, stomach, brain, thymus, auxiliary lymph nodes (ALN), bronchial
lymph nodes (BLN), cervical lymph nodes (CLN), mesenteric lymph nodes (MLN). The tissues
were homogenized in 3 mL Triton X-100 (0.5% by weight) in PBS (0.5 M, pH 7.4) with D1000
Hand-held Homogenizer (Thermo Scientific) and DOX were extracted into the PBS at 37 oC for a
period of 72 h in darkness. For liver, 5 mL solution was needed instead. The homogenate was
pelletized by centrifugation (22,000 g, 4 oC, 10 min) and a 200 µL of the supernatant was taken to
measure DOX fluorescence using Biotek Synergy 2 Multi-Mode Microplate Reader
(excitation/emission=480±20/595±20 nm). The amount of DOX in each tissue was determined
with respect to an established calibration curve, which was measured by spiking predetermined
amount of DOX or dendrimer-DOX conjugate directly into corresponding tissue.

The

determination was performed in triplicate.
5.3.9 Statistical analysis
GraphPad Prism 5 software was used for data analysis. The statistical analysis between
two systems was performed by Student’s t test, while that among multiple systems by one-way
analysis of variance (ANOVA) with either Dunnett’s test or Tukey post hoc test. A P-value of 0.05
or less was considered to be statistically significant.
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5.4 Results and discussion
5.4.1 Synthesis and characterization of the dendrimer-DOX conjugates (G4COOHnDOX)
PAMAM dendrimers have been widely used as drug delivery nanocarriers in cancer
chemotherapy due to highly controlled size, low toxicity, non-immunogenicity, and multiple
functionalizable surface groups.[167] Hydrazone bonds have been recognized as one of the most
promising acid-labile spacers in covalently bonding DOX to polymer due to its high sensitivity to
mild acidity and relatively straightforward chemistry.[113, 283]

In the study, DOX was

conjugated G4COOH via hydrazone bonds. G4COOH was firstly modified on surface with Bocprotected hydrazide. The successful modification of -COOH groups was evidenced by two peak
shifts –NHNH2 in TBC: 7.83 ppm (-NH-) to 9.52 ppm (-NHBoc) and 3.89 ppm (-NH2) to 8.67
ppm (-NHCO- adjacent to G4COOH). The protective Boc groups were subsequently removed to
give rise to hydrazide groups (-NHNH2), which was evidenced by the shift of -NHCO- (adjacent
to G4COOH) peak from 8.67 to 9.02 ppm and disappearance of the peak at 9.52 ppm. The
resulting –NH2 groups of hydrazides were further reacted with carbonyl group of DOX, leading to
formation of the hydrazone bonds, which are cleavable at mild acidic condition (pH≤5; e.g.
intracellular lysosomal pH), but stable at near neutral condition (e.g. extracellular physiological
pH). The detailed 1H NMR and MALDI spectra of dendrimer-DOX conjugates and important
intermediates are shown in Figure 5.2. DOX payload and molecular weight of dendrimer
conjugate are quantified and summarized in Table 1. Approximately 12 DOX molecules are
attached to each dendrimer according to 1H NMR spectra, which was in agreement with MALDI
results.
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Table 5.1 Molecular weight (MW), number of conjugated doxorubicin (DOX) (n),
hydrodynamic diameter (HD), and zeta potential (ζ) of generation 4, carboxylterminated PAMAM dendrimer (G4COOH) conjugate. DOX was conjugated
through an acid-labile hydrazone linker. Results obtained by 1H NMR, MALDI,
and light scattering (LS) at 25oC. s.d. = standard deviation.
Conjugates

MW

DOX content (n)

HD ± s.d. (nm) ζ ± s.d. (mV)

1

HNMR MALDI

G4COOH

17104

0

0

4.7 ± 1.8

-6.6 ± 4.1

G4COOH-30Hyd

17780

0

0

3.6 ± 0.9

-0.5 ± 2.6

G4COOH-12DOX

23861

12.2

11.5

9.7 ± 3.5

+13.8 ± 7.0

Size and surface charge and chemistry are some of primary parameters to be considered in
the design of drug delivery systems as they strongly affect the interaction with the physiological
environment, including the bioavailability, pharmacokinetics and pharmacodynamics of the
conjugates. It can be seen that the hydrodynamic diameter (HD) of the dendrimer slightly
decreased upon surface modification with hydrazides (4.7 to 3.6 nm), whereas it dramatically

G4COOH = 17104
G4COOH-TBC = 20532
G4COOH-Hyd = 17780
G4COOH-12DOX=23861

(b)

(a)

G4COOH-12DOX
G4COOH-30Hyd
G4COOH-30TBC
G4COOH
10.0 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0
ppm
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25

30

35

m/z (kDa)

Figure 5.2 (a) 1H NMR spectra of acid-labile G4COOH-12DOX conjugate. Inset:
chemical structure of G4COOH-12DOX. Spectral shifts for all compounds are
provided in Section 2.4 and (b) MALDI spectra of G4COOH-12DOX conjugate and
intermediates.
increases upon conjugation of DOX (4.7 to 9.7 nm). The partial conversion of negatively charged
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carboxylates to neutral tert-butyl groups (G4COOH-mTBC) attenuates the repulsion of peripheral
carboxylates. Additionally, hydrophobic tert-butyl group will tend to be less solvated by the
aqueous environment. Both effects lead to more collapsed architecture with respect to G4COOH.
In contrast, the HD increase upon DOX attachment is mainly due to large number of bulky and
rigid DOX molecules bonded onto the dendrimer surface. The dendrimer structure is expanded to
some extent by the rigid DOX molecule through the interaction including hydrogen bonding and
electrostatic force. It is also observed that the  increased from a negative value of -6.6±4.0 mV
for bare G4COOH, to a moderately high positive charge of +13.8±7.0 mV upon DOX conjugation.
The remaining hydrazides (ca. 18) on surface and primary amines of DOX (ca. 12) are protonated
at physiological pH (7.2-7.4), which cannot only offset negative charges from carboxylates, but
provide extra positive charges. Therefore, the overall surface potential of dendrimer-DOX
conjugate is positive, which may potentially enhance cellular internalization and promote
interaction with the local epithelia.[49]
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5.4.2 Sustained in vitro release of acid-labile G4COOH-12DOX conjugate
The ability of DOX release from dendrimer-DOX conjugate was determined at two pH
values — mild acidic (e.g. lysosomal pH 5~4.5) and physiological (e.g. pH 7.4~7.2)
conditions.[113, 115] The results are summarized in Figure 5.3.

Cumulative Release (%)
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G4-11DOXTPP
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G4COOH-12DOX pH 7.4
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20
0
0
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40

60
Time (h)
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100
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Figure 5.3 In vitro release profiles of DOX from acidlabile G4COOH-12DOX at (i) lysosomal pH = 4.5 and
physiological pH = 7.4, both at 37 oC. Results represent
mean ± s.d. (n=3 per group). s.d. = standard deviation. The
diffusion of free DOX out of dialysis membrane
(MWCO=3000Da) is used as control.
As shown in Figure 3, the release of DOX from G4COOH was shown to be dependent on
pH. A negligible (<4%) amount of DOX was released at pH 7.4, while in an acidic medium over
80% DOX was released from the conjugate at 48 h. In contrast, free DOX diffused out of dialysis
membrane at a fairly rapid rate (over 90% release at approximately 7 h) for both pH values. Based
on the release profile of free DOX, approximately 7% of DOX cannot be recovered likely due to
interactions of DOX with the dialysis bag and photobleaching. Similar losses can be expected for
the conjugates, indicating a recovery of over 86% from the “viable” DOX.
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The acid-labile dendrimer-DOX conjugate demonstrates high stability at extracellular
physiological pH, while a sustained DOX release at pH similar to that in acidic compartment. The
high sensitivity of the dendrimer-DOX conjugates merely to acidic condition is of great relevance
as it potentially decreases the concentration of free DOX in plasma by promoting intracellular
release of DOX – spatial control. The decreased DOX concentration in plasma mitigates acute
and chronic cardiac toxicity of DOX which limits long-term use as well as application in certain
patient population.[284, 285] In lung tumor chemotherapy, only a few percent of dose of DOX
can reach tumor lesion upon systemic administration.[8] The incidence of fatal myelosuppression
(decreased bone marrow activity) and cardiomyopathy is significantly increased when cumulative
dose is over a certain limit (e.g. 400-550 mg/m2 of body surface area).[286] Therefore, spatially
controlled DOX release — intracellularly — could potentially reduce the access of free DOX to
systemic bloodstream and bone marrow.
5.4.3 Cell kill of B16F10 melanoma cells lines by the G4COOH-12DOX conjugates
The cytotoxicity of free DOX and G4COOH-12DOX against B16F10 cells was assessed
by MTT assay. As shown in Figure 5.4, the G4COOH-12DOX (IC50=6.01 µM) conjugate was
slightly less toxic (2.3-fold less potent) than free DOX is against B16F10 melanoma cells at 48 h
incubation. The difference in toxicity can be mainly ascribed to sustained release of conjugated
DOX (see discussion in Section 3.2), differing cellular uptake extent and different subcellular
trafficking pathways of free and conjugated DOX. Free DOX can directly diffuse through cellular
membrane and reach the nucleus,[216] while the trafficking of conjugated DOX to nucleus is more
complex. That is, dendrimer-bound DOX is internalized through endocytic pathways, followed
by DOX release from dendrimers upon the cleavage of hydrazone in acidic compartments. The
diffusion of released DOX out of lysosome is a time-consuming process as the internal membrane
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of lysosomes is permeable to the base form of weak bases.[219] Mild acidity in lysosomes
protonates a substantial majority of DOX ([DOX+H]+) which need to be converted to free base for
outflow. The forward conversion of cationic DOX to free base (both forms are at equilibrium) is
driven by DOX efflux from lysosomes.[219]
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Figure 5.4 Cell kill of acid-labile G4COOH-12DOX as
determined by MTT assay after 48 h incubation with
B16-F10 melanoma cells. Free DOX is used as control.
Results represent mean ± s.d. (n=8 per group). s.d. =
standard deviation. IC50 was calculated based on nonlinear regression Log(inhibitor) vs. Response (variable
slope) with G4COOH-12DOX being 6.0 µM and free
DOX being 2.6 µM.

It is also important to note that the therapeutic efficacy in vivo depends on the ability of the
payload to reach the tumor site first and foremost (before it can be internalized), and nanocarrier
systems are expected to perform better than the free therapeutic.[34, 287] Therefore, while less
cytotoxic at a certain time point, the expectation is that the nanocarrier conjugates will outperform
the free drug.
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5.4.4 Enhanced cellular internalization of DOX by its conjugation to dendrimer conjugate
The cellular internalization of free DOX and G4COOH-12DOX conjugate by B16F10 cells
was investigated as a function of time by flow cytometry (a period of 5 h at early stage of
internalization). The early kinetics was evaluated by a plot of median fluorescence intensity (MFI)
of DOX internalized within the cells as a function of time, as shown in Figure 5.5.
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Figure 5.5 Cellular internalization of the acid-labile G4COOH12DOX in B16-F10 melanoma cells as a function of time, as
determined by flow cytometry. Results denote mean ± s.d. (n=3 per
group). Statistical significance is calculated with respect to free
DOX by Student’s t test (*p<0.05, **p<0.01, and ***p<0.001). The
rates of internalization of G4COOH-12DOX (conjugated DOX)
and free DOX are 268.7 a.u.h-1 (R2 = 0.963) and 35.7 a.u.h-1 (R2 =
0.981), respectively. The rate is calculated by linear fitting of 3
initial time points.
It is observed that the rate and extent of internalization of DOX were enhanced upon the
conjugation to dendrimer nanocarriers. The conjugated DOX had a rate of internalization of 268.7
a.u.h-1 within early times, which was approximately 7.5 fold greater than that of free DOX (35.7
a.u.h-1). The overall extent of internalization of conjugated DOX was significantly different from
that of free DOX, at least within the time frame of the experiment - 5h. However, the difference
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narrowed down over time — the overall uptake of G4COOH-12DOX was 7.8, 4.1, and 2.5 times
as high as free DOX at 0.5, 2, and 5 h incubation, respectively.
Earlier works show passive diffusion is responsible for cellular uptake of hydrophobic
DOX, which is determined by concentration gradient and hydrophobicity of DOX,[216, 224]
while dendrimers are internalized via various endocytosis including macropinocytosis,[226]
receptor-mediated endocytosis,[217, 225, 226] and non-specific, adsorptive endocytosis.[225, 227,
228] The endocytosis is dictated by size, shape and surface chemistry. The significantly enhanced
rate and extent of internalization of G4COOH-12DOX by B16F10 cells can be attributed to its
positive charged surface upon DOX attachment. G4COOH-12DOX conjugate with a  of +13.8
mV is readily adsorbed on negative plasma membrane and quickly saturates the membrane,[227]
which results in rapid internalization and uptake plateau (found at 1.5 - 2 h incubation). The nonspecific, adsorptive endocytosis is faster and less energy-dependent than other endocytic pathways
due to its electrostatic interaction.[217]
The apparent paradox between weaker in vitro potency and enhanced uptake of the
conjugates, which has been also observed for other polymer-DOX systems conjugated through
acid-labile bonds[34, 130] could be interpreted in the following way: (1) incubation time has a
stronger effect on cell kill of acid-labile conjugates than free DOX due to sustained release from
the conjugate. The ability of dendrimer-DOX conjugates to kill cancer cells in vitro is very close
to that of free DOX as incubation is prolonged; (2) to a lesser extent, dendrimers are likely to
disrupt endosomes and lysosomes due to the protonation of tertiary amines as their concentration
in acidic compartments increases; The disruption of acidic compartment fails to release DOX from
dendrimer conjugates, resulting in an underestimation of cell kill of the dendrimer-DOX conjugate
by MTT assay when the concentration of conjugate is relatively high ; (3) dendrimer conjugates
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are internalized through various endocytic pathways, including those whose vesicles do not evolve
into acidic compartments.[166, 230] For instance, caveolae-mediated endocytosis ends up in
neutral caveosomes, where DOX will have a lesser change to be released from dendrimers.
In summary, the cellular uptake of DOX is significantly enhanced upon its conjugation to
the dendrimer nanocarriers discussed here. This is relevant as greater intracellular concentration
of DOX may be achieved while also minimizing also potentially decrease plasma concentration,
which in turn is expected to mitigate systemic adverse effect, especially to the cardiac tissue.
5.4.5 Effect of the G4COOH-12DOX conjugates in treating lung metastasis
We investigated the impact of conjugation and route of delivery (p.a. and i.v.) on the
efficacy of DOX in reducing the metastatic lung tumor burden. As shown in Figure 5.6, the
development of numerous black nodules in the lungs showed that neither free nor conjugated DOX
suppressed the proliferation of lung tumors when administered i.v. – note, however, that the
intensity of tumor nodules appears to be slightly less in the case of G4COOH-12DOX compared
to the free DOX group. Because the density of nodules is so high, it is hard to clearly count them
and thus only a qualitative assessment can be achieved by visually inspecting the lung tissue.
In contrast, only a small number of lung nodules were observed in the treatment groups
where DOX was administered via pulmonary route, revealing that either free or conjugated DOX
delivered directly to the lungs significantly inhibits the growth of metastatic tumor in the lungs,
and it is thus a superior route of administration when compared to i.v. . Additionally, the number
of lung nodules in the G4COOH-12DOX p.a. group was also significantly fewer than that of DOX
p.a. group (6.8±0.5 : 10.3±1.0; p=0.0063), demonstrating that conjugation further enhances
treatment efficacy. While the counting of lung nodules can be employed to qualitatively evaluate
tumor burden, it is somewhat limited as it is difficulty to delineate single nodules, especially when
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nodules are numerous and are of different sizes. Therefore, other methods should be also
employed to further assess the effectiveness of therapeutics in reducing tumor burden. We selected
the overall weight of lungs as a complementary parameter to the counting nodules protocol. The
results are summarized in Figure 5.7 as a function of delivery route and conjugation.
The lung weights of two positive control groups — PBS i.v. (213±24 mg, p=0.0098) and

Figure 5.6 Images of lungs collected from C57BL/6 mice bearing lung metastases
(n=6 per group). PBS, free DOX or G4COOH-12DOX is administered through i.v.
or p.a. route. i.v.: intravenous injection; p.a.: pharyngeal aspiration (pulmonary route).
The lungs excised from normal mice are used as negative control (top row). “+” in
tumor column denotes mice bearing lung tumors from metastatic melanoma and “–”
represents the lungs excised from negative control group.
PBS p.a. (201±30 mg, p=0.0177) — were significantly greater than those of healthy mice (142±11
mg). Among all treatment groups, neither DOX i.v. nor G4COOH-12DOX i.v. altered overall
lung weights (DOX: 202±22 mg and G4COOH-12DOX:195±26 mg; both were not significant)
compared to their positive group (PBS i.v.). In contrast, the tumor-bearing mice treated with either
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DOX p.a. (159±18 mg, p=0.0336) or G4COOH-12DOX p.a. (152±15 mg, p=0.0259) significantly
reduced lung weights compared to PBS p.a. positive group. We also observed that the groups
treated with same therapeutics but different routes showed significant difference in lung tumor
burdens. That is, DOX group: i.v. : p.a. = 202±22 mg : 159±18 mg (p=0.0415); and G4COOH12DOX group: i.v. : p.a. = 194±26 mg : 152±14 mg (p=0.0489).
The Kaplan−Meier survival curves (Figure 5.8) showed that 100% of mice were alive when
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Figure 5.7 Weight of lungs excised from healthy C57BL/6
mice (negative control group; n=3 per group) and tumormetastases bearing mice treated with different therapies (n=6
per group) at 17 days post implantation (DPI17). Results
represent mean ± s.d. Statistical analysis is performed with
one-way ANOVA Tukey’s test. *p<0.05, **p<0.01, and
***p<0.001. p.a. = pharyngeal aspiration; i.v. = intravenous
injection; s.d. = standard deviation.
treated with either DOX p.a. or G4COOH-12DOX p.a., which represents a significant
improvement in treatment (p=0.0185 for both groups) compared to no treatment group (PBS p.a.),
with only 1 mouse alive (16.7% survival rate) at terminal point. In contrast, the treatments via i.v.
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5.4.6 Impact of administration route and DOX conjugation on systemic biodistribution
Our in vitro results have showed that conjugation of DOX to dendrimer nanocarriers
enhances the cellular uptake of DOX, while promoting intracellular release, demonstrating the
potential to reduce systemic toxicity of DOX. However, the in vivo fate and distribution of DOX
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Figure 5.9 Systemic distribution of DOX and G4COOH-12DOX delivered via (a) p.a.
and (b) i.v.. Mice bearing lung metastases were euthanized at 17 days post implantation
(DPI17) or terminal point prior to DPI17. Results represent mean ± s.d. (n=6 per
group). The groups of same administration (p.a. or i.v.) are analyzed using one-way
analysis of variance (ANOVA) with Tukey’s post hoc test. *p<0.05, **p<0.01 and
***p<0.001. % of TD = % of total dosage. p.a. = pharyngeal aspiration; i.v. =
intravenous injection; s.d. = standard deviation.
free or in conjugate form is much more complex as it is impacted by several factors, such as various
in vivo barriers, which vary as a function of the delivery route. We investigate, therefore, the
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distribution of systemically and locally (lung) delivered DOX (free or in conjugate form) in major
organs. The systemic distribution results are summarized in Figure 5.9.
The results show that the DOX tissue distribution is strongly impacted by the route of
administration and conjugation. The amount of DOX in the lungs at DPI17 (8 days after last
dosing) followed the sequence: G4COOH-12DOX p.a. (26.8±5.0% of total dose - TD) > DOX p.a.
(9.8±4.3% of TD) >> G4COOH-12DOX i.v. (1.1±0.4% of TD) ≈ DOX i.v. (0.5±0.1% of TD).
These results demonstrate that pulmonary delivery can potentially increase drug dose and prolong
drug retention in lungs compared to systemic administration. This can be seen as an extra
advantage compared to free DOX, which was not captured on the results presented while
discussing number of tumor nodules or lung weight. It suggests that upon further optimization of
dosages (concentration and number), there is the potential to either decrease total dosage or the
number of dosages. For comparison, it is worth noticing that previous studies have shown that a
large amount of DOX-loaded PLGA nanoparticles remained in the lungs one week after inhalation,
and a detectable amount of DOX was still found up to 14 days post treatment.[142] Similarly,
PEI-conjugated DOX could be still clearly seen 7 days after i.t. administration.[143]
We further analyzed the statistical difference of drug retention among all groups at DPI17.
As shown in Figure 5.10 (a), one-way ANOVA Tukey’s test showed the amount of DOX in the
lungs of G4COOH-12DOX p.a. group was significantly greater with respect to that of all other
groups — DOX p.a. group (p=0.0194), G4COOH-12DOX i.v. (p<0.0001), and DOX i.v.
(p<0.0001). Additionally, the amount of DOX in the lungs of DOX p.a. group was also much
greater than that of G4COOH-12DOX i.v. (p=0.0038) and DOX i.v. group (p=0.0050). However,
no statistical difference was found between DOX i.v. and G4COOH-12DOX i.v. group.
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Figure 5.10 (a) Accumulation of DOX (free/conjugated form) in the lungs at terminal
point (DPI17). Therapeutics were given through i.v. or p.a. route. Statistical analysis
is performed with one-way analysis of variance (ANOVA) with Tukey’s post hoc test.
(b) Temporal effect on accumulation of DOX in the lungs. Therapeutics were given
through p.a.. The mice were euthanized at DPI13 (n=3 per group) and DPI17 (n=6 per
group). Statistical analysis is performed in 2 different ways: (i) all groups at DPI13 or
DPI17 are analyzed with one-way analysis of variance (ANOVA) with Tukey’s post hoc
test; (ii) same therapy groups (e.g. DOX p.a.) at DPI13 and DPI17 are analyzed with
Student’s t test. *p<0.05, **p<0.01 and ***p<0.001. Results represent mean ± s.d.. %
of TD = % of total dosage. i.v. = intravenous injection; p.a. = pharyngeal aspiration;
DPI = days post implantation; s.d. = standard deviation.
Our recent results demonstrated that the fate of PAMAM dendrimer nanocarriers
administered to the lungs is greatly impacted by their surface charge — positively charged
PAMAM dendrimers tent do reside locally (lungs) for longer, while neutral dendrimers have tend
to more effectively translocate into systemic circulation.[168] The HD of G4COOH-12DOX is
ca. 10 nm, which is larger than the fenestration of the endothelial lining of vascular vessels (4-5
nm).[175] Compared to small molecule drugs, reverse diffusion of dendrimer conjugates into
vascular vessels for clearance is thus reduced.[175] In the meantime, the reabsorption of interstitial
dendrimer conjugates through lymphatics is also much attenuated in tumor tissues due to a lack of
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effective lymphatic drainage.[287, 288] These conditions thus lead to a preferred retention of
dendrimer-bound DOX in the lungs compared to free DOX.
Due to the enhanced local concentration of drug upon pulmonary administration, we
investigated the temporal effect on pulmonary retention of locally delivered DOX and G4COOH12DOX. We compared the content of DOX in the lungs at DPI13 (4 days after last dosing) and
DPI17 (8 days after last dosing). The results are summarized in Figure 5.10 (b). At DPI13, the
amount of DOX in the lungs was 39.1±8.5% of total dose (TD) for G4COOH-12DOX p.a. and
25.2±5.3% of TD for free DOX p.a. (p=0.0765). At DPI17, the % of TD decreased for both free
and conjugated DOX. However, the elimination of free DOX from the lung tissue was much more
substantial, decreasing at almost twice the rate when compared to conjugated DOX, being at
26.8±5.0% of TD for G4COOH-12DOX p.a. and 9.8±4.0% TD for free DOX p.a. (p=0.0089) at
DPI17. Therefore, a higher DOX retention and a much greater p value between DPI13 and DPI17
demonstrates that conjugation to the dendrimer nanocarriers slow down the elimination of DOX
from the lungs. The processes responsible for dendrimer-DOX and DOX clearance may include
mucociliary escalator, pulmonary alveolar macrophage phagocytosis, translocation to systemic
circulation and enzymatic degradation.[39, 72, 152, 201]
Interestingly, the groups treated with either DOX p.a. or G4COOH-12DOX p.a. showed
lower cardiac accumulation of DOX compared to the distribution upon i.v. administration. No
statistical difference was found between the two p.a. groups. Noticeably, intravenous injection of
free DOX was the system that resulted in the greatest accumulation of DOX in the cardiac tissue
compared to all other groups— Figure 5.11 (a). Considering the limited accumulation of DOX in
heart upon pulmonary administration, the cardiac content of locally delivered DOX as a function
of time (sampled at DPI13 and DPI17) was further investigated. As shown in Figure 5.11 (b), we
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observed that at DPI13, the cardiac content of DOX in the groups treated with either DOX or
G4COOH-12DOX were statistically greater than that of no treatment group, whereas they
decreased slightly at DPI17 and only DOX p.a. group showed significant difference with respect
to no treatment group at that terminal point. Comparing with i.v. injection route, however, the
cardiac accumulation of DOX (even in DOX p.a. group) was still much less at DPI17.
The results show that the distribution of DOX to the heart tissue can be mitigated upon
pulmonary delivery, and further upon conjugation to dendrimers. This is of great relevance as
major adverse effects, including lethal cardiomyopathy, are known to limit the applicability of
DOX in the treatment of a variety of cancers including lung metastasis.[289]
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Figure 5.11 (a) Accumulation of DOX (free/conjugated form) in the heart at terminal
point (DPI17). Therapeutics were given through i.v. or p.a.. Statistical analysis is
performed with one-way analysis of variance (ANOVA) with Tukey’s post hoc test. (b)
Temporal effect on accumulation of DOX in the lungs. Therapeutics were given
through p.a.. The mice were euthanized at DPI13 (n=3 per group) and DPI17 (n=6 per
group). Statistical analysis is performed in 2 different ways: (i) all groups at DPI13 or
DPI17 are analyzed with one-way ANOVA Tukey’s test; (ii) same therapy groups (e.g.
DOX p.a.) at DPI13 and DPI17 are analyzed with Student’s t test. *p<0.05, **p<0.01
and ***p<0.001. Results represent mean ± s.d.. % of TD = % of total dosage. i.v. =
intravenous injection; p.a. = pharyngeal aspiration; DPI = days post implantation; s.d.
= standard deviation.
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Besides the ability to modulate the distribution of DOX in the lungs and heart, the results
shown here demonstrate that the route of elimination of DOX is also impacted by the choice of
delivery route and conjugation.

As shown in Figure 5.9 (a) and (b), higher

concentrations/percentage dosage of DOX was found in spleen and liver upon their conjugation to
dendrimers independent of routes of administration. The clearance of polymeric delivery systems
is dictated mainly by surface charge and particle size.[49] Positively charged nanocarriers (e.g.
G4COOH-12DOX in our case) can be cleared and processed by mononuclear phagocytic system
(MPS), whose targets are opsonized by plasma proteins and subsequently captured by
phagocytes.[290, 291] Phagocytes, such as macrophages, mainly reside in or migrate to bone
marrow, lymph nodes, liver and spleen.[292] It is also reported that dendrimer nanocarriers are
cleared by glomerular filtration in kidneys.[193] In this work, small amounts of DOX in the case
of G4COOH-12DOX conjugate (i.v.: 0.84±0.37% of TD and p.a.: 0.60±0.29% of TD) was found
in kidneys at DPI17 (8 days after last dosing). This may be to some extent due to the fat that the
time for observing renal accumulation of DOX is too long. Previous research has shown that
PAMAM dendrimers can be detected in urine 2 h after i.v. injection.[199] On the other hand, it is
also possible that renal pathway may not play a vital role in clearing these dendrimer-DOX
conjugates. Renal glomeruli have round pores of approximately 6 nm in diameter. Therefore, the
nanocarriers with diameter < 6 nm are rapidly to be cleared by glomerular filtration. The
hydrodynamic diameter of G4COOH-12DOX (9.7±3.5 nm) is greater than the size threshold for
glomerular filtration.[49, 291] Additionally, nanocarrier-biomolecule coronas are instantaneously
formed when nanocarriers are exposed to physiological fluids, since plasma proteins are readily
adsorbed on positively charged nanocarriers with formed,[293, 294] leading to much greater
physiological diameters than as light scattering measured.[291]

134

5.5 Conclusion
In this work, we demonstrated the potential of PAMAM-DOX conjugates upon pulmonary
delivery for lung cancer treatment using an in vivo lung metastasis model. DOX was conjugated
to G4COOH through an acid-sensitive bond, which has shown to provide a sustained intracellular
release of DOX, but to be stable at extracellular physiological conditions. Upon conjugation to
dendrimer, significant increase has been observed on the rate and extent of internalization of DOX
by B16F10 cells at short times (up to 5 h). Nuclear colocalization study indicated that DOX can
rapidly colocalize with nucleus, after being released from the conjugates. The dendrimer-DOX
conjugates showed similar ability to kill cancer cells as free DOX did. The acid-labile dendrimerDOX conjugates administered via pulmonary route remarkably reduced the mass and nodule
number of lung tumors derived from metastatic B16F10 melanoma, thus significantly increasing
survival rate of tumor-bearing mice. A high amount (ca. 30% of TD) of locally delivered
dendrimer-DOX conjugates remained in the lungs 8 days after last dosing, significantly higher
than that through i.v. injection. Interestingly, little DOX accumulated in heart tissues upon
pulmonary delivery compared to systemic injection, which implicates greatly reduced risk of acute
and chronic cardiac toxicity. Therefore, the dendrimer-based chemotherapeutic delivery system
in combination with pulmonary administration technology (e.g. oral inhalation) is a potentially
promising strategy for lung cancer treatment.
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CHAPTER 6 — CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Conclusions and future directions
Lung cancer is the leading cause of cancer death among both men and women in the United
States. Adenocarcinoma accounts for more than 40% of all lung cancer cases. Doxorubicin (DOX)
is an FDA-approved chemotherapeutic that has been widely used as primary anticancer drug in the
treatment of a variety of cancers including lung cancers. However, rapid elimination, uncontrolled
release, and life-threatening cardiotoxicity, has hindered the applicability of DOX and other potent
anti-cancer agents.

The treating efficacy for lung adenocarcinoma is also limited by low

accumulation of DOX in the lungs which is generally administered through systemic route, and by
severe cardiac toxicity. The development of polymeric carriers for the modulation of transport,
targeting and controlled release of potent anti-cancer agents and their aerosol formulation for local
lung delivery is of great relevance in the treatment of lung adenocarcinoma.
The main conclusions drawn from our studies and suggested future directions are discussed
here:
(i). We have characterized the effect of PEGylation and route of administration on systemic
and local distribution of PAMAM dendrimer. Our pharmacokinetic results show that dendrimers
with high density of surface modification with PEG not only present long circulation times upon
I.V. administration, but they also reach systemic circulation much faster and are found at much
greater concentrations (ca. 13% of administered dose) than the non-PEGylated counter parts (2%
of administered dose) upon pulmonary administration at tmax.

PEGylation and route of

administration also have profound effects on systemic and local (lung cell) distribution. While ca.
83% of G3NH2 is found in the lungs upon pulmonary delivery at 6.5 hours post administration,
only 2% reaches the lungs upon I.V. delivery.

Interestingly, pulmonary delivery provide
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dendrimers with ability to accumulate in lymph nodes, while no measurable concentration of
neither bare dendrimers nor highly PEGylated dendrimers is found in the lymph nodes upon I.V.
administration. Moreover, PEGylation also increased the transport of dendrimers to the lymph
nodes upon lung delivery.

The findings are valuable for the design of new dendrimer-based

nanovaccines. No statistical difference was observed in terms of the overall percentage of cells
found to take up the unmodified vs. PEGylated dendrimers in the lung. Myeloid and epithelial
cells from the alveoli and airway internalized dendrimers effectively, independent of chemistry,
with myeloid cells being responsible for most of the uptake. The biggest impact of the dendrimer
chemistry was observed regarding uptake in endothelial cells, where PEGylated dendrimers were
observed to be taken up by a large extent. This observation is in agreement with the idea of the
fast transport across extracellular barriers and the lung epithelium leading to enhanced endothelial
internalization en route to systemic circulation. The results shown here suggest that the pulmonary
route of administration in combination with dendrimer chemistry can be used to passively target
tissues of interest for treating a variety of medically relevant diseases of the lungs and other target
tissues of tissues outside the lungs.
As the results show significantly higher local concentration of dendrimer nanocarriers in
the lungs and potential to passively target various lymph nodes. The suggested further studies may
focus on the following aspects: (1) the concentration of PAMAM dendrimers in lungs and lymph
nodes as a function of time should be studied in details; (2) the mechanism for the accumulation
of pulmonary delivered PAMAM dendrimers in various lymph nodes should be further elucidated
— activation of antigen-presenting cells or passively leaking into draining lymph nodes; (3) One
of major challenges that may limit the delivery of polymeric nanocarriers (e.g. PAMAM)
to/through the lungs is the potential acute and chronic toxicological issues caused by delivered
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particulates. To evaluate the acute toxicity PAMAM dendrimers caused in the lungs, inflammatory
cytokines and immune response elicited in animal models should be studied with
immunochemistry staining and flow cytometry. Tumor damage may be screened by histological
staining; (4) in this work, PAMAM is used as model dendrimer to exploit the feasibility of
dendrimers as anticancer drug carriers delivered to/through the lungs. Due to its non-degradable
nature, potential chronic toxicity and biocompatibility may limit its clinical application. The
transition from PAMAM to biodegradable dendrimers (e.g. hyperbranched polyester) are helpful
to expand biomedical application of dendrimer.
(ii). We have developed PEGylated, acid-labile dendrimer-DOX conjugates which can
achieve spatially and temporally sustained release of DOX. The conjugates upon pulmonary
delivery can significantly inhibit tumor growth in vivo and improve survival rate. In detail,
PEGylated poly(amidoamine) dendrimer nanocarriers with acid-labile DOX conjugates were
synthesized. Due to hydrophobicity of DOX, dendrimer may crash out of aqueous solution when
high payload DOX are attached. Aqueous solubility of dendrimer-DOX conjugates can be
increased upon PEGylation of dendrimer nanocarriers. We developed direct PEGylation to
synthesize dendrimer conjugates with low DOX payload and varying PEGylation degree, and twostep PEGylation especially for dendrimer conjugates with high drug payload and high PEGylation
degree. The resulting PEGylated, acid-labile dendrimer-DOX conjugate released DOX only in
acidic medium, and also intracellularly. The release can be modulated by PEG density on
dendrimer surface. We also observed that the kinetics of cellular entry of the nanocarrier with
DOX increased significantly compared to free DOX. At the highest PEGylation density, the rate
of internalization of the nanocarrier containing DOX was even higher than that of free DOX.
PEGylation density also affects cytotoxicity as seen by an increase in IC50 for DOX-conjugated
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dendrimer compared to free DOX, due to the controlled release of the therapeutic. PEGylation
significantly helped dendrimer nancarriers escape mucus trapping compared to bare dendrimer,
aiding their transport to the basolateral side. It is in accordance with in vivo pharmacokinetics.
Reduced transepithelial electrical resistance (TEER) and limited cellular internalization
demonstrated that paracellular transport plays a vital role in transporting dendrimer-DOX
conjugates across airway epithelium. Upon pulmonary delivery of the acid-labile dendrimer-DOX
conjugate, lung tumor burdens were significantly reduced and survival rate of mice were
considerably improved, while i.v delivered therapeutics showed a very limited efficacy. The
results can be correlated to significant greater concentration of therapeutics in the lungs — the
observation extended to 8 days showed approximately 30% of total DOX remained in the lungs.
On the other hand, less DOX were accumulated in heart tissues upon lung delivery, which can
potentially mitigate cardiac toxicity.
The acid-labile dendrimer-DOX conjugates delivered to the lungs showed great promise in
lung tumor treatment in this work, it thus deserves continuing studies in the following aspects: (1)
combination therapy are believed to be an more effective way to fight cancers including lung
tumors, it is potentially relevant to develop dendrimer conjugates for co-delivery of two or more
therapeutics at the same time; (2) The acid-labile dendrimer-DOX conjugates are able to release
DOX intracellularly. Although systemic toxicity of DOX can be significantly reduced by local
delivery, the dendrimer conjugates are incapable of targeting to lung tumor cells. Therefore, next
step may be focused on designing dendrimer conjugates with ability to selectively enter tumor
cells. For example, the conjugation of MUC1 aptamer to dendrimer, whose receptors are
overexpressed on lung cancer cells;[295] (3) gene therapy and immunotherapy are gaining more
and more attention due to their significantly reduced side effects and high ability to kill cancer
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cells. The conjugation of nucleic acid or antigens to dendrimers can significantly may prevent
them from enzymatic degradation and increase their cellular uptake as well. Therefore, the
combination of dendrimer-based immunotherapy/gene therapy in conjunction with dendrimerbased chemotherapy may be a potent therapy against lung cancers, while reduces systemic/local
side effects; (4) we used pharyngeal aspiration to perform lung delivery, which may make
difference in terms of aerosol deposition in the lungs compared to aerosolization. Therefore,
further study may focus on the use of real aerosolizer such as Penn-Century Microsprayer.
(iii) Oral inhalation is well known for its high efficiency of lung deposition and noninvasive nature. The development of oral inhalation formulations for lung cancer treatment is
potentially beneficial to millions of lung cancer patients. Our PEGylated, acid-labile dendrimerDOX conjugates can be directly formulated in the propellant-based metered-dose inhalers (pMDIs)
with a trace amount of ethanol (ca. 0.4% v/v), forming a solution aerosol formulation. The pMDI
formulations containing high PEGylated dendrimer-DOX conjugates can also be readily
formulated into propellant with a co-solvent free method. It is for the first time, to our best
knowledge, that polymer nanocarrier drug delivery system is formulated into a solution aerosol
formulation. The stability and aerosol characteristics increased significantly as PEG density
increased and DOX payload decreased. The formulation of highly PEGylated dendrimer-DOX
conjugates showed superior aerosol characteristics.

The pMDI formulation is suitable for

delivering drug to deep lung area such as alveolar region and terminal bronchi. Furthermore, the
lung deposition position of dendrimer-DOX conjugates can be further modulated by adding
biodegradable surfactants, in order to treat tumors in different pulmonary regions. Broadly, the
PEGylated dendrimer conjugate in combination with metered dose inhalers showed great
potentials to deliver therapeutics to/through the lungs.
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Although the pMDI formulations containing PEGylated dendrimer-DOX conjugates
showed superior aerosol properties, the drug dose in these formulations is still low (ca. 0.2 mg/mL).
A few attempts can be made in future to address the low dose issue: (1) a simple method to increase
DOX dose is to increase concentration of the conjugates in propellant. The aerosol properties
could be compromised as the concentration is over a certain limit. Therefore, the guideline to
improve drug dose is to maximize DOX payload in dendrimer nanocarriers, while minimize the
fraction of other components (dendrimer+PEG). To achieve this goal, thorough studies on the
effect of PEG density and DOX payload on aerosol performance should be performed to find the
highest DOX payload and lowest PEG density, as well as optimal concentration without aerosol
properties compromised. The smaller size of PEG (e.g. 750 Da or 550 Da) may be attempted for
this purpose. However, the consequent alterations of in vivo pharmacokinetics and biodistribution
are also needed to be taken into account and evaluated; (2) previous computational work showed
ester and ether bonds have strong interaction with HFA propellant, enhancing the
solubility/dispersibility of these bonds-containing molecules in HFA propellant. Hyperbranched
polyester contains an abundance of ester bonds.[237] Much lower PEG density on surface are
needed to solvate polyester dendrimer in HFA propellant. Therefore, a much higher concentration
of PEGylated dendrimer-DOX can be reached; (3) a significant advantage DPI formulations hold
over pMDI formulations is much higher dose of drug delivered to the lungs.

Therefore,

development of DPI formulations containing acid-labile dendrimer-DOX conjugates may also be
considered.
.
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APPENDIX A
SUPPLEMENTAL INFORMATION OF CHAPTER 2
S1. Proton magnetic nuclear resonance spectra (1H NMR) and peak assignment
1

H NMR spectra were recorded with a 400 MHz Agilent Mercury spectrometer (Santa Clara, CA).

Proton chemical shifts were reported in ppm (δ) and the peak of deuterated DMSO (DMSO_d6) at
2.483 ppm was set as the reference peak. 1H NMR (DMSO_d6, ppm) of G3NH2-3Cy3: δ 7.9727.772 (m, 50.27H, NHCO of G3NH2), 7.614 (m, 3.28H, aromatic H of Cy3), 7.427 (m, 6.07H,
aromatic H of Cy3), 7.163 (m, 17.94H, aromatic H of Cy3), 6.476 (d, 5.73H, =CH of Cy3), 3.104
(m, 139.92H, CONHCH2 of G3NH2), 2.599 (m, 86.75H, NCH2 of G3NH2), 2.391 (m, 58.50H,
CH2N of G3NH2), 2.161 (m, 120H, CH2CONH of G3NH2), 1.658 (s, 32.97H, CH3 of Cy3), 1.509
(m, 5.88H, CH2 of Cy3), 1.353 (m, 6.03H, CH2 of Cy3). 1H NMR (DMSO_d6, ppm) of G3NH224PEG1000-3Cy3: δ 7.907-7.784 (m, 40.82H, NHCO of G3NH2), 7.609 (m, 3.49H, aromatic H
of Cy3), 7.431 (m, 6.34H, aromatic H of Cy3), 7.179 (m, 18.32H, aromatic H of Cy3), 6.481-6.444
(s, 5.51H, =CH of Cy3), 4.014 (m, 47.64H, CH2NHCO of G3NH2), 3.647-3.402 (m, 2043.61H,
CH2CH2O of PEG1000), 3.216 (69.95H, OCH3 of PEG1000), 3.056 (m, 153.05H, CONHCH2 of
G3NH2), 2.622 (m, 87.78H, NCH2 of G3NH2), 2.396 (m, 63.38H, CH2N of G3NH2), 2.157 (m,
120H, CH2CONH of G3NH2), 1.664 (s, 32.48H, CH3 of Cy3), 1.537 (m, 6.02H, CH2 of Cy3),
1.341 (m, 5.80H, CH2 of Cy3).
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Figure S1. 1H NMR spectra of G3NH2-Cy3 (pink line) in deuterated oxide (D2O) and G3NH224PEG1000-3Cy3 (black line) in deuterated dimethylsulfoxide (DMSO_d6). Detailed chemical
shifts discussed above. The inset is chemical structure of G3NH2-24PEG1000-3Cy3.
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S2. Mass-assisted laser desorption/ionization-Time of Flight (MALDI-TOF)
MALDI-TOF mass spectra were performed on a Bruker Ultraflex spectrometer equipped with a
pulsed nitrogen laser (337 nm) under positive ion reflector mode. 10 μl of sample (1.0 mg/ml) in
DI H2O was mixed with 10 μl of DHB (10 mg/ml) in methanol. 2 μl of the sample was spotted on
a Bruker Daltonics MALDI plate. The spotted sample was dried gently by air flow. MALDI:
G3NH2-3Cy3 (m/z, 8285) and G3NH2-24PEG1000-3Cy3 (m/z, 33312).
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Figure S2. MALDI-TOF spectra of G3NH2-3Cy3 and G3NH2-24PEG1000-3Cy3.
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S3. Single cell staining of pulmonary cellular populations
Lung cell populations tagged by fluorescent probe-labeled antibodies includes myeloid cells
tagged by Percp-Cy5.5, endothelial cells tagged by PE-Cy7, surfactant protein C-secreted alveolar
type II cells tagged by AF647 and ciliated airway epithelial cells tagged by pacific blue. These
cells were prepared according to a preceding reported method [296] with slight modification as
described below.
Primary Antibodies
Rat anti-mouse CD16/CD32 (Fc-Block; BD Biosciences. San Jose, CA, USA), 1:100 dilution in
0.15 or 0.3% saponin buffer. (Preparation: 1 µl Fc-Block + 99 µl 0.15 or 0.3% saponin buffer)
Rabbit polyclonal anti-mouse pro-surfactant protein-C (pro-SPC) antiserum, reactive with human
and mouse proSPC (Abcam. Cambridge, MA, USA), 1:500 dilution in 0.15 or 0.3% saponin buffer.
(Preparation: 1 µl + 499 µl0.15% or 0.3% saponin buffer)
Rat anti-mouse β-tubulin (BD Biosciences. San Jose, CA, USA), 1:500 dilution in 0.15 or 0.3%
saponin buffer. (Preparation: 1 µl + 499 µl saponin buffer)
Rat anti-mouse CD45-PerCP/Cy5.5, clone 30-F11 (BioLegend. San Diego, CA, USA), 1:50
dilution in 0.15 or 0.3 % saponin buffer. (Preparation: 2 µl + 98 µl saponin buffer)
Rat anti-mouse CD31-PE/Cy7, clone MEC13.3 (BioLegend. San Diego, CA, USA), 1:100 dilution
in 0.15 or 0.3% saponin buffer. (Preparation: 1 µl + 99 µl saponin buffer)
Secondary antibodies
F(ab’)2-goat anti-rabbit IgG(H+L) secondary antibody, Alexa Fluor®647 conjugate (Life
Technologies. Grand Island, NY, USA) 1:500 dilution in 0.15 or 0.3% saponin buffer. (Preparation:
1 µl AF647 + 499 µl saponin buffer)
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F(ab’)2-goat anti-mouse IgG(H+L) secondary antibody, Pacific Blue conjugate (Life
Technologies. Grand Island, NY, USA), 1:500 dilution in 0.15 or 0.3 saponin buffer solution.
(Preparation: 1 µl + 499 µl saponin buffer).
2. Incubated lungs connected with trachea in an additional 3 ml dispase per lung for 30 min at
37°C in a 6-well plate.
3. Placed the lungs into a 6 cm petridish filled with 6 ml DMEM containing 100 U/ml DNase and
25 mM HEPES. Removed the lung tissue from the trachea by gentle tapping with the back of a
pair of tweezers.
4. Incubated for 10 min at room temperature with slight agitation.
5. Added 4 ml medium with a 10 ml serological pipet.
6. To further disarticulate the tissue, homogenize by pipetting up and down with a 1 ml pipet.
7. Pipetted the lung homogenate up and down again with a 10 ml serological pipet and transferred
it to a 100 µm nylon cell strainer placed on a 50 ml tube. Added 5 ml medium without DNase and
processed the tissue through the cell strainer.
8. Passed the lung homogenate through the 40 m cell strainer into a fresh 50 ml tube.
9. Centrifuged the single cell suspension for 10 min at 350 g.
10. Discarded the supernatant and resuspended the pellet in 5 ml fresh medium.
11. To determine the amount of cells, dilute the suspension 1:2,000 in 10 ml CasyTon™ and
count the cells using a Casy TT cell counter.
12. Centrifuged the single cell suspension for 10 min at 350 g.
13. Discarded the supernatant and resuspended the pellet in 4 ml fresh 1% paraformaldehyde
solution and incubate for 15 min on ice.
14. Centrifuged the fixed cells for 10 min at 350 g.
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15. Discarded the supernatant and resuspended in 5 ml wash buffer.
16. Centrifuged cells for 10 min at 350 g.
17. Discarded the supernatant and resuspended the pellet in 4 ml wash buffer.
18. Transferred about 200,000 cells per lung sample into FACS tubes.
19. Prepared additional samples as blank controls.
20. Centrifuged the aliquots of 200,000 cells per FACS tube for 10 min at 350 g.
21. Discarded the supernatant, added 100 µl 0.15% saponin buffer per sample for permeabilization,
mix, and incubated for 20 min at 4 °C.
22. Centrifuged FACS tubes for 5 min at 350 g.
23. Discarded the supernatant, added 10 µl diluted Fc-block, added 20 µl of the appropriate
dilutions of the antibodies against CD45, CD31, and pro-SPC and β-tubulin. Vortexed, and
incubated for 25 min at 4°C in the dark.
24. Centrifuged the stained cells for 5 min at 350 g.
25. Discarded the supernatant, washed with 100 µl 0.15% saponin once, and centrifuged the cells
for 5 min at 350 g.
26. Discarded the supernatant, added 20 µl of the appropriate dilution of the secondary antibody
to pro-SPC and β-tubulin group. Mixed, and incubate for 25 min at 4°C in the dark.
27. Centrifuge the stained cells for 5 min at 350 g.
28. Discarded the supernatant, wash with 100 µl 0.15% saponin buffer once and centrifuged the
cells for 5 min at 350 g.
29. Discarded the supernatant, wash with 100 µl once with wash buffer, centrifuged the cells again
for 5 min at 350 g, and resuspended them in 200 µl wash buffer.
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30. Gated the cells to exclude debris and cell clumps using flow cytometer. 160,000 events were
at least counted.
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Examples of FACS cellular biodistribution results for control groups, G3NH2-3Cy3 and
G3NH2-24PEG1000-3Cy3
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Endothelial cells
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Figure S3. Dot plot of antibody-dye vs. Cy3-dendrimer, determined by flow cytometry.
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Biodistribution of the conjugates in a per tissue mass basis.
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Figure S4. Effect of the PEGylation and route of administration on the whole body distribution of
the conjugates. The statistical analysis was performed between G3NH2 and G3NH2-24PEG1000
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with Student t-test (*p<0.05, **p<0.01, and ***p<0.001). Panel (a) pharyngeal aspiration and (b)
intravenous administration, 6.5 h post administration. n=3 per group.
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APPENDIX B
SUPPLEMENTAL INFORMATION OF CHAPTER 3
S1. Characterization
S1.1. Electrospray ionization (ESI)
A trace of sample (a few µg) was dissolved in methanol (mass spectrometry grade), and
then diluted 50 times, also with methanol. The methanolic solution was injected into ZQ-Waters
TERS/Micromass spectrometer (Waters) for determining the m/z value of the analyte.
S1.2. Mass-assisted laser desorption/ionization-time of flight mass spectrometry (MALDITOF)
MALDI-TOF was performed on a Bruker UltrafleXtreme mass spectrometer (Bruker)
equipped with a pulsed nitrogen laser (337 nm) under positive ion reflector mode. The conjugates
were dissolved in deionized water at a concentration of 1.0 mg/mL. 2, 5-dihydroxybenzoic acid
(2, 5-DHB) in methanol (10 mg/mL) was used as matrix. 10 μL of conjugate solution was mixed
with equal volume of 2, 5-DHB solution and 2 μL of the mixed solution was spotted on a Bruker
Daltonics MALDI plate. The spotted sample was dried gently by air flow.
S1.3. Proton magnetic nuclear resonance (1H NMR)
1

H NMR spectra were recorded on a Varian Mercury 400 (400 MHz) spectrometer (Agilent

Technologies) using deuterated DMSO (DMSO_d6). Proton chemical shifts were reported in ppm
(δ) and DMSO_d6 at 2.48 ppm was set as reference peak.
S1.4. Light scattering (LS)
Sample (1.0 mg/mL) was dissolved in phosphate buffer saline (PBS, pH 7.4). pH test
indicated all sample solutions were neutral. Hydrodynamic diameters and zeta potentials were
measured using Zetasizer Nano ZS (Malvern Instruments). The average and standard deviation
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for hydrodynamic diameters and zeta potentials were calculated based on at least three
measurements.
S2. Synthesis of PEGylated PAMAM dendrimer conjugates with acid-labile DOX (G3NH2mPEG-nDOX) and acid-nonlabile DOX (G3NH2-mPEG-nDOXNL)

Figure S1. Protons in cis-aconityl DOX and succinic DOX.
S2.1. Synthesis of cis-aconityl DOX
The synthesis of cis-aconityl DOX was performed using a similar strategy to that reported
in the literature,[297] with modifications. Briefly, 3 mL anhydrous p-dioxane solution of cisaconityl anhydride (188.4 mg, 0.60 mmol) was added dropwise to a 6 mL DI H2O DOX solution
(86.7 mg, 0.15 mmol). The pH value of the aqueous solution was immediately adjusted to 9.0-9.2.
The reaction was vigorously stirred for 20 min at 0-5 oC, and additionally 15 min at room
temperature. The product was precipitated by acidifying the solution to pH 2.0 with 1 M
hydrochloric acid (HCl aq) at 0 oC and then collected by centrifugation. The precipitate was
redissolved in cold DI H2O and the pH was adjusted to 9.0 with 1 M sodium hydroxide solution
(NaOH aq). The precipitation-dissolution process was repeated twice. Finally, the red powder
was lyophilized and stored at 4°C for future use. Yield: 61.7%. TLC (chloroform/methanol/acetic
acid = 17/3/1 v/v, retention factor (Rf): 0.05 (DOX), 0.33 (cis-aconityl DOX)). ESI (m/z):
700.2016 ([cis-aconityl DOX + H]+), 722.1509 ([cis-aconityl DOX + Na]+), 738.1769 ([cis-
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aconityl DOX + K]+). 1H NMR (DMSO_d6, ppm) δ: 7.947 (s, 1.03H, Ar-H (H-2) in DOX), 7.771
(s, 0.97H, Ar-H (H-3) in DOX), 7.443 (s, 0.94H, Ar-H (H-1) in DOX), 6.397 (s, 0.96H, -CH=C(H-16) in cis-aconitic acid), 5.263 (s, 0.99H, -CH- (H-9) in DOX), 4.890 (d, 1.02H, -CH- (H-5) in
DOX), 4.570 (m, 1.95H, -CH2OH (H-6) in DOX), 4.173 (s, 1.02H, -CH- (H-13) in DOX), 3.936
(s, 3.03H, -OCH3 (H-15) in DOX), 3.575 (s, 1.03H, -CH- (H-12) in DOX), 2.986 and 2.807 (d,
1.95H, -CH2- (H-4) in DOX), 2.161 and 2.054 (d, 2.05H, -CH2- (H-7) in DOX), 1.859 and 1.647
(d, 1.96H, -CH2- (H-10) in DOX), 1.122 (s, 3.10H, -CH3 (H-14) in DOX). The sequence of all
protons for cis-aconityl DOX was shown in Figure S1.
S2.2. Synthesis of succinic DOX
DOX (53.8 mg, 92.7 µmol) and TEA (32.6 µl, 0.23 mmol) were dissolved in 2.2 mL
anhydrous DMSO. To the mixture a 1.0 mL anhydrous p-dioxane solution of succinic anhydride
(13.9 mg, 0.14 mmol) was added dropwise. The reaction was stirred and monitored with TLC for
completion. The purification for succinic DOX was same as that of cis-aconityl DOX described
above. Finally, the precipitate was lyophilized until constant weight and stored at 4 °C for future
use. Yield: 67.2%. TLC (chloroform/methanol/acetic acid = 17/3/1 v/v, Rf: 0.07 (DOX), 0.79
(succinic DOX)). ESI (m/z): 666.1815 ([succinic DOX + Na]+), 682.1591 ([succinic DOX + K]+).
1H

NMR (DMSO_d6, ppm) δ: 7.942 (s, 0.99H, Ar-H (H-2) in DOX), 7.739 (m, 1.04H, Ar-H (H-

3) in DOX), 7.441 (s, 0.97H, Ar-H (H-1) in DOX), 5.263 (s, 0.97H, -CH- (H-9) in DOX), 4.896
(d, 2.08H, -CH2- (H-5) in DOX), 4.566 (m, 1.88H, -CH2OH (H-6) in DOX), 4.195 (s, 0.95H, -CH(H-13) in DOX), 3.922 (s, 3.06H, -OCH3 (H-15) in DOX), 3.575 (s, 1.00H, -CH- (H-12) in DOX),
2.989 and 2.807 (d, 2.01H, -CH2- in DOX), 2.732 (m, 4.14H, -CH2- (H-17, 18) in succinic linker),
2.161 and 2.046 (d, 2.02H, -CH2- (H-7) in DOX), 1.859 and 1.647 (d, 1.99H, -CH2- (H-10) in
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DOX), 1.125 (s, 3.09H, -CH3 (H-14) in DOX). The sequence of all protons for succinic DOX was
shown in Figure S1.
S2.3. Synthesis of acid-labile G3NH2-mPEG-nDOX conjugates
Direct PEGylation
S2.3.1. Synthesis of acid-labile G3NH2-nDOX conjugates (n=3)
Cis-aconityl DOX (23.6 mg, 33.6 µmol), EDC (6.4 mg, 33.5 µmol) and NHS (5.6 mg, 40.2
µmol) were dissolved in 1 mL anhydrous DMSO and stirred for 1.5 h. To the mixture, a 2.2 mL
solution of G3NH2 (22.8 mg, 3.3 µmol) and p-toluenesulfonic acid monohydrate (p-TSA) (5.6 mg,
29.7 µmol) in anhydrous DMSO were added. The reaction was stirred for 48 h in darkness. The
product was dialyzed against PBS (0.1 M pH 7.4) for 48 h, followed by DI H2O for 24 h. The
precipitate was removed by 0.45 µm nylon syringe filter (VWR Internationals) and then
lyophilized for 48 h. MALDI-TOF (m/z): 9133.32. 1H NMR (DMSO_d6, ppm) δ: 8.053-7.689
(m, 57.61H, -NHCO- in G3NH2 and Ar-H (H-2, 3) in DOX), 7.429 (s, 2.95H, Ar-H (H-1) in DOX),
6.397 (s, 3.10H, -CH=C- (H-16) in aconityl linker), 5.252 (s, 3.12H, -CH- (H-9) in DOX), 4.896
(d, 3.19H, -CH- (H-5) in DOX), 4.560 (m, 5.82H, -CH2OH (H-6) in DOX), 4.175 (s, 2.85H, -CH(H-13) in DOX), 3.938 (s, 9.88H, -OCH3 (H-15) in DOX), 3.054 (m, 128.66H, -CH2- in G3NH2),
2.620 (m, 119.14H, -CH2- in G3NH2), 2.380 (m, 52.09H, -CH2- in G3NH2), 2.181 (m, 120H, CH2- in G3NH2), 1.647 (d, 5.66H, -CH2- (H-10) in DOX), 1.126 (s, 9.69H, -CH3 (H-14) in DOX).
S2.3.2. Synthesis of acid non-labile G3NH2-nDOXNL conjugates (n=3)
The synthesis and purification of G3NH2-3DOXNL was similar as to that for G3NH23DOX. MALDI-TOF (m/z): 8914.62. 1H NMR (DMSO_d6, ppm) δ: 8.119-7.653 (m, 60.34H,
-NHCO- in G3NH2 and Ar-H (H-2, 3) in DOX), 7.437 (s, 2.91H, Ar-H (H-1) in DOX), 5.249 (s,
3.38H, -CH- (H-9) in DOX), 4.902 (d, 3.10H, -CH- (H-5) in DOX), 4.560 (m, 6.38H, -CH2OH

159
(H-6) in DOX), 4.173 (s, 3.12H, -CH- (H-13) in DOX), 3.968 (s, 10.63H, -OCH3 (H-15) in DOX),
3.078 (m, 114.72H, -CH2- in G3NH2), 2.673 (m, 101.63H, -CH2- in succinic linker (H-17, 18)
and -CH2- in G3NH2), 2.430 (m, 57.37H, -CH2- in G3NH2), 2.183 (m, 120H, -CH2- in G3NH2),
1.653 (d, 6.16H, -CH2- (H-10) in DOX), 1.123 (s, 10.14H, -CH3 in DOX).
S2.3.3. Synthesis of acid-labile G3NH2-mPEG-3DOX and acid non-labile G3NH2-mPEG3DOXNL conjugates (m=9 or 21)
The G3NH2-mPEG-3DOX and G3NH2-mPEG-3DOXNL conjugates were synthesized in
the same way. G3NH2-21PEG-3DOX: a 0.3 mL anhydrous p-dioxane of PEG1K-SE (35.5 mg,
33.0 µmol) was added to G3NH2-3DOX (5.2 mg, 0.58 µmol) which was in 2.0 mL PBS (0.1 M,
pH 8.6). The reaction was stirred at 4 °C for 1 h and at room temperature for another 5 h. MALDITOF (m/z): 31219.72. 1H NMR (DMSO_d6, ppm) δ: 8.053-7.689 (m, 57.61H, -NHCO- in G3NH2
and Ar-H (H-2, 3) in DOX), 7.429 (s, 3.19H, Ar-H (H-1) in DOX), 6.393 (s, 2.93H, -CH=C- (H16) in aconityl linker), 5.252 (s, 3.32H, -CH- (H-9) in DOX), 4.896 (d, 3.07H, -CH- (H-5) in DOX),
4.560 (m, 6.27H, -CH2OH (H-6) in DOX), 3.996 (m, 52.82H, -OCCH2O- in PEG and -OCH3 (H15) in DOX), 3.431 (m, 1587.3H, -OCH2CH2- in PEG and -CH- (H-12) in DOX), 3.215 (s, 64.49H,
-OCH3 in PEG), 3.054 (m, 128.66H, -CH2- (H-4) in DOX and -CH2- in G3NH2), 2.667 (m,
119.14H, -CH2- in G3NH2), 2.410 (m, 52.09H, -CH2- in G3NH2), 2.181 (m, 120H, -CH2- in
G3NH2), 1.659 (d, 4.95H, -CH2- (H-10) in DOX), 1.123 (s, 9.33H, -CH3 (H-14) in DOX).
Two-step PEGylation
S2.3.4. PEGylation of G3NH2 (G3NH2-xPEG) (x = 7)
A 0.5 mL anhydrous p-dioxane of PEG1K-SE (65.7 mg, 56.7 µmol) was added dropwise
to a 5 mL PBS (0.1 M, pH 8.6) of G3NH2 (48.8 mg, 7.1 µmol). The reaction was stirred at 4 °C
for 1 h and then at room temperature for another 5 h. The product was purified by dialysis against
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DI H2O for 48 h, and then lyophilized for 48 h. MALDI-TOF (m/z): 13979.13.

1H

NMR

(DMSO_d6, ppm) δ: 8.047-7.769 (m, 52.86H, -NHCO- in G3NH2), 4.025 (m, 14.29H, -OCCH2Oin PEG), 3.461 (m, 714.9H, -OCH2CH2- in PEG), 3.215 (s, 21.09H, -OCH3 in PEG), 3.057 (m,
112.43H, -CH2- in G3NH2), 2.676 (m, 100.17H, -CH2- in G3NH2), 2.419 (m, 47.23H, -CH2- in
G3NH2), 2.181 (m, 120H, -CH2- in G3NH2).
S2.3.5. Synthesis of G3NH2-xPEG-nDOX (x = 7, n = 7)
Cis-aconityl DOX (17.9 mg, 22.0 µmol), EDC (5.1 mg, 26.4 µmol) and NHS (3.1 mg, 26.4
µmol) were reacted in 1.0 mL anhydrous DMSO at room temperature for 1.5 h. To the cis-aconityl
DOX solution was added a 5 mL solution of G3NH2-7PEG (20.5 mg, 1.7 µmol) in anhydrous
DMSO. The reaction was stirred for 48 h at room temperature. The product was dialyzed against
DI H2O for 48 h and then lyophilized for 48 h. MALDI-TOF (m/z): 18705.66.
S2.3.6. Synthesis of G3NH2-mPEG-nDOX (m = 21, n = 7)
A 0.6 mL anhydrous p-dioxane solution of PEG1K-SE (57.4 mg, 49.6 µmol) was added
dropwise to a 7.0 mL PBS (pH 8.6, 0.1 M) of G3NH2-7PEG-7DOX (22.6 mg, 1.2 µmol). The
reaction was stirred at 4 °C for 1 h and room temperature for another 5 h. The product was purified
by dialysis against DI H2O for 48 h and then lyophilized for 48 h. MALDI-TOF (m/z): 33844.20.
1H

NMR (DMSO_d6, ppm) δ: 8.130-7.811 (m, 67.26H, -NHCO- in G3NH2 and Ar-H (H-2, 3) in

DOX), 7.421 (s, 7.07H, Ar-H (H-1) in DOX), 6.399 (s, 6.4H, -CH=C- (H-16) in aconityl linker),
5.284 (m, 6.99H, -CH- (H-9) in DOX), 4.896 (d, 6.19H, -CH- (H-5) in DOX), 4.547 (m, 15.82H,
-CH2OH (H-6) in DOX), 4.033 (m, 68.92H, -OCCH2O- in PEG and -OCH3 (H-15) in DOX), 3.453
(m, 1928.8H, -OCH2CH2- in PEG and -CH- (H-12) in DOX), 3.214 (s, 65.37H, -OCH3 in PEG),
3.068 (m, 135.78H, -CH2- (H-4) in DOX and -CH2- in G3NH2), 2.658 (m, 76.09H, -CH2- in
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G3NH2), 2.424 (m, 59.28H, -CH2- in G3NH2), 2.182 (m, 120H, -CH2- in G3NH2), 1.659 (d,
11.96H, -CH2- (H-10) in DOX), 1.118 (m, 21.26H, -CH3 (H-14) in DOX).
Table S1. IC50 (µM) of free DOX and acid-labile G3NH2-mPEG-nDOX conjugates calculated
from Figure 3 (c) and (d). The cell viability profiles were fitted with a non-linear regression
Log(Inhibitor) vs Response (variable slope).
Conjugates

72 h

144 h

DOX

0.52

0.45

G3NH2-3DOX

21.80

1.41

G3NH2-9PEG-3DOX

29.94

1.73

G3NH2-21PEG-3DOX 48.53

2.38

G3NH2-21PEG-7DOX 56.95

2.91
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Table S2. Aerosol mass deposition (µg) of the pMDI formulation containing G3NH2-mPEGnDOX on stages of Andersen Cascade Impactor (ACI). The results was represented with mean±s.d.
(n=3). AC, IP, 0-7, and F denote actuator, induction port, stage 0-7 and filter, respectively.
Stage G3NH2-3DOX G3NH2-9PEG-3DOX G3NH2-21PEG-3DOX G3NH2-21PEG-7DOX

AC

65.7 ± 22.3

92.1 ± 26.9

155.1 ± 17.4

163.3 ± 25.6

IP

389.1 ± 45.6

909.9 ± 58.0

368.4 ± 28.7

185.6 ± 7.9

0

61.6 ± 29.2

26.8 ± 9.9

31.9 ± 9.0

11.3 ± 6.6

1

23.6 ± 14.7

26.2 ± 17.4

27.1 ± 9.0

20.6 ± 1.2

2

19.3 ± 8.2

26.4 ± 4.6

19.6 ± 18.1

34.3 ± 5.2

3

16.5 ± 6.5

20.4 ± 13.5

18.1 ± 25.1

10.3 ± 10.8

4

14.9 ± 14.7

76.6 ± 37.5

129.3 ± 7.6

76.3 ± 6.9

5

16.7 ± 8.2

120.0 ± 25.1

939.8 ± 115.3

494.8 ± 57.5

6

16.3 ± 13.2

96.3 ± 12.9

689.8 ± 91.9

317.4 ± 28.8

7

19.5 ± 14.0

84.8 ± 10.6

508.2 ± 39.9

100.3 ± 12.1

F

24.1 ± 22.9

41.1 ± 4.8

201.3 ± 72.4

13.7 ± 8.2
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APPENDIX C
SUPPLEMENTAL INFORMATION OF CHAPTER 5
S1. Characterization
S1.1 Mass-assisted laser desorption/ionization-time of flight mass spectrometry (MALDITOF)
MALDI-TOF mass spectra were performed on a Bruker UltrafleXtreme mass spectrometer
equipped with a pulsed nitrogen laser (337 nm) under positive ion reflector mode. The conjugates
were dissolved in deionized water at a concentration of 1.0 mg/mL. 2, 5-DHB in methanol (10
mg/mL) was used as matrix. 10 μL of conjugate solution was mixed with equal volume of 2, 5DHB solution and 2 μL of the mixed solution was spotted on a Bruker Daltonics MALDI plate.
The spotted sample was dried gently by air flow.
S1.2 Proton magnetic nuclear resonance (1H NMR)
1

H NMR spectra were recorded on a Mercury 400 (400 MHz) spectrometer using

deuterated DMSO (DMSO_d6). Proton chemical shifts were reported in ppm (δ) and DMSO_d6
at 2.48 ppm was set as reference peak.
S1.3 Light scattering (LS)
Sample (1.0 mg/mL) was dissolved in phosphate buffer saline (PBS, pH 7.4). pH test
indicated all sample solutions were neutral. Hydrodynamic diameters and zeta potentials were
measured using Zetasizer Nano ZS. The average and standard deviation for hydrodynamic
diameters and zeta potentials were calculated based on at least three measurements.
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Lung cancers are leading cause of cancer death for both men and women in the world. Lungs
are also one of the primary organs to which almost all cancer can spread. Chemothepray plays a
crucial role in the fight against both primary lung cancers and lung metastases. Doxorubicin (DOX)
is a potent anticancer drug that has been approved for treating many cancers including lung cancers.
However, only a few percent of systemically administered DOX can be found in the lungs. The
issue is further complicated by dose-limiting toxicity of DOX. Another major challenge in the use
of DOX is its cardiac toxicity. Free DOX in bloodstream can accumulate in cardiac tissues, thus
leading to fatal heart damages. On the other hand, the lungs are considered as a portal to external
environment and suitable for local delivery. Additionally, oral inhalation (OI) has long been
accepted as the preferred mode of administration of therapeutics to the lungs. To address these
discussed challenges, we used a strategy — polymeric nanocarriers (PNCs) to achieve the spatial
and temporal drug release and local delivery of drug to the lungs. In this work, we desgined
polyamidoamine dendrimer (PAMAM) conjugates which can only release DOX intracellularly,
while being stable in physiological environment. We observed the PAMAM-DOX conjugates
upon local delivery to the lungs can significantly inhibit tumor growth both in vitro and in vivo.
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We also successfully prepared the PAMAP-DOX conjugates into propellant-based aerosol
formulations which is conducive to deep lung areas. To our knowledge, it is for the first time that
polymeric nanocarrier-based drug delivery system has been formulated into propellant-based
aerosol formulations.

203

AUTOBIOGRAPHICAL STATEMENT
Qian Zhong received his B.E degree (Bachelor of Engineering) in Materials Science and
Engineering from Tongji University, China in 2006 and M.S degree (Master of Science) in
Materials Science and Engineering from Tongji University, China in 2009. He joined department
of Chemical Enigneering and Materials Science at Wayne State University, MI, US in winter of
2011 to pursue a degree of Doctor of Phylosophy in Materials Science. His research, under the
guidance of Dr. Sandro da Rocha is focused on strategies to develop dendrimer-based
nanomedicines for lung cancer chemotherapy and immunotherapy, as well as oral inhalation
formulation of nanomedicnes for lung delivery. He has authored or coauthored 6 peer reviewed
publications and 3 patents/patent disclosure. He will be submitting 4 more publications with
contributions as a first author and 5 more publications with contributions as second author.

